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Abbreviations 
Ar      Aryl  
atm.    atmosphere  
Bn    Benzyl 
Boc    tert-butyloxycarbonyl 
c      concentration 
d      days 
dba    dibenzylideneacetone 
DCC    N,N`-dicyclohexylcarbodimide 
DCM     dichloromethane 
DIPEA   N,N-diisopropylethylamine 
DMAP    dimethyl aminopyridine 
DMSO   dimethylsulfoxide 
EA    ethyl acetate 
ee     enantiomeric excess 
ent   enantiomer 
eq.  Equation 
equiv.  Equivalents 
Et  ethyl  
EtOH  Ethanol  
g  gram 
H  hours 
HPLC  high pressure liquid 
  Chromatography 
HRMS  high resolution mass 
spectrometry 
iPr iso-propyl 
iPrOH iso-propanol 
IR infrared spectroscopy 
L liter 
LiHMDS lithium 
bis(trimethylsilyl)amide 
Me Methyl 
MeCN acetonitrile 
MeOH methanol 
mg milligram 
min minutes 
mmol millimoles 
mL milliter 
m.p. melting point 
MS  mass spectroscopy 
nBu n-butyl 
NMR nuclear magnetic resonance 
Nu nucleophile  
PE petrol ether 
Ph phenyl 
quant. Quantitative 
rt room temperature 
rac racemic 
p pressure 
t time 
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T temperature 
TBAF tetrabutyl ammoniumfluoride 
TBDMS tert-butyldimethyl silyl  
THF tetrahydrofuran 
V volume 
W watt 
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A. INTRODUCTION 
1. Bioactive substituted cyclopent-2-enone compounds and its derivatives 
Cyclopent-2-enone is one of the most important core structure in many bioactive prostaglandin 
derivatives and sesquiterpenes. Prostaglandins are a group of physiologically active compounds 
having hormone like effects.1 Every prostaglandin contains 20 carbon atoms. Prostaglandins show 
wide range of activities. They regulates cell growth, calcium ion levels, hormones, inflammation, and 
act on parietal cells in the stomach wall to inhibit acid secretion.2 The biological activity of cyclopent-
2-enone containing compounds is manifested in their ability to undergo conjugate addition with  
various biological nucleophiles such as L-cysteine or thiol containing enzymes (E-SH). Based on the 
SAR studies it was concluded that the cyclopent-2-enone moiety enhances the cytotoxic activity.3 5-
(1´-hydroxy)-4-disubstituted cyclopent-2-enones 1 (Fig 1) act against malignant tumors.4 Cyclopent-2-
enone prostaglandin derivatives show anti-inflammatory and antiviral activity and inhibit NF-B 
activation in human cell stimulated with tumor necrosis factor-. The prostaglandin analog 2 acts 
against L1210 murine leukemia cells with IC50= 4.0 (µg/mL).5 TEI-9826 3 was shown to retain in vivo 
activity against cis-platin-resistant tumors.6 The IC50 value of TEI-9826 for the inhibition of human 
ovarian cancer is 7.5 µM. 15-deoxy -12-iso-7-PGA1 4 shows promising anti-proliferative activity with 
IC50= 0.23 (µg/mL) on colon 26 cancer cells.2 Prostaglandin-A1 (PGA1)2 5 causes renal vasodilation, 
increase urine sodium excretion and lower the arterial pressure in hypertensive patients (Fig 1). 
                       
Figure 1: Bioactive cyclopent-2-enone prostaglandin derivatives. 
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2. Literature precedents for the synthesis of substituted cyclopent-2-enones and 
prostaglandin derivatives  
The consecutive addition of two side chains to the cyclopent-2-enone core (three-component 
coupling in one pot) is a well known procedure in prostaglandin synthesis. A one pot, high yield 
construction of the whole prostaglandin skeleton is accomplishable by combination of the copper-
mediated conjugate addition of alkyl or alkenyl nucleophiles to 4-siloxy cyclopent-2-enones followed 
by trapping the intermediate enolate with aldehydes. Deprotection of 4-siloxy followed by 
dehydration gives prostaglandin derivatives. Since organo cuprates have been widely used for the 
addition of organic groups to the -position of the -unsaturated carbonyls, it is known that the 
cuprate mediated conjugate addition of nucleophiles, followed by trapping intermediate enolate 
with strong electrophiles useful for synthesis of substituted cyclopent-2-enones or prostaglandin 
derivatives.  
In 1975, Gilbert Stork et al. reported the synthesis of PGF2 9 (Scheme 1) from 6 by using E-vinyl 
iodide 7 as nucleophile and HCHO7 as electrophile. The resulting 8 was converted in 5 further steps to 
the prostaglandin 9.8 
Scheme 1: Stork approach to the PGF2a. 
Ryoji Noyori et al. developed new routes for the prostaglandin derivatives 12, 15, and 17 from 
cyclopent-2-enone 10 (Scheme 2).9 They synthesized various prostaglandin derivatives by trapping an 
intermediate enolate with different types of aldehydes followed by deprotection and dehydration of 
–OTBS group. The 1-octenyl substituent of 17, was derived from 1-octyne through the 1-octenyl 
zirconocene, which has been formed in situ from 1-octyne and Schwartzs̒ reagent,10 followed by 
treatment with t-BuLi.                                 
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 Scheme 2: Noyori approach towards the prostaglandin derivatives. 
Smitrovich et al. developed a Cu(I) catalyzed addition of alkylzirconocenes to the -unsaturated 
carbonyl compounds (Scheme 3).11 This method allows the synthesis of substituted cyclopentanones 
from cyclopent-2-enoens. In the presence of 3-10 mol% of Cu(I) salts, alkylzirconocenes react readily 
with -unsaturated carbonyl compounds. The reaction yields are sensitive to the presence of Lewis 
acids and bases. Steric hindrances as well as a broad range of functional groups are tolerated. 
Cyclopent-2-enone 19 readily underwent tandem conjugate addition with hexyl zirconocene 18 
(which has been formed in situ from 1-hexene and Schwartz reagent) followed by aldol reaction with 
benzaldehyde in the presence of 10 mol% of CuBr.Me2S gave 20 in 58% yield with 2:1 mixture of 
epimers.  
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Scheme 3: Synthesis of substituted cyclopentanone by Smitrovich et al. 
In the year, 1994 Lipshutz B. H. et al. reported enantiopure synthesis of substituted cyclopentanones 
and non-prostaglandin skeletal from cyclopent-2-enone 25.12 In this case, alkenyl zirconocene acts as 
nucleophiles, which has been derived from the corresponding terminal alkyne by using Schwartzs̒ 
reagent. This was a one pot 6 steps sequence could be developed for the synthesis of prostaglandin 
and non-prostaglandin skeletons of type 24. This method involves the trans metalation13 between a 
organozirconium14 to a cuprate species (Scheme 4). Alkenyl zirconocenes 22, which upon exposure to 
Me3ZnLi (which has been derived from Me2Zn and MeLi) in THF at -78 oC effects the transmetaltion. 
After conjugate addition, the trapping of the resulting enolate 23 with aldehydes is rapid at -78 oC 
and affords aldol adduct 24 as mixture of diastereomers with respect to the newly formed stereo 
center (Table 1). 
                             
Scheme 4: Catalytic Cuprate-induced vinyl ligand 1,4-addition to 25 by Lipshutz et al. 
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Table 1: Synthesis of 4-alkenyl substituted cyclopentane derivatives by Lipshutz et al. 
a) One isomer by 1H-NMR. b) Two isomers by 1H-NMR. c) Five isomers by 1H-NMR. d) Four isomers by 
1H-NMR.  
With cyclopent-2-enone as starting material, various successful examples were developed by 
combination of different alkynes and aldehydes providing yields between 70-80%. The number of 
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epimers was based on substituents on alkyne as well as aldehde. Alkyne with no substituents gave 
only one isomer (entry 1, Table 1) and alkyne with substituent’s furnished epimers more than two 
(entry 2-6, Table 1). 
 In the year 2002, Kobayashi et al. reported the application of Ni-catalysis for the synthesis of 
enantiopure cyclopentanoid molecules 30.15 They have developed the installation of aryl and alkenyl 
groups on to the readily available monoacetate 2616 using lithium borate 2717 and nickel catalyst in 
the presence of additive gave 4-substituted hydroxy cyclopentenes 28.  
 
Scheme 5: a) General route for synthesis of aldol adducts 30. b) Synthetic root to 7-PGA1 methyl 
ester by Kobayashi et al. 
Among several additives t-BuCN and NaI in ratio of 13:1 was found to be the best additive. The 
oxidation of 28 furnished 29, followed by trapping of the resulting enolate of 29 with aldehydes gave 
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4-substituted cyclopent-2-enone 30 (Table 2). After treatment with a base such as LDA at -78 oC 
followed by trapping of resulting enolate with aldehydes afforded an aldol adduct 30 (Table 2). They 
reported synthesis of 7-PGA1 methyl ester 35 from 31 and 32 by using this methodology as key step 
(Scheme 5). 
The yield of aldol adducts 30 depend on time and temperature, it was shown that the intermediate 
enolate is unstable . The authors found that 60 min and >-50 oC were suitable reaction parameters 
for aldol adduct formation. The assignment of the anti and syn aldols 30 was made by using coupling 
constants between Ha and Hb. The anti-aldols show Ja,b =7-9 Hz and syn-aldols shows Ja,b = 3 Hz. In all 
cases, aromatic aldehydes gave nearly the same ratio of epimers (entry 1-3, 5, 7 and 8, Table 2), 
where as aliphatic aldhehyde provided anti-aldol as the major diastereomer (entry 4, 6 and 9, Table 
2).  
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Table 2: Synthesis of 4,5-disubstituted cyclopent-2-enone derivatives 29 by Kobayashi et al. 
 
a) Synthesized from 29 by using oxidation. b) Calculated from the isolated yields. c) Anti: syn aldols 
determined by coupling constants. d) Determined by 1H NMR. 
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Approximately at the same time, Feringa et al. published their results of the synthesis of enantiopure 
substituted cyclopentanones 37 by using catalytic tandem 1,4-addition and aldol reaction in the 
presence of a catalyst generated in situ from Cu(OTf)2 and phosphoramidate 38.18 They used alkyl 
zinc compounds19 as nucleophiles in the presence of aromatic aldehydes. Enantioselectivities were 
obtained upto 94% and de upto 97:3. Alternatively, PGE1 methyl ester 43 could be synthesized from 
the compound 39 and zinc compound 41 applying the conditions developed for the synthesis of 37. 
The key compound 42 was obtained in 60% yield and a 87:13 ratio of epimers, which was further 
converted to PGE1-methyl ester 43 in five steps (Scheme 6b).  
 Scheme 6: a) General method for synthesis of enantiopure substituted cyclopentanones by Feringa 
et al. b) Synthetic route to PGE1-methyl ester. 
In the year 2006, Helmchen et al. reported synthesis of enantiopure 2,4-disubstituted cyclopent-2-
enones 50 by iridium catalyzed allylic alkylations.20 The key steps involved in their synthesis are 
iridium catalyzed allyl alkylation, acylation and ring closing metathesis. In this case, sodium enolates 
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of Weinreb amides21 44, allylic carbonates 45 and Grignard reagents are the starting materials. 
Enolate 44 and carbonate 45 are reacted with each other in the presence of iridium catalyst and 
ligand 4622-24 gave amide 47 with high stereoinduction through the catalyst. Saponification with 
NaOH and decarboxylation at 180 oC gave amide 48. After Grignard reaction at -78 oC followed by 
ring closing metathesis25 on 49 the 2,4-disubstituted cyclopent-2-enones 50 were obtained as 
products with high enantiomeric excess (Scheme 7) .  
 
Scheme 7: Iridium catalyzed synthesis of substituted cyclopent-2-enones by Helmchen et al. 
Table 3: Examples of 4-substituted cyclopent-2-enone derivatives by Helmchen et al. 
           
 
 
 
 
 
  a) Yields based on 44+45. b) Determined by HPLC on chiral column. 
On the other hand, in 2014 Hartwig et al. published enantioselective allylic substitution of 
unstabilized enolates 52 (derived from 51) by using iridium catalysis.26 In this case, unstabilized 
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enolates 52 and allylic carbonates 53 are starting materials. These two starting materials reacts with 
each other in the presence of [Ir(COD)Cl]2 and ligand (ent)-46 to afford allylated products 54 having 
new stereo center at the -position to the keto group. The additives played a key role for the 
reaction of allylic carbonate with enolate. Among the several additives tested, it was found that KF 
with 18-crown-6 is key to the success of the reaction. The -allylated unsaturated ketone 54 should 
be useful intermediates for synthesis of enantiopure 4-substituted cyclopent-2-enones 55 by using 
ring-closing metathesis (Scheme 8).  
 
Scheme 8: Iridium catalyzed synthesis of -substituted unsaturated ketones by Hartwig et al. 
Moreover, recently Nakajima group published synthesis of enantipoure 4-substituted cyclopent-2-
enones 59 from dienones 56 (Table 4).27 The key steps involved O-monoacyltartaric acid catalyzed 
enantioselective conjugate addition of boronic acids to dienones followed by Ru-catalyzed RCM.28 
With styryl boronic acid as starting material various successful examples are presented by changing 
the substituents on dienone providing mono styrylated products in 42-81% and ee with 86-94% along 
with bis styrylated product 60 (Table 4). 
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Table 4: Synthesis of mono-styryl enones by Nakajima et al. 
 
The actual reaction time was 24 h. To suppress the amount of 60, the reaction time was reduced to 
14 h. On the other hand, using exactly 1 equivalent of boronic acid 58 significantly suppressed the 
yield of 60 (entry 3 and 7, Table 4). The higher amount of boronic acid favors the formation 60 in 
equal yield with respect to the 59 (entry 4, Table 4). With compound 59a in their hand, they 
concentrated on the construction of cyclopent-2-enone by using RCM reaction. Various Ru-catalysts 
were tested for ring closing metathesis. The Schrodi-Grubbs catalyst29 in the presence of 1, 6-
heptadiene (additive) gave desired product in moderate yield (entry 1, Table 5). The Grubbs-II30 also 
showed similar activity in the presence of additive (entry 2, Table 5). The Grubbs-I catalyst31 failed 
completely in this RCM (entry 3, Table 5). When switched to Hoveyda-Grubbs II catalyst32 gave better 
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results. 15 mol% of Hoveyda-Grubbs II furnished desired compound 61 in 84% yield after 48 h (entry 
4, Table 5). Whereas lowers the amount to 10 mol% provides desired compound 61 in very good 
yield 98% after 24 h (entry 7, Table 5). The additive diene generates active Ru- species from the 
catalyst, which would promote less reactive enones into the RCM reaction.                           
Table 5: Synthesis of 4-substituted cyclopent-2-enones using RCM by Nakajima et al. 
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a) The catalyst (5 mol %) was added every 24 h (15 mol %). b) The catalyst was added in one portion. 
c) In toluene at 80 oC. d) With 1, 6-heptadine (0.4 equiv). e) Without 1,6-heptadiene. f) With diallyl 
ether (0.2 equiv). 
Entry 9 provides a derivative 62 with n-octyl group. After successive RCM with Hoveyda-Grubbs II in 
the presence of 1,6-heptadiene at 80 oC for 24 h furnished 4-octyl cyclopent-2-enone 63 in 76% yield, 
which is know intermediate for TEI-9826 (Scheme 9). 
                   
Scheme 9: Synthesis of enantiopure 4-octyl cyclopent-2-enone by Nakajima et al. 
TEI-9826 3 is one of the most prominent anti-cancer drugs. Many groups reported the synthesis of 
this anti-tumor agent. In 2003, Monneret et al. reported the synthesis of TEI-9826 from commercially 
available propargyl alcohol 64 in 11 steps.33c Key steps involved in their synthesis are a Claisen 
rearrangement34 and a RCM. However, no experimental details have been published. In 2006, 
Helmchen et al. synthesized this molecule from (E)-methyl undec-2-enyl carbonate 65, Weinreb 
amide 66 and vinyl magnesium bromide by using iridium catalyzed allylic substitution followed by Ru-
catalyzed ring closing metathesis.20  
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 Scheme 10: Various synthetic approaches towards the TEI-9826. 
Iqbal and co-workers reported the synthesis of TEI-9826 by using Pauson-Khand reaction between 
TMS-acetylene 67 and norbornadiene 68, which gave rise to cyclopent-2-enone core.33b Zurawinski et 
al. described the synthesis of TEI-9826 from cyclopent-2-enone derivative 69 in 7 steps.33a The key 
steps were involved here, Horner-Wardsworth-Emmons-olefination35 followed by aldol reaction. 
Recently Hartwig et al. accomplished from silylenol ether 70 and compound 71 in 6 steps by using 
iridium catalyzed enantio selective allylic substitution of unstabilized silyl enol ethers and subsequent 
RCM with Grubbs-II catalyst (Scheme 10).26 Moreover, all the above methods need more than two 
pots, harsh conditions and longer reaction time for the synthesis of prostaglandin derivatives. 
3. Bio-active guaianes and guaianolides 
Guaianes and guaianolides,36 represent one of the largest subgroup of naturally occurring 
sesquiterpenes and lactones exhibiting strong biological activity.37,38 Plants containing different 
guaianes and guaianolides as the active principles have been used in traditionally medicine for 
treating cancer, inflammatory etc. Guaianes consisting of 5,7-bicyclic hydroazulene system and 
guaianolides consisting 5,7,5-tricyclic system.  
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Figure 2: Bioactive guaiane sesquiterpens. 
Guaianes are 5,7-bicyclic sesquiterpenes, widely obtained from many plants. These molecules exhibit 
strong anti-tumor, anti-inflammatory and anti diabetic activities.39 The functionalities on guaiane 
core structure affect the nature of activity in biological systems. The representative members shown 
below exemplify the structural diversity found within this class of compounds. Teuclatriol 72 isolated 
from teucrium leucocladum,40 shows a significant anti-proliferative activity against human activated 
peripheral blood lymphocytes with IC50 = 72.5 µg/mL.41 Another guaiane molecule with exo-
methelene group teucladiol 73 also isolated from teucrium leucocladum,40 exhibit moderate anti-
cancer activity on human breast cancer cell lines. Molecule 74 from acorus calamus, shows promising 
anti-diabetic activity on a insulin mediated glucose consumption model of HepG2 cells.42 Kadsuguain-
A 75 isolated from piper kadsura, shows moderate anti-neuroinflammatory activity.43 Guaiane core 
structure with Oxygen bridge also exhibits strong bioactivity. Chrysothol 76 isolated from 
chrysothamnus viscidiflorus, shows anti-cancer activity on human breast cancer cells.44,45 Buchariol 77 
which was isolated from salvia bucharica, shows cytotoxic activity against a panel of human cancer 
lines.46,47 Orientalol-F 78 isolated from Alisma orientalis acts anti-diabetic.48 Another similar molecule 
englerin-A 79 was isolated from phyllanthus engleri, and shows anti cancer activity on human renal 
cancer cell lines49 (Fig 2). 
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The pseudoguaianolide skeleton along with the 5,7-bicyclic hydroazulene ring system often contains 
a third ring, an unsaturated -methylene--butyro lactone fused to the 7 membered ring. Along with 
structural diversity guaianolides exhibit strong biological activity. Here we showed some bio-active 
molecules with guaian 8,12-olide core structure. Helenalin 81 is a sesquiterpene lactone found in 
Arnica Montana has a variety of observed anti-inflammatory and antitumor activities. Helenalin50 has 
been shown to selectively inhibit the NF-B, which plays a key role in the regulating immune 
response. The sesquiterpen lactone carpesiolin51 82 shows significant inhibitory activity against 
Cochlioblous miyabeanus. On the other hand, sesquiterpenoid lactone 8052 was found to be 
submicromolar inhibitors against LPS-induced nitric oxide production in RAW264.7 macrophages (Fig 
3). 
        
 
 
 
Figure 3: Bioactive pseudoguaianolide sesquiterpens 
4. Pot economy in natural product synthesis by using cascade sequence  
The total synthesis of natural products and biologically active compounds, such as pharmaceuticals 
and agrochemicals, has reached an extraordinary level of sophistication. The efficient total synthesis 
of natural products has always been a critical issue for organic chemists. A lot of effort has been 
devoted to the development of an ideal synthesis. When synthesizing molecules, one not only has to 
consider efficiency but also sustainability, such as atom economy, step economy, redox economy, 
Protecting-group-free53 and toxic metal free synthesis also contributes to sustainability. Only a single 
reaction solvent, workup procedure, and purification step may be required to provide a product that 
would otherwise have to be made over the course of several individual steps.  
                         
 
 
Scheme 11: Robinson approach to the tropinone. 
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As such, cascade reaction/ domino reaction/ tandem reaction can be considered as one pot economy 
reaction. A cascade reaction is an efficient method to achieve several transformations and by 
forming several bonds, while at the same time save purifications steps, and thus minimize chemical 
waste and time. Indeed, cascade reactions have attracted the attention of organic chemists, since 
Robinson`s one pot synthesis of tropinone (Scheme 11).54 Subsequent classic examples include the 
endiandric acid-C 8755 cascade by Black and co-workers through the electrocyclic reactions (Scheme 
12a).56  Radical based synthesis of hirsutene57 and other triquinane natural products by Curran and 
co-workers are the other prominent examples.58 They used tandem radical approach starting from 
intermediate 88, which leads to tricyclic core of hirsutene 89 in a one pot operation (Scheme 12b).  
                              
Scheme 12: a) Black electrocyclic cascade for endiandric acid-C. b) Radical cyclization cascade for 
hirsutene by Curran et al. 
Hayashi and co-workers reported one-pot synthesis of (-)-oseltamivir59,60 94 by using an asymmetric 
Michael reaction of aldehyde 90 with (Z) - N-2-nitroethnylacetamide 92 catalyzed by diphenyl 
prolinol silyl ether. They used two one-pot sequences for the target. In the first one pot operation, 
they achieved core structure of (–)-oseltimivir 93 by using an asymmetric enantioselective Michael 
addition,61 Horner-Wadsworth-Emmons reaction35 followed by cyclization. In the next one pot 
operation, they achieved six further transformations, which led to the target 94 with good yield 
(Scheme 13).62 
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Scheme 13: Pot economy cascade for (-)-Oseltimivir by Hayashi et al. 
On the other hand, the same group reported synthesis of PGE1-methyl ester 43 by using a three-pot 
cascade. In the first pot they achieved the synthesis of cyclopentane core 98 with two stereogenic 
centers by using an enantio selective Michael addition, Horner-Wadsworth-Emmons followed by 
cyclization, which was reduced selectively to 99 by using (-)-diisopinocamphenyl chloroborane. A 
further one pot protocol combining 4 transformations was then demonstrated, which led to PGE1-
methyl ester with 14% overall yield (Scheme 14).63 
 
Scheme 14: Three pot economy for PGE1-metghyl ester by Hayashi et al. 
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5. Protecting group free access to the natural product synthesis 
Total synthesis is a big tool for synthesis of derivatives of naturally occurring bioactive molecules with 
different functionalization. When we start synthesis of some complex molecules, selectivity plays a 
crucial role. One strategy that allows the differentiation of similar functional groups is the use of 
protecting groups. Nevertheless, adding protecting group and removal of protecting group needs 2 
steps, thus reducing yield and requiring more reagents. It is therefore desirable to develop reaction 
sequences that avoid the use of protecting groups. Some prominent examples are shown in the 
following: In 1917 Robinson reported the synthesis of tropinone from the simple starting materials 
succinaldehyde, methylamine and acetone di-carboxylic acid. This one may be considered first 
protecting group free synthesis as well as one pot synthesis. In 1968, Danieshfsky et al. reported the 
total synthesis of racemic patchouli alcohol 102 from 100 and 101 without using any protecting 
groups.64 In his synthesis, each intermediate has limited reactive sites and diminishing chemo 
selective transformations (Scheme 15a). Phil. S. Baran et al. reported the first synthesis of ambiguine-
H 104 by using a protecting group free strategy.65 They used commercially available material 103 as 
starting material by using direct indole coupling in the presence of copper salts as key step66 (Scheme 
15b). 
 Scheme 15: Protecting group free strategy for Patchouli alcohol by Danishefsky et al (a), (+)-
ambiguine-H by Baran et al (b). 
Moreover, in 2008 B. M. Stoltz group reported first synthesis of cyantwigin-F 106 from di-allyl 
succinate 105 without using any protecting groups.67 The key steps involved double enantioselective 
alkylation68 in the presence of Pd2(dba)3 and PHOX ligand followed by RCM (Scheme 16a). Alois 
Fürstner et al. reported the total synthesis of ecklonialactone 108 without using any protecting 
groups and alkyne metathesis as key step (Scheme 16b).69 In 2010, D. Ma et al. reported the total 
synthesis of englerin-A 79 from 109 by using gold-catalyzed cyclization of keto enynes and without 
using any protecting groups (Scheme 16c).70 The protecting group free synthesis needs intermediates 
with active sites, which are diminishing chemoselective transformations. 
A. INTRODUCTION 
   
29 
 
                         
Scheme 16: Protecting group free approach to the various natural products. 
Recently J. K. Taylor et al. reported first total synthesis of Dievidiamine 112 from commercially 
available materials 110 and 111. The key steps include the first example of an organometallic 
addition into a DHED adduct and Stille coupling between two sterically hindred alkenes. Moreover, 
they completed the synthesis without using any protecting groups; this could be an example of 
protecting group free synthesis (Scheme 17).71 
 
                            
Scheme 17: Protecting group free approach to theDievodiamine by Taylor et al. 
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6. Kinetic resolution 
Many of the building blocks in biological systems and bioactive natural products are mostly available 
in pure enantiomeric forms. Their synthesis as well as that of analogues needs an asymmetric 
synthetic strategy. The enantioselective synthesis can be achieved by using chiral catalysts or achiral 
catalysts with chiral ligands. Separation of enantiomers from racemic mixture by using kinetic 
resolution is a well known strategy in asymmetric synthesis. Two enantiomers in racemic mixture 
react with different rates with a chiral reagent, resulting in an enantiomeric excess of an unreacted 
enantiomer in a racemic mixture. The first kinetic resolution reported by Louis Pasteur.72 However, 
Marckwald and McKenze reported the first synthetic kinetic resolution in 1899.73 They separated 
enantiopure (+)-113 from (±)-113 by using enantiselective esterfication with 114. In which (+)-113 
reacts faster than (-)-113, gave ester 115, saponification on 115 furnished (+)-113 in pure 
enantiomeric form (Scheme 18). 
 
Scheme 18: Kinetic resolution of racemic mandelic acid by Marckwald and McKenze. 
B. M. Trost et al. published asymmetric synthesis of butenolides 118.74 In this case, palladium catalyst 
forms a chiral complex with ligand 127. The two enantiomers of butenolide generated -
allylpalladium complex 117a and 117b with Pd-catalyst. These 2 complexes undergo interconversion 
with each other. If interconversion is fast relative to nucloephilc addition one of the complexes reacts 
with nucleophile faster than the other, then effective dynamic kinetic resolution would be result 
(Scheme 19). 
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Scheme 19: Kinetic resolution of butenolides by using Pd-(R,R)-Trost complex by Trost et al. 
G. Fu et al. reported kinetic resolution of secondary alcohols 120 as enantipure acetates 122 by using 
a planar-chiral DMAP analogue 121 in the presence of 119 (as acetylation agent) and triethyl amine 
gave selectivities ranging from 12-52. In these cases, enantioselectivity observed are better than 
previously reported non-enzymatic asymmetric acylation catalyst (Scheme 20).75    
               
Scheme 20: Kinetic resolution of racemic secondary alcohols by G. Fu et al. 
Recently O.Reiser et al. published enantioselective synthesis of 4-hetero substituted cyclopent-2-
enones 126 from (±)-125. In this case, they used Pd-catalyzed kinetic resolution of (±)-125 with 
various nucleophiles in the presence of ligand 127. Excellent enantioselectivities of both substitution 
products 126 and recovered starting material (+)-125 were obtained even at low catalyst loading 
(Scheme 21). This method could be useful for synthesis of various starting materials for 
cyclopentanoid bioactive molecules and prostaglandin derivativies.76 
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Scheme 21: Kinetic resolution of racemic 4-Boc cyclopent-2-enones by using Pd- ligand 127 complex 
by Reiser et al. 
7. Conclusion 
Since last 40 years, the synthesis of substituted cyclopent-2-enones was expanded significantly. 
Prostaglandins exhibit a broad range of biological activity and stimulate the development of research 
in their synthesis. As there are more and more number of prostaglandins discovered, the full 
evaluation of their bioactivity is still of current interest. Besides this, methods were developed to 
synthesize substituted cyclopent-2-enones from various starting materials, which were highly 
valuable in view of growing interest in their synthesis. On the other hand, cyclopentanoid 
sesquiterpenes are also exhibit a broad range of bioactivity. Therefore, the total synthesis of 
sesquiterpenes plays an important role in inventing new methods in organic synthesis.   
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B. Main Part 
1. One pot synthesis of substituted cyclopent-2-enones by using a traceless 
stereoinducing directing group 
1.1 Introduction 
Substituted cyclopent-2-enones represents one of the most important core structures in many 
bioactive prostaglandin derivatives and sesquiterpenes. Prostaglandins1 are a group of physiologically 
active compounds having hormone like effects. They show wide range of activities, such as regulating 
cell growth, calcium ion levels, hormones, inflammation, and they act on parietal cells in the stomach 
wall to inhibit acid secretion.2 Cyclopent-2-enone compounds have been shown, to react by 
conjugate addition with various biological nucleophiles such as L-cysteine or thiol containing enzymes 
(E-SH). Based on the SAR studies it was concluded that cyclopent-2-enone moiety enhances the 
cytotoxic activity. 5-(1-hydroxy)-4-substituted cyclopent-2-enones 1 (Fig 1, Introduction part) act 
against malignant tumors. Cyclopent-2-enone prostaglandin derivatives showed anti-inflammatory 
and antiviral activity, and inhibit NF-B activation in human cells stimulated with tumor necrosis 
factor-77Based on the biological activity of such substituted cyclopent-2-enones many groups have 
reported the synthesis this moiety by using chiral pool, chiral reagents and various catalytically 
strategies.78 Addition of organo lithium or Grignard reagents to cyclopent-2-enones in the presence 
of copper (I) salts followed by trapping of the resultion enolate intermediate with an aldehyde is a 
well known process for synthesis of prostaglandin derivatives. However, extensive studies along this 
line have revealed that such direct vicinal functionalization is not easy to achieve. The difficulty is 
presumably attributable to the complex nature of the reaction system, which causes a facile double 
bond migration of the initial formed enolate 129, causing concomitant dehydration to give undesired 
products 132. By using highly reactive electrophiles, such side reactions are avoided.79  
B. Main Part 
   
34 
 
                         
Scheme 22: Consecutive addition of 2-side chains to the cyclopent-2-enoen and mechanistic proposal 
As I showed in introduction, with the pioneering work of Noyori et al. utilizing 4-siloxy-2-
cyclopentenone 10 as a key building block for the synthesis of prostaglandins, a reliable strategy 
towards enantiopurecyclopentenones was established, being broadly applied by many. Conjugate 
anti-addition of nucleophiles to 10 in the 3-position controlled by the adjacent siloxy group followed 
by an aldol reaction in the 2-position anti to the nucleophile just introduced was developed. 
Subsequently, the siloxy group can be eliminated to generate the substituted 2-cyclopentenone. 
With the advent of asymmetric conjugate additions, it was demonstrated that 2-cyclopentenone 
could be used directly as a starting material for the synthesis of enantiopurecyclopentanones 
(Scheme 2, Introduction part). Other strategies towards the target structure have been reported as 
well, however, mixtures of epimers at C-1', often in ratios close to 1:1, are generally obtained with 
only few exceptions that require sterically demanding aldehydes. In my thesis I have found that the 
pseudoenantiomeric building blocks (R)-125 and (S)-134 are exceptional starting materials for the 
one-flask synthesis of the target structure (+)-133 and (-)-133 (both enantiomeric forms with 
excellent enantio- and diastereocontrol including the C-1' position. The 4-oxo-substitutents in (R)-125 
and (S)-13480 act as traceless stereoinducing elements that not only relay 1,2- but also remote 1,4-
stereocontrol in a cascade of nucleophile addition/ aldol reaction / elimination sequence (Scheme 
23).  
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 Scheme 23: Stereoselective synthesis of 5-(1-hydroxy)-4-substituted cyclopent-2-enones.                   
1.2 Synthesis of (R)-125 and (S)-134:  
(R)-125 and (S)-134 are readily available in enantiopure form from the bulk chemical furfurylalcohol 
135 in a two-step sequence.  In the first step,  (±)-136 was synthesized on kilogram scale from 135 by 
an acid catalyzed  Piancatelli rearrangement81 carried out in a micro reactor setup afforded (±)-136 in 
87% yield,  which  was converted to (±)-125 with (Boc)2O and Et3N gave (±)-125 in 85% yield (Scheme 
24).82 
                      
Scheme 24: Synthesis of (±)-125. 
With the compound (±)-125 in our hand we decided to synthesize (R)-125 and (S)-134 via a Trost-
Tsuji asymmetric allylation technology.83,84 Reacting 4-methoxy phenol 137 as nucloephile with (±)-
125 in the presence of Pd2(dba)3.CHCl3 and 12785 gave corresponding 4-methoxy phenol substituted 
compound (S)-134 along with unreacted (R)-125. The yield and ee of the (R)-125 and (S)-134 depend 
on the equivalents of the 137 (Table 6).  
 
 
B. Main Part 
   
36 
 
Table 6: Optimization studies for (R)-125 and (S)-129. 
 
When we used 137 in lower amounts, the formation (S)-134 with good enantiomeric excess but low 
yield is achieved (entry 1, Table 6). However, the higher amount of 137 favors the (R)-125 with good 
yield and enantiomeric excess (entry 5, Table 6). Decreasing the amount of the Pd-catalyst from 1 
mol% to 0.4 mol% was tolerated well, while a decrease to 0.2 mol% gave some better results for both 
(R)-125 and (S)-134 (entries 5, 6 and 7). We have resolved (±)-125 on 50 g scale with 137 (0.5 equiv) 
under the condtions shown in entry 5, giving rise to (R)-125 (42%, >99% ee) and (S)-134 (48%, >92% 
ee).  
1.3 Synthesis of (+)-133 and (-)-133 
 Copper (I)-catalyzed Grignard additions to (R)-125 followed by trapping of the resulting enolate with 
aldehydes were investigated next. First it was set out to identify best copper (I) source for the 
envisioned one pot operation. Test reactions were performed with (R)-125, isopropenyl 
magnesiumbromide and trans-2-methyl-2-butenal (Table7): Using copper (I) iodide in THF,86 the 
desired adduct (+)-133g was obtained with 48% yield (entry 1, Table 7). Switching to diethyl ether, 
the yield decreased to 38% (entry 2, Table 7). Variation of the copper(I)-species by adding PBu3, 
which has been shown to be stabilize the intermediate oregano copper reagent,87 also gave 
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disappointing yields(entries 4-6, Table 7). Higher order cyanocuprates88 were examined next: 
Applying CuCN.2LiCl in combination with Grignard reagents in THF afforded (+)-133g with an 
improved yield of 66% (entry 7, Table 7). Further variation of solvent demonstrated that the mixture 
of THF and diethyl ether led to lower yields than THF alone (entries 3, 6 and 9, Table 7). These results 
suggest that the CuCN.2LiCl mixture89,90 in THF proved to be the best condition for the one-pot 
strategy, offering good yields in short reaction times. 
Table 7: Optimization studies for one pot strategy. 
 
Under the optimized conditions, the addition of organometal compounds to (R)-125 followed by 
trapping of the resulting intermediate enolates was investigated: Irrespective of the Grignard reagent 
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employed (aryl-, vinyl- and alkyl) or the aldehydes (aromatic, -unsaturated or aliphatic) the 
adducts (-)-133 were obtained with high stereoselectivity. The level of enantioselectivity is 
determined by the anti-selectivity of the Grignard reagent in the initial conjugate addition to (R)-125, 
and small differences in selectivity are observed correlating with its steric bulk (Table 8). Introducing 
a vinyl group as the smallest nucleophile investigated,  the enantioselectvitiy was ≥95% ee, while 
octyl, isopropenyl, cyclohexyl and phenyl generally gave ≥99% ee with the exception of (+)-133i (98% 
ee). Good yields (59-77%) were obtained in all cases with the exception of octyl magnesiumbromide, 
which gave rise to (+)-133s-x (30-38%). It was subsequently found (vide infra) that this Grignard 
reagent gave considerable higher yields when (S)-134, being pseudo enantiomericto (R)-125, was 
used.  
Table 8: One pot strategy of (R)-125 with different Grignard reagents and aldehydes. 
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All products were obtained with ≥ 99% de as determined by 1HNMR of the crude products. 
Enantioselectivities (133a-d, 133f-h, 133n, o, p and r, 133s, 133t: ≥ 99% ee, 133i: 98% ee; 133k: 96% 
ee, 133m: ≥95% ee,) of (+)-133 for each Grignard reagent were determined by chiral HPLC of the pure 
against a racemic reference samples of 133a-d, f-h, n-p and r, s, t and from these data extrapolated 
to 133e, j, l, q and u-x. 
Employing the 4-OPMP derivative (S)-134 as starting material gave access to the enantiomeric 
cycopentenones (-)-133 with equally good selectivity. Gratifyingly, good yields were obtained in all 
cases, even for octyl magnesium bromide (Table 9). 
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Table 9: One pot strategy of (S)-134 with different Grignard reagents and aldehydes. 
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aAll products were obtained with ≥95%d.r.as determined by 1HNMR of the crude products. (-)-133a, 
c, d, g, h, j, k, l, n and r: 94% ee (Chiral HPLC against reference samples reference). 
As depicted in Scheme 25, upon addition of a nucleophile to (R)-125, the enantiopure enolate 138 is 
formed, which is then converted to the aldol adduct (+)-133 by reacting with an aldehyde.  The 
excellent stereocontrol achieved for (+)-133 at the C-1'-position can be understood by the 
terminating anti-elimination of ROH (R=–OBoc,) from intermediate 139, which we reckon is initially 
formed along with (epi)-139 (Scheme 25).  
 Scheme 25: Stereochemical model for the remote 1,4-stereocontrol of the –OBoc group. 
139 can adopt a favorable conformation that triggers elimination to (+)-133, while in (epi)-139, the 
conformation that is required to invoke R-OH elimination suffers from steric repulsion caused by the 
axial position of R1.91-93 
1.4 Applications of the methodology towards biologically relevant cyclopent-2-enones 
Prostaglandins are lipid compounds having hormone type activities that are found in many tissues 
and organs. They are produced following the sequential oxidation of arachidonic acid by 
B. Main Part 
   
42 
 
cyclooxygenase and have a wide variety of effects in bio-systems. Prostaglandins are responsible for 
constriction and dilation of vascular smooth muscle, regulate calcium movement, regulate 
hormones, and control cell growth.94,95 Owing to the bioactivity of these compounds, many groups 
reported syntheses of these molecules by consecutive addition of two side chains to the enantiopure 
4-oxo cyclopent-2-enones 10 in the presence of Cu (I)-salts (Scheme 2, Introduction part). All these 
methods need separate reaction steps, quite drastic reactionconditions and longer reaction times. To 
overcome these problems, we decided to use the strategy developed above for the synthesis of 
some prostaglandinsand derivatives thereof.  
           
Scheme 26: One-pot synthesis of anti tumor agents 2 and 3. 
Compound 2, acts against L1210 murine leukemia cells with IC50= 4.0 (µg/mL),5 could be obtained 
from (R)-125 by using n-butyl magnesium bromide as Grignard reagent and heptanal as trapping 
reagent for the intermediate enolate in 38% yield. The anti-tumor agent 3 (TEI-9826) was synthesized 
from (S)-134 by using n-octyl magnesiumbromide as Grignard reagent and trapping the resulting 
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enolate by methyl-6-formylhexanoate afforded 140, which was used for the next dehydration with 
MsCl96 in the same flask without further separation gave 3 in 48% yield (Scheme 26) . 
 
Scheme 27: Synthesis of 141 and 143. 
Two more prostaglandin derivatives 141 (butyl derivative of 3) and 143 (methyl ester of 4) could be 
obtained starting from (S)-134. To synthesize 141 we used n-butyl magnesiumbromide as nucleophile 
and methyl-6-formylhexanoate. The resulting aldol adduct was then dehydrated by using MsCl and 
DMAP to give rise 141 in 42% yield. Using vinyl zirconium instead of Grignard reagents was also 
possible. We were able to synthesize 143 in 45 % yield starting from (S)-134, 1-octyne, Schwartzs̒ 
reagent (Cp2ZrHCl) and methyl-6-formylhexanoate giving rise to 142, followed by dehydration to 143. 
The later strategy could be in general useful for the synthesis of prostaglandin derivatives with 
alkenyl groups at C4, without the need to transmetallate another organometal precursor (Scheme 
27).97 
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2. Studies towards the synthesis of teuclatriol and iso-teucladiol 
2.1 Isolation and bioactivity 
The second aim of this work is synthesis of some bioactive guaiane natural products by using the 
previously described one-pot strategy as key step. Here we successfully achieved the total synthesis 
of teucltriol 72,46 iso-teucladiol 144,46 (Fig 4). 
                                    
Figure 4: Structure of teuclatriol 72 and teucladiol 144. 
Teuclatriol (72) is another guaiane sesquiterpene was isolated from teucrium leucocladum. This 
compound showed a significant anti-proliferative activity on human activated peripheral blood 
lymphocytes with IC50 = 72.5 µg/ml. A number of sesquiterpene lactones have shown anti-
inflammatory and anti-cancer activity. Various studies revealed that these lactones most likely induce 
their immunoinhibitory activity through apoptosis. Teuclatriol does not have a lactone ring, its anti- 
proliferative activity probably follows a different mode of action. Using bioassay-guided 
fractionation, it appears that teuclatriol is one of the responsible compounds for the 
immunoinhibitory activity of Salvia mirzayanni.    
2.2 Retrosynthetic analysis 
In our retro synthesis, the main goal was to achieve an adduct 146 with 4 contiguous stereo centers 
in a single step by using our one-pot strategy. We envisioned that the target molecule 72 can be 
obtained from compound 144 by hydration of the double bond.98,99 144 might be obtained from 145 
via stereo selective methylation.100-102 Compound 145 was expected to arise from aldol adduct 146 
through ring closing metathesis followed by selective reduction of -unsaturated double bond. 
Aldol adduct 146 could be accomplished by kinetic resolution of racemic achiral aldehyde (±)-148103 
with enantiopure enolate 147 (Scheme 28).  
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Scheme 28: Retrosynthetic analysis of teuclatriol 72. 
2.3 Kinetic resolution of racemic enolates 
Kinetic resolution is a well known process for the separation of enantiomers from a racemic mixture. 
In this process, one of the enantiomer reacts faster than the other enantiomer with a chiral reagent . 
In 2010 Vanderwal and co-workers reported the kinetic resolution of racemic enolates 151 by using 
enantiopure achiral aldehyde (-)-148.104 Using aldehyde (-)-148 (95% ee) in the reaction of the 
racemic enolate 151 afforded aldol adduct 152 in 38% yield with 83% ee. Apparently, (–)-148 
underwent epimerization under the reaction conditions. The authors therefore noted that an ideal 
enantioselective synthesis would incorporateenantioenrcihe enolate, but the asymmetric conjugate 
addition of sp2-hybridized organometallics to the cyclopentenone is not a well-developed process. 
From adduct 152 five steps were needed to complete the synthesis of teucladiol 73 (Scheme 29). 
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Scheme 29: Vanderwal et al. approach towards the teucladiol 73. 
2.4 Kinetic resolution of racemic aldehyde (±)-149 and synthesis of teuclatriol 
Using our one-pot strategy demonstrated that racemic -chiral aldehydes (±)-154 are resolved 
allowing the one-step construction of cyclopent-2-enones 156 with 4-contiguous stereocenters. 
Extending the stereochemical model to -chiral aldehydes (±)-154 suggests that 155 is favored over 
(epi)-155: By placing the smallest substituent (hydrogen) on the -center axial to minimize 1,3-
interactions with the cyclopentanone moiety allows RL in 156 to orient away from the chair 
conformation, being most favorable to trigger the elimination of Boc-OH (Scheme 30). 
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Scheme 30: Stereochemical model for the remote 1,4-stereocontrol of the –OBoc group with achiral 
aldehydes. 
As depicted in the retrosynthetic analysis of 72 (Scheme 28), the guaiane core 145 could be obtained 
from aldol adduct 146. Reacting (R)-125, isopropenyl magnesiumbromide and aldehyde (±)-148 gave 
aldol adduct 146 in 68% yield and with >99% ee and. With this compound 146 in our hand, we 
further proceeded towards the teuclatriol 72 (Scheme 31). 
                                
Scheme 31: Kinetic resolution of aldehyde (±)-148 by using enantiopure (R)-125. 
With this compound 146 in our hand, we further proceeded towards the teuclatriol 72. Ring closing 
metathesis (92% yield) gave rise to 157 followed by selective reduction of its -unsaturated double 
bond using Ph2SiH2  in the presence of Pd(TPP)4 afforded 145 in 80% yield.105 The alcohol function in 
the resulting 145 was protected by reaction with TESCl to yield 158 in 88%.106 Regio and 
stereoselective methylation of 158 by MeLi, CeCl3 in THF at -78 oC followed by deprotection with 
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TBAF107, 108 afforded diol 144 in 76% yield. The final step in our synthesis was hydration of the alkene 
double bond to a tertiary alcohol at C-10. Initially, oxymercuration-deoxymercuration109 on 144 was 
applied, however compound 72 was obtained low yield and accompanied with undesired side 
products. Gratifyingly, cobalt-catalyzed hydration in the presence of PhSiH3 and oxygen110,111 
afforded teuclatriol 72 in 52% yield along with 10-epi teuclatriol 159 in 20% yield (Scheme 32).  
 
Scheme 32: End game for teuclatriol. 
The spectroscopic data (1H NMR, 13C NMR, UV and HRMS) and optical rotation were in accordance 
with literature.46  
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Table 10. 1H and 13C NMR chemical shift comparison of synthetic and natural (-)-teuclatriol. 
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Table 11. 1H and 13C NMR chemical shift comparison of synthetic and natural (–)-10 epi-teuclatriol. 
 
 
 
 
 
 
 
 
 
 
 
2.5 Studies towards Kadsuguain-A 
Kadsuguian-A 75 is a guaianesesquiterpene, which was isolated from piper kadsura.43 Based on our 
previous synthesis of 78, we assume that an intermediate 145 could be useful starting material for 
the synthesis of C-7 epimer of (ent)-75. Reaction of 145 with Co (acac)2 and PhSiH3 in the presence of 
oxygen gave 160 in 72% yield. We expected that the newly formed C10-OH would be in anti position 
to the C1-H. Unfortunately, we have observed the newly formed C10-OH group was in syn to the C1-
H. Based on the proposed mechanism (scheme 33b),110 we thought that the intermediate 
peroxocobalt complex reacts with alkene from the less hindered side and form 145a, which provides 
us 160 as a major compound. The next step of our synthesis was the introduction of an exo-
methylene group in 160. Wittig methylenation,112,113 gave the expected product 161 only in low yield. 
Selective methylenation in the presence of TiCl4 and magnesium in DCM/THF mixture afforded the 
desired target 161 in 62% yield (Scheme 33a).114 However, the newly synthesized molecule 161 
showed a different configuration at C7 and C10 positions with respect to (ent)-75.  
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Scheme 33: Synthesis of isomer of Kadsuguain-A. 
3. Studies towards the orientalol-F 78 and englerin-A 79 
3.1 Isolation and bioactivity 
Guaianes are representatives of the largest group among naturally occurring sesquiterpenes.115 
Orientalol-F 78 is an oxo-bridged guaianesesquiterpene isolated from Alismaorientalis JUZEP and has 
been widely cultivated in China and Japan; its dried rhizomes have been used as folk medicines to 
treat diabetes. Another oxo-bridged guaianesesquiterpene is englerin-A 79, which was isolated from 
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phyllanthusengleri in Zimbabwe and Tanzania region. It showed a 1000-fold selectivity against six of 
eight renal cancer cell lines with IC50 values 1-87 nM. The C-9 glycolate ester moiety is important for 
the anti-cancer activity for the engelrin-A,116 because the glycolic acid is well known metabolite of 
ethylene glycol that causes acute renal toxicity in mammals (Fig 5). 
                                         
Figure 5: Structure of orientalol-F 78 and englerin-A 79. 
3.2 Retro synthetic analysis 
As depicted in scheme 34, we envisioned that the mercuric salt 162 could be the common 
intermediate for the targets 78 and 79. 78 could be obtained from 162 through reductive 
demercuration, followed by inversion of C9-OH.  
            
Scheme 34: Retrosynthetic analysis of orientalol-F 78 and englerin-A 79. 
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162 was expected to arise from 163 by allylation, RCM117 and subsequent oxymercuration.  Ketone 
163 might be accessed from an unsaturated aldehyde 164 by umpolung method. Aldehyde 164 could 
be assembled from enone 165 through the selective reduction of -unsaturated double bond, 
methylation and subsequent oxidation.  
3.3 Previous reports for orientalol-F and englerin-A 
Up to date only two groups have reported the synthesis of the orientalol-F. In 2009, Echavarren et al. 
reported the first synthesis of oriental-F 78 from 166 by gold-catalyzed cycloaddition of 
functionalized ketoenynes.118 In 2012, Wang et al. achieved the synthesis of 78 from 167 and 168 by 
4+3 cycloaddition119 catalyzed by a proline derivative in the key step (Scheme 35). 
 
Scheme 35: Previous reports for Orientalol-F. 
Based on its strong bioactivity against renal cancer cell lines many groups focused on the synthesis of 
79. In 2009 M. Christmann et al. reported the first synthesis of 79 from commercially available 
nepatalactone 169 in 15 steps and found that the assignment of the absolute stereochemistry in 
naturally occurring 79 has been wrong.120 In 2010, D. Ma et al. and Echavarren et al. achieved the 
synthesis of 79 by gold catalyzed cyclization of enynes as key step from 109 and 170.70,121 Notably the 
synthesis developed by D. Ma is protecting group free. In the same year, Nicolaou et al. reported the 
synthesis of 79 in 25 steps from 171.122 
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Scheme 36: Previous reports for Englerin-A. 
The synthesis of W. J. Chain et al. (2012)123 feuters SmI2 mediated reductive cyclization between 172 
and 173 as key step and K. Takahshi et al.(2012)124 showcase CrCl2 catalyzed enantio selective Barbier 
allylation125 as key step for 79. Moreover, P.Metz et al. (2013),126 and J. Zhang et al. (2014)127 also 
synthesized 79 starting from 176 and 177 (Scheme 36). 
B. Main Part 
   
55 
 
3.4 Towards the construction of guaiane core structure of 78 and 79 
3.4.1 Synthesis of aldehyde 164 
The total synthesis of 78 and 79, began by subjecting (S)-134, isopropenyl magnesiumbromide and 
formaldehyde to the conditions developed for our one-pot operation to cyclopentenones, giving rise 
165 in 66% yield as a single stereoisomer (Scheme 37). 
                                         
Scheme 37: Synthesis of enone 165 by using one pot strategy on (S)-134.    
The next step of our synthesis consisted of the selective reduction of the unsaturated double 
bond in 165. The combination of catalytic amounts of ZnCl2 and to the Pd(TPP)4 in the presence of 
stoichiometric amounts of a hydride source has proved to be efficient in conjugate reductions of  
-unsaturated double bonds.105,151,152 First Bu3SnH was tried as hydride source, however no 
reduction was observed at room temperature after 24 h.128 In contrast, Ph2SiH2 as hydride source 
furnished 178 in 75% yield after 30 minutes at room temperature (Scheme 38).105 
                                 
Scheme 38: Selective reduction of unsaturated double bond in 165. 
As the next step, the chemo selective methylation of 178 by MeLi, CeCl3 in THF at -78 oC was carried 
out to afford syn-diol 179a in 70% and anti-diol 179b in 15% (Scheme 39). 
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Scheme 39: Synthesis of diol 179a by using MeCeCl2. 
Next, we planned to do an oxidation of the primary alcohol on syn-179a followed by dehydration to 
arrive at aldehyde 164. When compound 179a was subjected to the conditions of the Dess-Martin 
oxidation129 aldehyde 180 was obtained in 90% yield, which could be dehydrated to 164 in 55% yield 
in the presence of MsCl, Et3N and DMAP. Alternatively, oxidation of 179a under the conditions of a 
Swern oxidation131 directly furnished 164130 in 54% yield. On the other hand, 179b under the Swern 
conditions furnished epi-180 in low yield (Scheme 40).  
       
          
Scheme 40: Synthesis of aldehyde 164. 
3.4.2 Umpolung strategy 
Umpolung is known as a chemical modification of a functional group with reversal of polarity, a 
concept that was developed D. Seebach and E. J. Corey.132 It is a very important tool for the 
generation of carbanion synthons. A well-known Umpolung reagent in organic synthesis is the 
cyanide ion. For example, cyanide is a key catalyst in the benzoin condensation.133 The net result in a 
benzoin condensation is that a bond is formed between two carbons that are normally electrophiles. 
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Moreover, dithiane chemistry is a classic example for Umpolung reaction. In aldehyde compounds, 
the carbonyl carbon behaves as an electrophile and oxygen behave like nucleophile, but if the 
aldehyde is converted to a 1,3-dithiane the polarity can be reversed by deprotanation, thus a 
carbanion synthon can be generated (Scheme 41). 
                     
Scheme 41: General Umpolung strategy in organic synthesis for the generation of carbanion 
synthons. 
The next steps in our synthesis are concerned with the construction of the guaiane core structure 
being present in 78 and 79. The reaction of aldehyde 164 with isopropyl dithiane (Umpolung 
synthon) in the presence of n-BuLi at -78 oC furnished 187 in 95% yield with 9:1 ratio.134 Exposure of 
allylalcohol 187 to the conditions of deprotection (NCS, AgNO3 in 9:1 (MeCN:H2O)) gave hydroxyl 
ketone 163 in 75% yield (Scheme 42).135    
 
Scheme 42: Synthesis of 163 by Umpolung. 
The next aim was to achieve the stereoselective allylation of 163 followed by RCM. Barbier-type 
allylation of 163 with allyl bromide in the presence of zinc in DMF did not give the desired product 
after 24 h.136 However, when allyl magnesiumbromide as an allylating agent at 0 oC was employed, 
diol 188 was obtained in 78% yield as a single diastereomer,137 we thought that the presence of the 
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-hydroxy group in 163 favors the addition of Grignard reagent through the 163a, which provides us 
188 as a major diastereomer. With 188 hand, the cyclization to obtain 189 was investigated. During 
the past decade, ring-closing metathesis developed as a powerful tool for the formation of carbon-
carbon bonds with concurrent cyclization.138 Which has been utilized for the synthesis of complex 
natural products. Reaction of diol 188 with Grubbs-II catalyst in DCM, after 3 h at refluxed 
temperature gave guaiane core 189 in 92% yield (Scheme 43). 
 
Scheme 43: Synthesis of guaiane core compound 189. 
3.4.3 Construction of oxo-bridge ring 
Having the guaiane core compound 189 in hand, the next aim was the construction of the oxo-bridge 
ring to complete the synthesis of 78 and 79. Phenyl seleniumchloride was investigated to initiate the 
desired intramolecular cyclization.139-141 Subjecting 189 to the PhSeCl and K2CO3 in DCM afforded the 
corresponding cyclized selenide compound 190 in 65% yield,142 which was used directly for the next 
elimination step. NaIO4 in MeOH-H2O and H2O2 in THF were tested for the elimination of the PhSe- 
group in 190. However, both of these procedures failed to produce compound 191 (Scheme 44). 
143,144 
                
Scheme 44: Formation oxo-bridge core in 189 by using selenide chemistry. 
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As an alternative, we turned our focus to an oxymercuration-deoxymercuration sequence. Reaction 
of compound 189 with Hg (OAc)2 in DCM followed by treatment with aq. NaCl solution gave organo-
mercuric compound 162 which was not further purified but directly subjected to the reduction with 
NaBH4 at -78 oC in methanol to give rise to epi-orientalol-F 192 in 62% yield (over 2 steps). 
Alternatively, 162 could be converted to 193 by oxidation with NaBH4, O2 (bubbling) in DMF in 58% 
yield over two steps (Scheme 45).145  
 
Scheme 45: Formation oxo-bridge core in 189 by oxymercuration method. 
3.5 The end game for orientalol-F 78 and englerin-A 79 
192 was oxidized with Dess-Martin reagent to give  enone 194 in quantitative yield after 1 h at room 
temperature. Luche reduction146,147 (NaBH4, CeCl3.7H2O) reduction of 194 the afforded final molecule 
orientalol-F 78 in 94% yield as a single stereoisomer (Scheme 46a).  Alternatively, 193 was oxidized 
with Dess-Martin reagent followed by reduction with NaBH4 in MeOH (72% over 2 steps) to give rise 
to 196 as a single stereoisomer. We thought that the oxo-bridge ring might form complex with 
intermediate borane (BH4-), which favors the attack of hydride nucleophile from the same side and 
leads to 78 and 196 as a majors. The diol-196 is known intermediate for englerin-A 7970 (Scheme 
46b). 
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Scheme 46: End game for orientalol-F and englerin-A. 
The spectroscopic data (1H NMR, 13C NMR, UV and HRMS) and optical rotation were in accordance 
with literature.48 In order to unambiguously prove the correct relative and absolute stereochemistry 
of (+)-orientalol-F 78 according to our synthetic route, a X-ray crystal structure was desired. Since 
orientalol-F 78 was obtained only as pale yellow oil, we synthesized a derivative, i.e. epoxy-
orientalol-F 197 by treatment of 78 with m-CPBA in dry DCM at 0 oC in 88% yield,148 which upon 
recrystallization from heptane afforded crystals suitable for X-ray analysis (Scheme 47). 
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Scheme 47: Synthesis of epoxy-orientalol-F 197 for X-ray analysis. 
One-pot reactions are especially efficient method to rapidly achieve several transformations with the 
necessity for work-up and purification, which minimizes the generation of chemical waste and safes 
time. Our previous described individual steps showed only the desired transformations as clean spot-
to-spot reactions on TLC. We therefore investigated if the guaiane core 192 or 193 can be 
constructed enroute to 78 and 79 from 163 without isolation of any intermediates. We started our 
one pot operation with allylation of 163 by using allylmagnesium bromide (1.5 equiv.) at 0 oC (the 
excess Grignard reagent was quenched by stirring the reaction in the open air).  
                   
Scheme 48: Pot economy for 192 and 193. 
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After 1.5 h the solvent was removed under reduced pressure, the crude was directly used for ring 
closing metathesis reaction with Grubbs-II catalyst in DCM in the same flask. After 3 h of reflux, 
Hg(OAc)2 was added at room temperature to the same flask without evaporation of solvent. After 15 
h at room temperature the reaction was quenched with aq. NaCl, yield in 162 (cf. Scheme 45) as 
crude product. In different reaction pots, 162 was done converted to 192 and 193 as described 
above. Overall 192 was obtained in 45% yield (over 4 steps starting from 163) and 193 was obtained  
in 40% yield (over 4 steps starting from 162) (Scheme 48). 
3.6 Other efforts for 78 and 79 
With the successful synthesis of orientaol-F 78 (total synthesis) and englerin-A 79 (formal synthesis), 
we next turned our focus to different aldehydes for trapping the intermediate enolate that is 
generated after nucleophile addition to (R)-125, which would provide alternative intermediates that 
might be useful towards the target molecules 78 and 79.  
                            
Scheme 49: Synthesis of 199. 
We began this study with the synthesis of 199. We subjected compound (R)-125, isopropenyl 
magnesium bromide and 198 to our one pot conditions, giving rise to aldol adduct 199 in 80% yield 
(Scheme 49). The next step of our synthesis was the selective reduction of the unsaturated 
double bond in 199. However, 199 possessing an allylic alcohol functionality gave 200 only in low 
yield under various reduction conditions with Pd (TPP)4. It was thought that the presence of the 
allylic –OH system, which is very reactive towards the Pd (0) catalysts and forms Pd-allyl type 
complex 201, interferes with the desired double bond reduction. Raney-Ni exhibits a good selectivity 
towards conjugate reduction of unsaturated double bonds in THF.149 However, with 199 as 
substrate we observed no conversion after 24h at room temperature. Another alternative is the, 
Lewis acid catalyzed selective reduction of unsaturated double bonds.150 Attempts to convert 
199 to 200 by an InCl3 catalyzed process with NaBH4 as stoichiometric reductant was also met with 
no success (Scheme 50).151 
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Scheme 50: Selective reduction of -unsaturated double bond in 199. 
We therefore planned to protect the allylic alcohol double bond in 199 to prevent a reaction with 
Pd(0). We synthesized compound 202 from 199 using m-CPBA in DCM at 0 oC.152 Subsequent reaction 
with Pd(TPP)4, Ph2SiH2 in the presence of ZnCl2 gave 203 in only 26% yield (Scheme 51a). Then we 
switched to protect free hydroxyl group in 199. We treated compound 199 with TESCl giving rise to 
204. Subsequent treatment with Pd(TPP)4, Ph2SiH2 and ZnCl2 resulted on in decomposition of 204 
after 30 min at room temperature (Scheme 51b). 
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Scheme 51: Selective reduction of unsaturated bond in derivatives of 199. 
Addition of nucleophile to the unsaturated system in the presence of Cu (I) salts affords 1,4-
addition products.153-155 Copper hydrides however are not readily accessible. CuI catalyzed selective 
1, 4- addition of hydride to the unsaturated system in the presence of LiAlH4 is known. We 
subjected therefore, compound 199 to the combination of CuI and LiAlH4 in a mixture of DMPU156: 
THF at -78 oC, yielding the desired 200 in 82 % yield after 3 h (Scheme 52). 
                          
 Scheme 52: Selective reduction of -unsaturated double bond in 199 with copper hydride. 
We next converted 200 to the methylated compound 205 with MeLi in the presence of CeCl3 at -78 
oC, which was obtained as a syn/anti mixture (2:3). The epoxide 206 was obatined from syn-205 by 
epoxidation with m-CPBA in 80% yield. For the final rearrangement of epoxide to the ketone 207, we 
planned to use an acid catalyzed rearrangement. We treated epoxide 206 with BF3.Et2O in DCM, 
which resulted in decomposition after 30 min at 0 oC157 and also applying TfOH in DCM gave no 
better results.158 Keto group formation could not be observed even after longer reaction time in both 
cases (Scheme 53). 
B. Main Part 
   
65 
 
 
 
Scheme 53: Towards 78 and 79. 
Having been unsuccessful to convert of 206 into 207, we turned our focus to use aldehyde 210, 
which is similar to the aldehyde 148 (with -hydroxy group). As we have shown in our retrosynthetic 
analysis (Scheme 54a), compound 208 could be a useful intermediate for the construction oxo-
bridged guaiane core of 78 by using ring-closing metathesis, which can then be used for the synthesis 
of 78 and 79. 208 was expected to arise from (R)-125, isopropenyl magnesiumbromide and aldehyde 
210. Aldehyde 210 synthesized from commercially available methyl isopropyl ketone 211. Silyl enol 
ether 212 was obtained from 211 by treatment with LDA followed by trapping the intermediate 
enolate with TMSCl in 70% yield.159 This was used directly for the Rubottom oxidation160,161 with m-
CPBA affording 213 in 80% yield. 213 was converted to 210 by allylation with allyl 
magnesiumbromide (75% yield) followed by Swern oxidation (70% yield). 210 was found to be very 
stable at room temperature (Scheme 54b). The reaction of (R)-125, isopropenyl magnesiumbromide 
and aldehyde 210 according to our one-pot protocol gave the desired compound 215, albeit in very 
low yield (10%). We thought that the protonation of the intermediate enolate might retard the 
formation of desired product in reasonable yield. Using the TES protected aldehyde 216 however 
gave also no conversion after 2 h at -78 oC (Scheme 54b).   
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Scheme 54: a) Retrosynthetic analysis of orientalol-F. b) Synthesis of aldehyde 210 and aldol adduct 
209. 
4. Studies towards the synthesis of pseudoguaianolide core structure  
Based on SAR studies it has been shown that almost all known bioactive pseudoguaianolides possess 
an -unsaturated lactone ring with an exomethylene group. This unsaturated lactone moiety 
enhances the cytotoxicity. The high toxicity can be attributed to the inhibition of DNA synthesis.162 
Based on this bioactivity we tried to construct pseudoguaianolide core structure for our building 
block by using our one pot strategy. 
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Scheme 55: Retrosynthetic analysis for pseudoguaianolide core. 
As outlined in scheme 55, aldehyde 220 was required for the construction of pseudoguaianolide core 
structure 217. Before that, we first used known literature aldehyde 221163 for the trapping of the 
intermediate enolate that is formed after Grignard addition to (R)-125. We subjected compound (R)-
125, isopropenyl magnesiumbromide and aldehyde 221 to the one-pot protocol to produce aldol 
adduct 222 in 62% yield. In the next step, we used Grubbs-II catalyzed ring closing metathesis to 
produce the unnatural pseudoguaianolide core structure 223, having a 8-membered ring, in 45% 
yield (Scheme 56). However, the newly formed 223 was showed cyctotoxicity against RAW264 cell 
lines with 240 µM.  
               
Scheme 56: Synthesis of unnatural pseudoguaianolide core structure 222. 
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Table 12: Anti-inflammatory activity of 223. 
  
inhibition of NO production [%] 
compound 
MTT 
IC50 [µM] 
minimum  
(conc [µM]) 
maximum (conc 
[µM]) 
 
208.6 ± 11.7 44.8 ± 2.9 (25) 78.8 ± 6.6 (50) 
 
           
We next, focused on the construction of 217 with aldehyde 220. As outlined in Scheme 55, the core 
structure 217 could be obtained from an aldol adduct 218, which we can easily achieved from 
compound (R)-125, aldehyde 220 and isopropenyl magnesiumbromide. Aldehyde 220 can be easily 
accessed from aldehyde 221 by treatment with Grubbs-II catalyst and MeOH as solvent.164 We used 
(R)-125, isopropenyl magnesiumbromide and aldehyde 220 to our one-pot protocol gave aldol 
adduct 218 in 64% yield. After successive ring closing metathesis with Grubbs-II catalyst afforded the 
natural pseudoguaianolide core structure 217 in 84% yield (Scheme 57). 
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Scheme 57: Synthesis of pseudoguaianolide core structure. 
With compound 218 in hand, we planned to synthesize anti-inflammatory drug 80. We began our 
studies with selective reduction of -unsaturated double bond in 218. We first focused on Pd 
(TPP)4 catalyzed selective reduction of -unsaturated double bond in 218 in the presence of 
Ph2SiH2 as hydride source and obtained desired product 224 in very low yield. When we switched to 
Bu3SnH under the above conditions, it gave decomposition after 1 h at room temperature. It was 
thought that the presence of allylic lactone system, which is very reactive towards the Pd (0) 
catalysts and forms Pd-allyl type complex 225. This may retard the attack of Pd (0) to the -
unsaturated system (Scheme 58).  
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Scheme 58: Selective reduction of -unsaturated double bond in 217. 
Raney-Ni catalyzed selective conjugate reduction of unsaturated double bond in THF was met 
with no success. We next focused on copper hydride for selective reduction of unsaturated 
double bond in 218. When we subjected, compound 218 to the CuI and LiAlH4 in the mixture of 
DMPU: THF at -78 oC, the 1,4-adduct 224 was obtained in 80 % yield after 3 h (Scheme 58). After 
successful reduction of the unsaturated double bond in 218, we directly applied Grubbs-II catalyzed 
ring closing metathesis to 224 in toluene at refluxed temperature to give rise to the 
pseudoguaianolide core structure 226 in 85% yield. 226 furnished 227 with TESCl and imidazole in 
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94% yield, and was then envisioned to be used for a stereoselective methylation to produce 228. 
Unfortunately, all attempts of this methylation faield. When we applied methylation conditions 
(MeLi, THF, -78 oC, 4 h and MeLi, CeCl3, -78 oC, 8 h), it gave many undesired spots on TLC (Scheme 
59).  
 
Scheme 59: Synthetic route to the 80. 
5. Conclusion 
In conclusion, the readily available (R)-125 and (S)-134 allow the stereoselective synthesis of (+)-133 
and (-)-133 with excellent selectivity and operational simplicity without using any harsh conditions, 
allowing the rapid assembly of natural scaffolds with complex architecture. The methodology 
described here offers a versatile approach for asymmetric synthesis of simple to complex various 
cyclopentanoid bioactive molecules. The first synthesis of (-)-teuclatriol 72 was achieved with 20% 
overall yield. This method allows the facile access to get guaiane and pseudoguaianolide core 
structures without using any protecting groups. On the other hand, with this method we have 
successfully finished total synthesis of (+)-orientalol-F 78 and formal synthesis of englerin-A 79 from 
our building block (R)-125.    
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C. Summary 
In the first chapter, an application for (R)-125 and (S)-134 on the basis of copper(I)-catalyzed 
Grignard additions followed by trapping of the resulting intermediate enolate with aldehydes were 
investigated. Adducts (+)-133 and (-)-133 could be synthesized from (R)-125 and (S)-134 in a facile 
procedure with a decent yields (Scheme 60).  
 
Scheme 60: Over view of (+)-133, (-)-133 and prostaglandin derivativies. 
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Excellent diastereo and enantioselectivities were obtained for adducts (+)-133a-x and (-)-133 a-r. The 
scope of participating Grignard reagents and aldehydes is very broad: aliphatic, aromatic and alkenyl 
organomagnesium compounds could be applied. This method provides a potentially useful access to 
a variety of bioactive cyclopentanoid prostaglandin derivatives such as TEI-9826 3, compound 2, 141 
and 143 (Scheme 60).   
In the second chapter, a successful synthesis of teuclatriol 72 from (R)-125 has been demonstrated. 
The key steps involved, were a one-pot construction of cyclopent-2-enone 146 with 4 contiguous 
stereo centers, ring-closing metathesis, selective reduction of a ,-unsaturated bond and 
subsequent chemoselective methylation.   The first synthesis of (-)-teuclatriol 72 was achieved with 
26% overall yield in six steps (Scheme 61).  
                                                                           
                                               
 
 
Scheme 61: Synthesis of 72. 
In the third chapter, a successful total synthesis of orientalol-F 78 from (S)-134 has been 
demonstrated. The key steps involved were a, one-pot construction of 165, an Umpolung, ring-
closing metathesis and subsequent formation of an oxo-bridge ring by oxymercuration. Compound 
162 furnished diol 196, which is a known intermediate for englerin-A 79 (Scheme 62).  
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Scheme 62: Synthesis of 78 and 79. 
Moreover, different aldehydes have been used for trapping the intermediate enolate that is 
generated after nucleophile addition to (R)-125, which would provide alternative intermediates that 
might be useful towards the target molecules 78 and 79. A study of a one-pot economy was carried 
out on 163 to get directly the desired 192 and 193 without isolation and purification of intermediates 
(Scheme 63). 
Scheme 63: Overview of one pot operation on 163. 
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In the fourth chapter, a successful construction of a pseudoguaianolide core structure 217 has been 
demonstrated.  
 
Scheme 64: Synthesis of 217 and 223. 
In this synthesis, the new aldehyde 220 was synthesized from known aldehyde 221 via Grubbs-II 
catalyst. Later, selective reduction of the ,-unsaturated bond was carried out on compound 218, 
which could be a useful intermediate for compound 80. Moreover, the synthesis of unnatural 
pseudoguaianolide core structure 223 and its bioactivity has been demonstrated (Scheme64).  
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D. Experimental Part 
1. General 
1H-NMR-Spectra were recorded on Bruker Avance 300, Bruker Avance 400, Bruker Avance 600, 
Varian Inova 600, Bruker DRX-400 with a H/C/P/F QNP gradient probe and Bruker Avance 500 with a 
dual carbon/proton CPDUL cryoprobe. The chemical shift is given in [ppm], calibration is set on 
chloroform-d1 (7.26 ppm). The spectra were evaluated in 1st order and the coupling constants are 
given in Herth [Hz]. The following abbreviations for the spin multiplicity were used: s = singlet, d = 
doublet, t = triplet, q = quartet, qt = quintet, m = multiplet, dd = doublet of doublet, dt = doublet of 
triplet, ddd = doublet of double doublet, sept = septet. The sued deuterated solvents are given 
separately. 
13C-NMR-Spectra were recorded on Bruker Avance 300, Bruker Avance 400, Bruker Avance 600, 
Varian Inova 600, Bruker DRX-400 with a H/C/P/F QNP gradient probe and Bruker Avance 500 with a 
dual carbon/proton CPDUL cryoprobe. The chemical shift is given in [ppm], calibration is set on 
chloroform-d1 (77.16 ppm). The multiplicity of signals were detected by DEPT 135 and 90 (DEPT- 
Distortionless Enhancement by Polarization Transfer) and are given as: + = primary and tertiary C-
atom (positive DEPT 135 signal; tertiary C-atom: DEPT 90 signal), - = secondary C-atom (negative 
DEPT 135 signal), Cq = quaternary C-atom (DEPT-signal intensity zero). 
Melting points were measured on a Büchi SMP-20 in a silicon oil bath. The melting points are 
uncorrected.   
Infrared-Spectra were recorded on a Bio-Rad Excalibur Series or Mattson Genesis Series FT-IR. Solid 
compounds were measured in KBr film, liquid compounds as a neat film between NaCl-plates. The 
wave numbers are given in [cm-1]. 
Masspectrometry was performed on a Varian MAT 311A, Finnigan MAT 95, Thermoquest Finnigan 
TSQ 7000, Nermag quadrupoles, VG-ZAB high resolution double focusing and VG Autospec-Q tandem 
hybrid with EBEqQ configuration. The percentage set in brackets gives the peak intensity related to 
the basic peak (I=100%). High Resolution Mass Spectrometry HRMS: The molecular formula was 
proven by the calculated precise mass. 
Elemental Analysis was prepared by the micro analytic section University of Regensburg using a 
Vario EL III or Mikro-Rapid CHN (Heraeus). 
D. Experimental Part 
   
77 
 
Optical rotation was measured at room temperature on a 241 MC Perkin-Elmer polarimeter at a 
wavelength of 589 nm (Na-D) in a 1 dm or 0.1 dm cell. The concentration is given in (g/100 mL). 
X-ray analysis was performed by the crystallography laboratory of the University of Regensburg 
(STOE-IPDS, Stoe & Cie GmbH). 
Chiral High Performance Liquid Chromatography was carried out using. Column: LabID 80/ Daicel 
Chemical Industries LTD./ CHIRALCEL (OD-H) (Lot No. ODH0CE-GB060)/ Cellulose tris (3,5-di 
methylphenyl carbamate) / coated on 5 m silica gel/ 250 mm x 4.6 mm ID/ part DAIC 14325 and 
CHIRALCEL OJ-H, 4.6 x 250 mm, 10 µm. LC system: Agilent 1100/3: DAD G1315B 
[DE03010828]/COLCOM G1316A [DE14925491] / ALS G1313A [DE23922434] / BIN pump GG1312A 
[DE43618259]/ HP 1050 DEGASSER. 
Thin Layer Chromatography (TLC) was prepared on TLC- aluminium sheets (Merck, silica gel 60 F254, 
0.2 mm). Detection in UV-light λ = 254 nm, staining with Iodine, Mostain, molybdatophosphoric acid 
(5% in ethanol), KMnO4 solution and vanillin-sulfuric acid. 
Ozone-Generator For ozone generation a Fischer process technology ozone generator OZ 500 MM 
was used, supplied by an oxygen tank. 
Solvents Absolute solvents were prepared according to usual lab procedures or taken from MB-SPS 
solvent purification system. EtOAc, Hexances and DCM were purified ny distillation before used. 
Further solvents and reagents were p.a. quality. Reaction with oxygen- and moisture sensitive 
reactants was performed in oven dried and in vacuo heated reaction flasks under pre-dried inert gas 
(nitrogen or argon) atmosphere. For cooling temperatures <-78 oC dry ice/acetone mixture was used.  
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2. Procedure for the synthesis of (R)-125 and (S)-134 in 50 gram scale: 
                              
 To a solution of 4-hydroxy-2-cyclopentenone (±)-136 (36.76 g, 375 mmol) and Boc2O (98.21 g, 450 
mmol) in THF (375 mL) were added triethylamine (63 mL, 450 mmol) and DMAP (0.75 g). After the 
reaction mixture was stirred at room temperature for 30 min, the solvent was removed under 
reduced pressure. After purification on silica (hexanes/ EtOAc 5:1) obtained (±)-125 (64.87 g, 87%). 
Physical state: White solid; 
TLC: Rf = 0.33 (hexanes/ EtOAc 9:1, UV-active, stains dark brown with vanillin); 
M.P= 39 oC; 
 1H NMR (300 MHz, CDCl3): δ 7.60 (dd, J = 5.7, 2.4 Hz, 1H), 6.33 (dd, J = 5.7, 1.3 Hz, 1H), 5.71 (ddt, J = 
3.6, 2.3, 1.8 Hz, 1H), 2.84 (dd, J = 18.7, 6.4 Hz, 1H), 2.40 (dd, J = 18.7, 2.2 Hz, 1H), 1.51 (s, 9H); 
13C NMR (75 MHz, CDCl3): δ = 204.6, 158.6, 152.7, 137.2, 83.3, 74.2, 41.0, 27.8, 27.8, 27.8; 
IR (neat) (cm-1) max : 1730, 1716; 
HRMS (m/z): calcd for C10H14O4 (M.+) 198.0892 , found 198.0896. 
 
 
 
 
Under nitrogen atmosphere to a solution of (±)-125 (50.00 g, 252.52 mmol, 2.0 equiv) 137 (15.67 g, 
126.26 mmol, 1.0 equiv) and Cs2CO3 (12.17 g, 37.37 mmol, 0.296 equiv) in DCM (1000 mL) at 0 oC was 
added the catalyst solution, being separately prepared by stirring Pd2(dba)3.CHCl3 (1.31 g, 1.262 
mmol, 1 mol% Pd based on 137) and ligand (R,R)-127 (3.07 g, 4.44 mmol, 0.035 equiv) in DCM (500 
mL) until the initially purple solution turned yellow-brown (4-5 min). After 2.5 h of stirring at 0 oC, 
D. Experimental Part 
   
79 
 
solvent was removed under reduced pressure. After purification on silica (hexanes/ EtOAc 7:1 to 3:1) 
(R)-125 (21.00 g, 42%, >99% ee) and (S)-134 (24.75g, 48%, > 92% ee) were obtained. 
Compound (R)-125:  
Physical state: brown oil; 
TLC: Rf = 0.33 (hexanes/ EtOAc 9:1, UV-active, stains dark brown with vanillin); 
 = 94 (c 1.1, CHCl3); 
 1H NMR (300 MHz, CDCl3): δ 7.60 (dd, J = 5.7, 2.4 Hz, 1H), 6.33 (dd, J = 5.7, 1.3 Hz, 1H), 5.71 (ddt, J = 
3.6, 2.3, 1.8 Hz, 1H), 2.84 (dd, J = 18.7, 6.4 Hz, 1H), 2.40 (dd, J = 18.7, 2.2 Hz, 1H), 1.51 (s, 9H); 
13C NMR (75 MHz, CDCl3): δ = 204.6, 158.6, 152.7, 137.2, 83.3, 74.2, 41.0, 27.8, 27.8, 27.8; 
IR (neat) (cm-1) max : 1730, 1716; 
HRMS (m/z): calcd for C10H14O4 (M.+) 198.0892 , found 198.0896. 
Compound (S)-134:  
Physical state: pale brown color solid; 
TLC: Rf = 0.43 (hexanes/ EtOAc 3:1, UV-active, stains dark green with vanillin); 
M.P. = 64 oC; 
 = 8.62 (c 1.00, CHCl3); 
 1H NMR (300 MHz, CDCl3): δ = 7.70 (dd, J=5.7, 2.4 Hz, 1H), 6.98 – 6.71 (m, 4H),  6.35 (dd, J=5.7, 1.3 
Hz, 1H), 5.37 (ddd, J=5.8, 3.4, 2.2 Hz, 1H), 3.78 (s, 3H), 2.85 (dd, J=18.4, 6.0 Hz 1H), 2.45 (dd, J=18.4, 
2.2 Hz, 1H); 
13C NMR (75 MHz, CDCl3): δ = 205.28, 159.90, 154.62, 151.31, 136.40, 116.71, 116.71, 114.89, 
114.89, 76.07, 55.72, 41.90; 
IR (neat) (cm-1) max : 1706, 1506, 1353, 1107, 1027, 821; 
HRMS (m/z): calcd for C12H13O3 (M+H)+ 205.0859, found 205.0863. 
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3. Synthesis and characterization of (+)-133. 
                    
 
General Procedure A: To a stirred solution of  CuCN (0.102 g, 1.14 mmol, 3.0 equiv) and anhydrous 
LiCl (0.096g, 2.28 mmol, 6.0 equiv) in THF (4 mL) was added the Grignard reagent (1.14 mmol, 3.0 
equiv) dropwise at –40 oC. The reaction mixture was cooled to –78 oC upon which a solution of (R)-
125 (0.075 g, 0.38 mmol, 1.0 equiv) in THF (1 mL) was added. After 4 min of stirring, aldehyde (0.63 
mmol, 1.68 equiv) was added. After the starting material had disappeared (ca. 5 min, monitored by 
TLC), NH4Claq (5 mL) was added and the reaction mixture was extracted with Et2O (2x10 mL). The 
combined organic extracts were washed with brine (10 mL), dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude was purified by flash chromatography on silica. 
 Compound (+)-133a: The title compound was prepared from (R)-125 (0.075 g, 0.38 
mmol) phenylmagnesium bromide (0.94 M solution in THF, 1.2 mL, 1.14 mmol) and 
hexanal (0.063 g, 0.078 mL, 0.63 mmol) according to the general procedure A. After 
purification on silica (hexanes/ EtOAc 5:1 to 3:1) title compound was obtained in 
72% yield (0.071 g). 
Physical state: pale yellow oil; 
TLC: Rf = 0.31 (hexanes/ EtOAc 5:1, UV-active, stains orange with vanillin); 
: 215.3 (c 0.32, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.62 (dd, J = 5.6, 2.4 Hz, 1H), 7.38 – 7.26 (m, 3H), 7.19 – 7.14 (m, 2H), 
6.29 (dd, J = 5.6, 2.1 Hz, 1H), 3.87 (ddd, J = 7.4, 6.2, 2.4 Hz, 2H), 3.76 (s, 1H), 2.44 (dd, J = 8.2, 2.9 Hz, 
1H), 1.66 – 1.47 (m, 2H), 1.33 – 1.12 (m, 6H), 0.82 (t, J = 6.8 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 212.96, 167.19, 140.52, 132.95, 129.11, 129.11, 127.51, 127.51, 127.51, 
72.24, 59.01, 50.91, 35.26, 31.71, 24.55, 22.58, 14.02; 
IR (neat) (cm-1) max: 3425, 2953, 2931, 2858, 1689, 1590, 1454, 1278, 1179, 1076, 1048, 1030, 757, 
700, 616, 494; 
HRMS (m/z): calcd for C17H22 NaO2 (M+Na)+ 281.1512, found 281.1510. 
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 Compound (+)-133b: The title compound was prepared from (R)-125 (0.075 g, 
0.38 mmol) phenylmagnesium bromide (0.94 M solution in THF, 1.2 mL, 1.14 
mmol) and trans-2-pentenal (0.053 g, 0.062 mL, 0.63 mmol) according to the 
general procedure A. After purification on silica (hexanes/ EtOAc 7:1 to 3:1) 
title compound was obtained in 68% yield (0.063 g). 
Physical state: brown color oil; 
TLC: Rf = 0.28 (hexanes/ EtOAc 5:1, UV-active, stains brown with vanillin); 
: 313.28 (c 0.28, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.64 (dd, J = 5.6, 2.5 Hz, 1H), 7.37 – 7.24 (m, 3H), 7.15 – 7.05 (m, 2H), 
6.30 (dd, J = 5.6, 2.1 Hz, 1H), 5.85 (dt, J = 15.2, 6.1 Hz, 1H), 5.41 – 5.29 (m, 1H), 4.29 (t, J = 8.3 Hz, 1H), 
3.91 – 3.81 (m, 2H), 2.48 (dd, J = 8.6, 2.7 Hz, 1H), 2.13 – 2.00 (m, 2H), 0.97 (t, J = 7.4 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 212.57, 167.37, 140.47, 136.20, 132.89, 128.91, 128.91, 128.80, 127.78, 
127.78, 127.36, 74.29, 59.30, 50.51, 25.06, 12.98; 
IR (neat) (cm-1) max: 3415, 2962, 1689, 1589, 1493, 1454, 1335, 1179, 1030, 969, 897, 758, 699, 533, 
505; 
HRMS (m/z): calcd for C16H18 NaO2 (M+Na)+ 265.1199, found 265.1200. 
 
Compound (+)-133c: The title compound was prepared from (R)-125 (0.075 g, 
0.38 mmol) phenylmagnesium bromide (0.94 M solution in THF, 1.2 mL, 1.14 
mmol) and trans-2-decenal (0.098 g, 0.11 mL, 0.63 mmol) according to the 
general procedure A. After purification on silica (hexanes/ EtOAc 7:1 to 3:1) 
title compound was obtained in 70% yield (0.083 g). 
Physical state: yellow oil; 
TLC: Rf = 0.31 (hexanes/ EtOAc 5:1, UV-active, stains dark red with vanillin); 
: 219.5 (c 0.56, CHCl3); 
1H NMR (600 MHz, CDCl3) δ 7.64 (dd, J = 5.6, 2.5 Hz, 1H), 7.34 – 7.30 (m, 2H), 7.28 – 7.26 (m, 1H), 
7.11 (dd, J = 5.2, 3.3 Hz, 2H), 6.29 (dd, J = 5.6, 2.1 Hz, 1H), 5.83 – 5.77 (m, 1H), 5.38 (ddt, J = 15.3, 7.8, 
1.4 Hz, 1H), 4.30 (t, J = 8.1 Hz, 1H), 3.86 (dd, J = 4.8, 2.4 Hz, 
1H), 2.50 (dd, J = 8.4, 2.7 Hz, 1H), 2.02 (qt, J = 10.8, 4.1 Hz, 2H), 1.34 (ddd, J = 12.0, 4.8, 2.3 Hz, 2H), 
1.32 – 1.23 (m, 9H), 0.88 (t, J = 7.1 Hz, 3H); 
13C NMR (151 MHz, CDCl3) δ 212.32, 167.25, 140.48, 134.83, 132.86, 129.56, 128.89, 128.89, 127.72, 
127.72, 127.32, 74.18, 59.28, 50.43, 32.06, 31.77, 29.22, 29.14, 28.85, 22.65, 14.08; 
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IR (neat) (cm-1) max: 3361, 2926, 2855, 1690, 1511, 1454, 1234, 1036, 827, 700, 637, 537, 497; 
HRMS (m/z): calcd for C21H28 NaO2 (M+Na)+ 335.1982, found 335.1983. 
 
Compound (+)-133d: The title compound was prepared (R)-125 (0.075 g, 
0.38 mmol) phenylmagnesium bromide (0.94 M solution in THF, 1.2 mL, 
1.14 mmol) and 4-methoxy benzaldehyde (0.086 g, 0.076 mL, 0.63 mmol) 
according to the general procedure A. After purification on silica (hexanes/ 
EtOAc 5:1 to 3:1) title compound was obtained in 78% yield (0.087 g). 
Physical state: green color oil; 
TLC: Rf = 0.2 (hexanes/ EtOAc 5:1, UV-active, stains dark brown with vanillin); 
: 242.0 (c 0.53, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.60 (dd, J = 5.6, 2.5 Hz, 1H), 7.23 – 7.16 (m, 2H), 7.17 – 7.06 (m, 3H), 
6.84 – 6.77 (m, 2H), 6.56 – 6.48 (m, 2H), 6.34 (dd, J = 5.6, 2.1 Hz, 1H), 4.74 (d, J = 9.5 Hz, 1H), 4.45 (s, 
1H), 3.80 (s, 3H), 3.67 – 3.59 (m, 1H), 2.66 (dd, J = 9.5, 2.6 Hz, 1H); 
13C NMR (75 MHz, CDCl3) δ 213.03, 167.52, 159.70, 140.05, 133.11, 132.88, 128.58, 128.58, 128.56, 
128.56, 127.16, 127.16, 127.05, 113.81, 113.81, 75.03, 60.91, 55.40, 50.25; 
IR (neat) (cm-1) max: 3445, 2836, 1689, 1612, 1587, 1513, 1454, 1247, 1174, 1031, 833, 701, 635, 
538, 496; 
HRMS (m/z): calcd for C19H18 NaO2 (M+Na)+ 317.1148, found 317.1150. 
 
Compound (+)-133e: The title compound was prepared (R)-125 (0.075 g, 0.38 
mmol) phenylmagnesium bromide (0.94 M solution in THF, 1.2 mL, 1.14 mmol) 
and benzaldehyde (0.067 g, 0.064 mL, 0.63 mmol) according to the general 
procedure A. After purification on silica (hexanes/ EtOAc 5:1 to 3:1) title 
compound was obtained in 72% yield (0.072 g).  
Physical state: white powder; 
TLC: Rf = 0.35 (hexanes/ EtOAc 5:1, UV-active, stains pale brown with vanillin); 
: 235.0 (c 0.16, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.62 (dd, J = 5.6, 2.5 Hz, 1H), 7.30 (d, J = 7.3 Hz, 5H), 7.15 – 7.04 (m, 3H), 
6.49 – 6.41 (m, 2H), 6.36 (dd, J = 5.6, 2.0 Hz, 1H), 4.78 (d, J = 9.5 Hz, 1H), 4.69 – 4.35 (m, 1H), 3.66 (dd, 
J = 4.7, 2.4 Hz, 1H), 2.66 (dd, J = 9.5, 2.6 Hz, 1H); 
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13C NMR (75 MHz, CDCl3) δ 213.05, 167.61, 140.71, 139.92, 132.90, 128.56, 128.56, 128.49, 128.49, 
128.46, 127.41, 127.41, 127.06, 127.06, 127.06, 75.55, 60.76, 50.10; 
IR (neat) (cm-1) max: 3392, 1677, 1590, 1492, 1437, 1340, 1266, 1196, 1034, 902, 853, 796, 752, 695, 
638, 555, 484; 
HRMS (m/z): calcd for C18H16 NaO2 (M+Na)+ 287.1150, found 287.1149. 
 
Compound (+)-133f: The title compound was prepared from (R)-125 (0.075 g, 
0.38 mmol) isopropenylmagnesium bromide (1.0 M solution in THF, 1.14 mL, 1.14 
mmol) and acrolein (0.036 g, 0.042 mL, 0.63 mmol) according to the general 
procedure A. After purification on silica (hexanes/ EtOAc 7:1 to 5:1) title 
compound was obtained in 64% yield (0.043 g). 
Physical state: yellow oil; 
TLC: Rf = 0.57 (hexanes/ EtOAc 3:1, UV-active, stains brown with vanillin); 
: 235.2 (c 0.14, CHCl3); 
1H NMR (300 MHz, d6-Acetone) δ 7.67 (dd, J = 5.7, 2.6 Hz, 1H), 6.14 (dd, J = 5.7, 2.0 Hz, 1H), 5.86 
(ddd, J = 17.1, 10.5, 5.6 Hz, 1H), 5.35 – 5.24 (m, 1H), 5.12 – 5.05 (m, 1H), 4.84 – 4.80 (m, 1H), 4.76 
(dd, J = 1.7, 0.8 Hz, 1H), 4.52 – 4.41 (m, 1H), 4.32 (d, J = 3.6 Hz, 1H), 3.50 (dd, J = 4.3, 2.0 Hz, 1H), 2.40 
(dd, J = 5.3, 2.4 Hz, 1H), 1.79 – 1.75 (m, 3H); 
13C NMR (75 MHz, d6-Acetone) δ 209.55, 167.52, 146.75, 138.73, 134.21, 115.84, 112.45, 73.32, 
57.55, 51.24, 21.30; 
IR (neat) (cm-1) max: 3468, 3390, 2973, 1689, 1645, 1587, 1438, 1378, 1273, 1184, 1052, 992,897, 
785, 667, 535, 495; 
HRMS (m/z): calcd for C11H14NaO2 (M+Na)+ 201.099, found 201.098. 
 
Compound (+)-133g: The title compound was prepared from (R)-125 (0.075 g, 
0.38 mmol) isopropenylmagnesium bromide (1.0 M solution in THF, 1.14 mL, 
1.14 mmol) and trans-2-methyl-2-butenal (0.053 g, 0.06 mL, 0.63 mmol) 
according to the general procedure A. After purification on silica (hexanes/ 
EtOAc 7:1 to 5:1) title compound was obtained in 66% yield (0.052 g). 
Physical state: yellow oil; 
TLC: Rf = 0.62 (hexanes/ EtOAc 3:1, UV-active, stains brown with vanillin); 
: 250.2 (c 0.37, CHCl3); 
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1H NMR (300 MHz, CDCl3) δ 7.47 (dd, J = 5.6, 2.5 Hz, 1H), 6.19 – 6.07 (m, 1H), 5.46 (qt, J = 19.5, 9.7 
Hz, 1H), 4.86 – 4.76 (m, 1H), 4.67 (d, J = 0.7 Hz, 1H), 4.38 (s, 1H), 3.94 (d, J = 10.1 Hz, 1H), 3.13 (q, J = 
2.3 Hz, 1H), 2.38 – 2.24 (m, 1H), 1.59 – 1.54 (m, 6H), 1.53 – 1.49 (m, 3H); 
13C NMR (75 MHz, CDCl3) δ 212.89, 167.14, 141.82, 134.62, 131.78, 122.90, 113.03, 78.41, 51.61, 
50.96, 18.16, 11.99, 9.68; 
IR (neat) (cm-1) max: 3489, 3462, 2916, 1682, 1647, 1586, 1504, 1440, 1410, 1378, 1343, 1261, 1187, 
1026, 943, 898,831, 793, 640, 624, 538, 464; 
HRMS (m/z): calcd for C13H18NaO2 (M+Na)+ 229.1199, found 229.1196. 
Compound (+)-133h: The title compound was prepared from (R)-125 (0.075 
g, 0.38 mmol) isopropenylmagnesium bromide (1.0 M solution in THF, 1.14 
mL, 1.14 mmol) and trans-2-decenal (0.098 g, 0.11 mL, 0.63 mmol) according 
to the general procedure A. After purification on silica (hexanes/ EtOAc 10:1) 
title compound was obtained in 70% yield (0.073 g). 
Physical state: pale yellow oil; 
TLC: Rf = 0.7 (hexanes/ EtOAc 5:1, UV-active, stains brown with vanillin); 
: 121.8 (c 0.71, CHCl3); 
1H NMR (300 MHz, d6-Acetone) δ 7.67 (dd, J = 5.7, 2.6 Hz, 1H), 6.13 (dd, J = 5.7, 2.0 Hz, 1H), 5.75 – 
5.61 (m, 1H), 5.48 (ddt, J = 15.4, 6.5, 1.2 Hz, 1H), 4.86 – 4.80 (m, 1H), 4.75 (dd, J = 1.6, 0.8 Hz, 1H), 
4.39 (dt, J = 9.4, 4.8 Hz, 1H), 3.50 (dd, J = 4.2, 2.0 Hz, 1H), 2.36 (dd, J = 5.5, 2.3 Hz, 1H), 2.07 – 2.02 (m, 
1H), 2.02 – 1.95 (m, 2H), 1.78 – 1.74 (m, 3H), 1.35 – 1.24 (m, 10H), 0.88 (t, J = 6.7 Hz, 3H); 
13C NMR (75 MHz, d6-Acetone): δ 210.00, 167.52, 134.21, 133.03, 130.53, 112.41, 73.33, 57.80, 
51.43, 32.60, 32.84, 29.96, 29.96, 29.78, 29.78, 23.34, 21.32, 14.39. 
IR (neat) (cm-1) max: 3420, 2925, 2855, 1689, 1586, 1510, 1440, 1348, 1233, 1100, 1037, 970, 900, 
826, 632, 537, 497; 
HRMS (m/z): calcd for C18H28NaO2 (M+Na)+ 299.1982, found 299.1984. 
 
Compound (+)-133i: The title compound was prepared from (R)-125 (0.075 
g, 0.38 mmol) isopropenylmagnesium bromide (1.0 M solution in THF, 1.14 
mL, 1.14 mmol) and 4-dimethylamino benzaldehyde (0.095 g, 0.63 mmol) 
according to the general procedure A. After purification on silica (hexanes/ 
EtOAc 5:1) title compound was obtained in 62 % yield (0.064 g). 
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Physical state: yellow colored oil; 
TLC: Rf = 0.13 (hexanes/ EtOAc 5:1, UV-active, stains dark green with vanillin); 
:  170.1 (c 0.6, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.51 (dd, J = 5.6, 2.6 Hz, 1H), 7.23 – 7.16 (m, 2H), 6.73 – 6.64 (m, 2H), 
6.20 (dd, J = 5.6, 2.0 Hz, 1H), 4.59 (dd, J = 5.3, 3.8 Hz, 2H), 4.29 (d, J = 4.1 Hz, 2H), 3.13 (dd, J = 4.4, 2.2 
Hz, 1H), 2.92 (s, 6H), 2.53 (dd, J = 9.2, 2.3 Hz, 1H), 1.34 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 212.90, 168.07, 150.72, 143.64, 132.72, 129.19, 128.02, 128.02, 113.07, 
112.41, 112.41, 75.26, 57.28, 51.57, 40.72, 40.72, 20.17; 
IR (neat) (cm-1) max: 3445, 2968, 2855, 2798, 1685, 1614, 1522, 1444, 1346, 1219, 1185, 1163, 1055, 
944, 899, 814, 739, 538; 
HRMS (m/z): calcd for C17H21NaNO2 (M+Na)+ 294.1572, found 294.1572. 
 
Compound (+)-133j: The title compound was prepared from (R)-125 (0.075 g, 
0.38 mmol) isopropenylmagnesium bromide (1.0 M solution in THF, 1.14 mL, 
1.14 mmol) and pyridine 4-carbaldehyde (0.068 g, 0.06 mL, 0.63 mmol) 
according to the general procedure A. After purification on silica (hexanes/ 
EtOAc 3:1 to 1:1) title compound was obtained in 59% yield (0.052 g). 
Physical state: pale brown coloedr oil; 
TLC: Rf = 0.25 (hexanes/ EtOAc 6:1, UV-active, stains green with vanillin); 
:  198.6 (c 0.18, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 8.53 (d, J = 4.5 Hz, 2H), 7.50 (dd, J = 5.7, 2.6 Hz, 1H), 7.28 (t, J = 5.5 Hz, 
2H), 6.22 (dd, J = 5.7, 2.0 Hz, 1H), 4.79 (d, J = 8.5 Hz, 2H), 4.63 – 4.59 (m, 1H), 4.35 (s, 1H), 3.17 (dd, J 
= 4.7, 2.2 Hz, 1H), 2.52 (dd, J = 8.5, 2.7 Hz, 1H), 1.41 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 211.41, 167.92, 149.97, 149.97, 149.52, 142.40, 132.89, 122.08, 122.08, 
113.84, 74.14, 55.63, 51.29, 19.56; 
IR (neat) (cm-1) max: 3424, 3174, 2358, 2326, 1699, 1603, 1559, 1416, 1271, 1186, 1067, 1003, 906, 
815, 652, 574, 468; 
HRMS (m/z): calcd for C14H15NaNO2 (M+Na)+ 252.1101, found 252.110. 
 
 Compound (+)-133k: The title compound was prepared from (R)-125 (0.075 
g, 0.38 mmol) vinylmagnesium bromide (0.80 M solution in THF, 1.4 mL, 1.14 
mmol) and 3, 5-di methoxy benzaldehyde (0.105 g, 0.63 mmol) according to 
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the general procedure A. After purification on silica (hexanes/ EtOAc 5:1 to 2:1) title compound was 
obtained in 72% yield (0.075 g). 
Physical state: yellow oil; 
TLC: Rf = 0.15 (hexanes/ EtOAc 5:1, UV-active, stains dark brown with vanillin); 
: 143.9 (c 0.14, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.59 (td, J = 5.5, 2.5 Hz, 1H), 6.53 (d, J = 2.3 Hz, 2H), 6.39 (t, J = 2.3 Hz, 
1H), 6.23 (dd, J = 5.7, 2.0 Hz, 1H), 5.30 (ddd, J = 13.5, 10.2, 7.3 Hz, 1H), 4.85 (d, J = 10.2 Hz, 1H), 4.74 – 
4.63 (m, 2H), 4.59 (s, 1H), 3.77 (d, J = 7.1 Hz, 6H), 3.22 – 3.14 (m, 1H), 2.42 (dd, J = 9.5, 3.0 Hz, 1H); 
13C NMR (75 MHz, CDCl3) δ 212.11, 166.98, 160.84, 143.21, 136.41, 132.99, 116.17, 116.17, 104.99, 
104.99, 100.25, 75.22, 57.79, 55.42, 55.42, 47.78; 
IR (neat) (cm-1) max: 3465, 2939, 1686, 1596, 1507, 1463, 1430, 1346, 1295, 1204, 1153, 1058, 920, 
837, 632, 538, 500; 
HRMS (m/z): calcd for C16H18 NaO4 (M+Na)+ 297.1097, found 297.1099. 
 
Compound (+)-133l: The title compound was prepared from (R)-125 (0.075 g, 
0.38 mmol) vinylmagnesium bromide (0.80 M solution in THF, 1.4 mL, 1.14 
mmol) and trans-2-methyl-2-butenal (0.053 g, 0.06 mL, 0.63 mmol) according to 
the general procedure A. After purification on silica (hexanes/ EtOAc 7:1 to 3:1) title compound was 
obtained in 68% yield (0.050 g). 
Physical state: pale red colored oil; 
TLC: Rf = 0.35 (hexanes/ EtOAc 5:1, UV-active, stains dark brown with vanillin); 
: 136.3 (c 0.45, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.52 (dt, J = 5.6, 3.0 Hz, 1H), 6.16 (dd, J = 5.6, 2.1 Hz, 1H), 5.65 – 5.47 (m, 
2H), 5.08 – 4.94 (m, 2H), 4.00 (d, J = 10.2 Hz, 1H), 3.13 – 3.03 (m, 1H), 2.25 (dd, J = 10.2, 2.7 Hz, 1H), 
1.74 – 1.62 (m, 1H), 1.62 – 1.55 (m, 6H); 
13C NMR (75 MHz, CDCl3) δ 213.67, 167.15, 136.70, 135.24, 132.86, 124.00, 117.03, 79.14, 53.61, 
49.03, 13.04, 10.71; 
IR (neat) (cm-1) max: 3418, 2920, 1682, 1585, 1510, 1440, 1345, 1233, 1100, 1036, 912, 828, 734, 
632, 536, 498; 
HRMS (m/z): calcd for C12H16 NaO2 (M+Na)+ 215.1150, found 215.1150. 
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 Compound (+)-133m: The title compound was prepared from (R)-125 (0.075 g, 
0.38 mmol) vinylmagnesium bromide (0.80 M solution in THF, 1.4 mL, 1.14 
mmol) and trans-4-methyl-2-pentenal (0.062 g, 0.63 mmol) according to the 
general procedure A. After purification on silica (hexanes/ EtOAc 7:1 to 3:1) 
title compound was obtained in 64% yield (0.050 g). 
Physical state: yellow oil; 
TLC: Rf = 0.31 (hexanes/ EtOAc 5:1, UV-active, stains dark brown with vanillin); 
: 147.4 (c 0.11, CHCl3); 
1H NMR (300 MHz, d6-Acetone) δ 7.70 (dd, J = 5.7, 2.6 Hz, 1H), 6.12 (dd, J = 5.7, 2.1 Hz, 1H), 5.95 – 
5.82 (m, 1H), 5.73 – 5.63 (m, 1H), 5.42 (ddd, J = 15.5, 6.5, 1.2 Hz, 1H), 5.11 (ddt, J = 12.9, 10.2, 1.3 Hz, 
2H), 4.39 (dt, J = 9.3, 4.7 Hz, 1H), 3.55 – 3.46 (m, 1H), 2.32 (dd, J = 6.1, 2.6 Hz, 1H), 2.22 (dd, J = 13.5, 
6.7 Hz, 1H), 2.08 – 2.03 (m, 1H), 0.94 (dd, J = 6.8, 0.9 Hz, 6H); 
13C NMR (75 MHz, d6-Acetone) δ 210.03, 167.04, 139.83, 139.59, 134.07, 127.70, 115.95, 73.09, 
58.21, 48.22, 31.50, 22.69, 22.64; 
IR (neat) (cm-1) max: 3474, 2959, 2872, 1694, 1637, 1587, 1467, 1346, 1182, 974, 917, 790, 631, 539, 
498; 
HRMS (m/z): calcd for C13H18 NaO2 (M+Na)+ 229.1199, found 229.1194. 
 
Compound (+)-133n: The title compound was prepared from (R)-125 0.075 g, 
0.38 mmol) cyclohexylmagnesium bromide (0.8 M solution in THF, 1.4 mL, 1.14 
mmol) and octanal (0.081 g, 0.098 mL, 0.63 mmol) according to the general 
procedure A. After purification on silica (hexanes/ EtOAc 10:1 to 5:1) title 
compound was obtained in 77% yield (0.085 g). 
Physical state: pale green oil; 
TLC: Rf = 0.52 (hexanes/ EtOAc 5:1, UV-active, stains brown with vanillin); 
: 136.75 (c 0.25, CHCl3); 
1H NMR (600 MHz, CDCl3) δ 7.70 (dd, J = 5.8, 2.6 Hz, 1H), 6.14 (dd, J = 5.8, 1.9 Hz, 1H), 3.63 (dd, J = 
12.3, 6.4 Hz, 1H), 2.59 (td, J = 4.4, 2.1 Hz, 1H), 2.17 (dd, J = 7.7, 2.1 Hz, 1H), 1.81 – 1.74 (m, 2H), 1.72 – 
1.65 (m, 3H), 1.55 (t, J = 5.5 Hz, 3H), 1.51 (s, 2H), 1.35 – 1.24 (m, 11H), 1.22 – 1.17 (m, 2H), 1.16 – 
1.11 (m, 1H), 0.87 (d, J = 7.1 Hz, 3H); 
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13C NMR (151 MHz, CDCl3) δ 212.69, 167.57, 133.33, 72.70, 53.51, 50.99, 40.94, 35.58, 31.80, 31.55, 
29.59, 29.53, 29.28, 26.50, 26.32, 26.30, 25.66, 22.63, 14.07; 
IR (neat) (cm-1) max: 3440, 2922, 2852, 1687, 1449, 1183, 1052, 891, 631, 534, 496; 
HRMS (m/z): calcd for C19H32 NaO2 (M+Na)+ 315.2295, found 395.2286. 
 
Compound (+)-133o: The title compound was prepared from (R)-125 
(0.075 g, 0.38 mmol) cyclohexylmagnesium bromide (0.8 M solution in 
THF, 1.4 mL, 1.14 mmol) and 4-methoxy benzaldehyde (0.086 g, 0.076 mL, 
0.63 mmol) according to the general procedure A. After purification on 
silica (hexanes/ EtOAc 5:1 to 3:1) title compound was obtained in 72% 
yield (0.082 g). 
Physical state: brown colored oil; 
TLC: Rf = 0.22 (hexanes/ EtOAc 5:1, UV-active, stains dark brown with vanillin); 
: 196.2 (c 0.48, CHCl3); 
1H NMR (600 MHz, CDCl3) δ 7.65 (dd, J = 5.8, 2.6 Hz, 1H), 7.30 – 7.27 (m, 2H), 6.89 – 6.85 (m, 2H), 
6.15 (dd, J = 5.8, 1.9 Hz, 1H), 4.57 (d, J = 9.3 Hz, 1H), 4.46 (s, 1H), 3.81 (s, 3H), 2.43 (d, J = 1.5 Hz, 1H), 
2.39 (dd, J = 9.3, 2.2 Hz, 1H), 1.56 (dd, J = 14.0, 11.2 Hz, 3H), 1.35 – 1.29 (m, 2H), 1.02 – 0.94 (m, 3H), 
0.88 – 0.82 (m, 2H), 0.63 (td, J = 11.9, 3.2 Hz, 1H); 
13C NMR (151 MHz, CDCl3) δ 212.95, 168.22, 159.45, 133.71, 132.68, 128.06, 128.06, 113, 68, 113.68, 
75.23, 55.33, 55.03, 50.45, 39.92, 31.09, 28.95, 26.34, 26.21, 26.17; 
IR (neat) (cm-1) max: 3422, 2923, 2851, 1686, 1613, 1513, 1448, 1247, 1174, 1035, 632, 536, 495; 
HRMS (m/z): calcd for C19H24 NaO3 (M+Na)+ 323.1618, found 323.1620. 
 
 Compound (+)-133p: The title compound was prepared from (R)-125 (0.075 g, 
0.38 mmol) cyclohexylmagnesium bromide (0.8 M solution in THF, 1.4 mL, 
1.14 mmol) and trans-2-decenal (0.098 g, 0.11 mL, 0.63 mmol) according to 
the general procedure A. After purification on silica (hexanes/ EtOAc 7:1 to 
5:1) title compound was obtained in 75% yield (0.090 g). 
Physical state: yellow oil; 
TLC: Rf = 0.48 (hexanes/ EtOAc 5:1, UV-active, stains dark brown with vanillin); 
: 140.71 (c 0.73, CHCl3); 
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1H NMR (600 MHz, CDCl3) δ 7.69 (dd, J = 5.8, 2.6 Hz, 1H), 6.13 (dd, J = 5.8, 1.9 Hz, 1H), 5.70 (dt, J = 
15.0, 6.7 Hz, 1H), 5.52 – 5.39 (m, 1H), 4.05 (t, J = 8.2 Hz, 1H), 3.77 (d, J = 9.8 Hz, 1H), 2.54 (td, J = 4.4, 
2.1 Hz, 1H), 2.23 (dd, J = 8.6, 2.0 Hz, 1H), 2.09 – 1.99 (m, 2H), 1.72 (dd, J = 21.3, 8.2 Hz, 3H), 1.63 (d, J 
= 11.7 Hz, 3H), 1.48 (ddd, J = 11.5, 8.0, 3.5 Hz, 1H), 1.35 (dd, J = 13.2, 5.7 Hz, 2H), 1.24 (d, J = 12.7 Hz, 
9H), 1.12 (ddd, J = 12.6, 9.6, 5.9 Hz, 3H), 0.87 (t, J = 6.6 Hz, 3H); 
13C NMR (151 MHz, CDCl3) δ 212.70, 168.98, 134.40, 132.49, 129.73, 74.21, 55.94, 44.80, 33.73, 
32.14, 31.83, 31.80, 29.69, 29.45, 29.23, 29.21, 29.17, 29.05, 27.14, 22.63, 14.07; 
IR (neat) (cm-1) max: 3418, 2920, 2852, 1690, 1586, 1449, 970, 536; 
HRMS (m/z): calcd for C21H34 NaO2 (M+Na)+ 341.2451, found 341.2451. 
 
  Compound (+)-133q: The title compound was prepared from (R)-125 (0.075 g, 
0.38 mmol) cyclohexylmagnesium bromide (0.8 M solution in THF, 1.4 mL, 1.14 
mmol) and cyclohexanal (0.071 g, 0.63 mmol) according to the general 
procedure A. After purification on silica (hexanes/ EtOAc 7:1 to 5:1) title 
compound was obtained in 70% yield (0.073 g). 
Physical state: yellow oil; 
TLC: Rf = 0.42 (hexanes/ EtOAc 5:1, UV-active, stains orange with vanillin); 
: 186.2 (c 0.75, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.70 (dd, J = 5.8, 2.5 Hz, 1H), 6.13 (dd, J = 5.8, 2.0 Hz, 1H), 3.44 – 3.37 (m, 
1H), 3.16 (s, 1H), 2.63 (td, J = 4.6, 2.2 Hz, 1H), 2.36 (dd, J = 7.0, 2.4 Hz, 1H), 1.81 – 1.65 (m, 10H), 1.30 
(t, J = 7.2 Hz, 2H), 1.21 (dd, J = 7.9, 4.2 Hz, 5H), 1.02 (d, J = 22.4 Hz, 3H), 0.91 – 0.84 (m, 2H); 
13C NMR (75 MHz, CDCl3) δ 213.13, 167.39, 133.58, 77.37, 51.63, 50.04, 41.31, 40.73, 31.56, 30.53, 
29.42, 27.17, 26.60, 26.47, 26.37, 26.37, 26.37, 26.03; 
IR (neat) (cm-1) max: 3444, 2922, 2850, 1686, 1588, 1511, 1449, 1183, 1059, 636, 576, 420; 
HRMS (m/z): calcd for C18H28 NaO2 (M+Na)+ 299.1982, found 299.1985. 
 
Compound (+)-133r: The title compound was prepared from (R)-125 (0.075 g, 
0.38 mmol) cyclohexylmagnesium bromide (0.8 M solution in THF, 1.4 mL, 1.14 
mmol) and benzaldehyde (0.067 g, 0.064 mL, 0.63 mmol) according to the 
general procedure A. After purification on silica (hexanes/ EtOAc 7:1 to 5:1) title 
compound was obtained in 74% yield (0.076 g). 
Physical state: yellow oil; 
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TLC: Rf = 0.45 (hexanes/ EtOAc 5:1, UV-active, stains brown with vanillin); 
: 220.3 (c 0.39, CHCl3); 
1H NMR (600 MHz, CDCl3) δ 7.65 (dd, J = 5.8, 2.6 Hz, 1H), 7.38 – 7.36 (m, 2H), 7.36 – 7.32 (m, 2H), 
7.31 – 7.28 (m, 1H), 6.16 (dd, J = 5.8, 2.0 Hz, 1H), 4.62 (d, J = 9.3 Hz, 1H), 4.55 (s, 1H), 2.46 (td, J = 4.4, 
2.2 Hz, 1H), 2.40 (dd, J = 9.3, 2.3 Hz, 1H), 1.61 – 1.52 (m, 3H), 1.28 (dd, J = 10.7, 8.9 Hz, 2H), 1.02 – 
0.91 (m, 3H), 0.86 – 0.80 (m, 1H), 0.79 – 0.73 (m, 1H), 0.60 (qd, J = 12.2, 3.6 Hz, 1H); 
13C NMR (151 MHz, CDCl3) δ 212.88, 168.23, 141.40, 132.67, 128.32, 128.32, 128.18, 126.88, 126.88, 
75.67, 54.91, 50.34, 39.81, 31.02, 28.86, 26.31, 26.18, 26.15; 
IR (neat) (cm-1) max: 3451, 2922, 2850, 1683, 1585, 1449, 1192, 1045, 903, 803, 760, 703, 550; 
HRMS (m/z): calcd for C18H22 NaO2 (M+Na)+ 293.1512, found 293.1504. 
Compound (+)-133s: The title compound was prepared from (R)-125 
(0.075 g, 0.38 mmol) octylmagnesium bromide (1.0 M solution in Et2O, 
1.14 mL, 1.14 mmol) and benzaldehyde (0.067 g, 0.064 mL, 0.63 mmol) 
according to the general procedure A. After purification on silica 
(hexanes/ EtOAc 10:1 to 5:1) title compound was obtained in 30% yield 
(0.035 g). 
Physical state: pale yellow oil; 
TLC: Rf = 0.44 (hexanes/ EtOAc 5:1, UV-active, stains pink with vanillin); 
: 111.0 (c 0.15, CHCl3); 
1H NMR (600 MHz, CDCl3) δ 7.65 (dd, J = 5.7, 2.5 Hz, 1H), 7.38 (dd, J = 8.2, 1.3 Hz, 2H), 7.36 – 7.33 (m, 
2H), 7.32 – 7.28 (m, 1H), 6.17 (dd, J = 5.7, 1.9 Hz, 1H), 4.74 (s, 1H), 4.64 (d, J = 9.7 Hz, 1H), 2.50 (ddd, J 
= 7.4, 5.0, 2.4 Hz, 1H), 2.27 (dd, J = 9.7, 2.4 Hz, 1H), 1.26 (dd, J = 14.1, 6.7 Hz, 2H), 1.22 – 1.12 (m, 4H), 
1.07 – 0.92 (m, 8H), 0.87 (t, J = 7.3 Hz, 3H); 
13C NMR (151 MHz, CDCl3) δ 213.03, 169.22, 141.38, 132.27, 128.43, 128.43, 128.24, 126.88, 126.88, 
75.43, 57.33, 44.53, 32.69, 31.76, 29.22, 29.10, 29.06, 26.19, 22.60, 14.07; 
IR (neat) (cm-1) max: 3441, 2923, 2853, 1686, 1585, 1511, 1455, 1200, 1044, 702, 632, 544, 494; 
HRMS (m/z): calcd for C20H28 NaO2 (M+Na)+ 323.1982, found 323.1980. 
 
Compound (+)-133t: The title compound was prepared from (R)-125 
(0.075 g, 0.38 mmol) octylmagnesium bromide (1.0 M solution in Et2O, 
1.14 mL, 1.14 mmol) and trans-2-decenal (0.098 g, 0.11 mL, 0.63 mmol) 
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according to the general procedure A. After purification on silica (hexanes/ EtOAc 7:1 to 5:1) title 
compound was obtained in 31% yield (0.041 g). 
Physical state: yellow oil; 
TLC: Rf = 0.52 (hexanes/ EtOAc 5:1, UV-active, stains brown with vanillin); 
: 48.5 (c 0.18, CHCl3); 
1H NMR (600 MHz, CDCl3) δ 7.69 (dd, J = 5.8, 2.6 Hz, 1H), 6.13 (dd, J = 5.8, 1.9 Hz, 1H), 5.72 – 5.67 (m, 
1H), 5.48 – 5.43 (m, 1H), 4.05 (t, J = 8.2 Hz, 1H), 2.54 (dt, J = 4.3, 2.1 Hz, 1H), 2.23 (dd, J = 8.5, 2.0 Hz, 
1H), 2.06 – 2.02 (m, 2H), 1.78 – 1.73 (m, 2H), 1.69 – 1.62 (m, 4H), 1.47 (ddd, J = 15.4, 7.8, 3.8 Hz, 1H), 
1.40 – 1.31 (m, 3H), 1.28 (ddd, J = 14.7, 10.2, 5.6 Hz, 10H), 1.22 – 1.18 (m, 2H), 1.18 – 1.09 (m, 3H), 
0.88 (t, J = 7.0 Hz, 6H); 
13C NMR (151 MHz, CDCl3) δ 212.54, 168.02, 134.39, 132.93, 129.87, 74.55, 53.39, 50.59, 40.69, 
32.13, 31.77, 31.45, 29.75, 29.17, 29.15, 29.09, 26.48, 26.30, 26.29, 22.65, 22.65, 14.07, 14.07; 
IR (neat) (cm-1) max: 3430, 2922, 2852, 1692, 1464, 970, 909, 733, 631, 542, 498; 
HRMS (m/z): calcd for C23H40 NaO2 (M+Na)+ 371.2921, found 371.2922. 
 
Compound (+)-133u: The title compound was prepared from (R)-125 
(0.075 g, 0.38 mmol) octylmagnesium bromide (1.0 M solution in 
Et2O, 1.14 mL, 1.14 mmol) and octanal (0.081 g, 0.098 mL, 0.63 
mmol) according to the general procedure A. After purification on 
silica (hexanes/ EtOAc 7:1 to 5:1) title compound was obtained in 34% yield (0.042 g). 
Physical state: pale yellow oil; 
TLC: Rf = 0.58 (hexanes/ EtOAc 5:1, UV-active, stains pale brown with vanillin); 
: 52.6 (c 0.85, CHCl3); 
1H NMR (600 MHz, CDCl3) δ 7.69 (dd, J = 5.7, 2.5 Hz, 1H), 6.13 (dd, J = 5.7, 1.9 Hz, 1H), 3.79 (s, 1H), 
3.67 (t, J = 8.1 Hz, 1H), 2.67 – 2.63 (m, 1H), 2.02 (dd, J = 8.4, 2.3 Hz, 1H), 1.64 (ddd, J = 10.7, 9.3, 5.3 
Hz, 1H), 1.59 – 1.52 (m, 3H), 1.51 – 1.46 (m, 1H), 1.43 – 1.37 (m, 2H), 1.34 – 1.25 (m, 19H), 0.88 (td, J 
= 7.0, 3.6 Hz, 6H); 
13C NMR (151 MHz, CDCl3) δ 213.03, 168.58, 132.84, 72.27, 55.94, 44.98, 35.59, 33.85, 31.82, 31.81, 
29.66, 29.56, 29.41, 29.28, 29.21, 26.91, 25.39, 22.63, 22.63, 14.07, 14.07; 
IR (neat) (cm-1) max: 3438, 2924, 2854, 1690, 1465, 1314, 1262, 1186, 634, 537, 497; 
HRMS (m/z): calcd for C21H38 NaO2 (M+Na)+ 345.2764, found 345.2764. 
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Compound (+)-133v: The title compound was prepared from (R)-125 
(0.075 g, 0.38 mmol) octylmagnesium bromide (1.0 M solution in Et2O, 
1.14 mL, 1.14 mmol) and 4-nitro benzaldehyde (0.096 g, 0.63 mmol) 
according to the general procedure A. After purification on silica 
(hexanes/ EtOAc 7:1 to 3:1) title compound was obtained in 38% yield 
(0.050 g).  
Physical state: pale yellow oil; 
TLC: Rf = 0.23 (hexanes/ EtOAc 5:1, UV-active, stains pale brown with vanillin); 
: 126.6 (c 0.85, CHCl3); 
1H NMR (600 MHz, CDCl3) δ 8.25 – 8.23 (m, 2H), 7.68 (dd, J = 5.7, 2.5 Hz, 1H), 7.60 – 7.58 (m, 2H), 
6.20 (dd, J = 5.7, 1.9 Hz, 1H), 4.84 (s, 1H), 4.81 (d, J = 9.5 Hz, 1H), 2.52 (ddd, J = 7.4, 5.0, 2.4 Hz, 1H), 
2.26 (dd, J = 9.5, 2.5 Hz, 1H), 1.27 – 1.23 (m, 2H), 1.20 – 1.12 (m, 4H), 1.03 (dd, J = 13.4, 7.7 Hz, 5H), 
0.99 – 0.92 (m, 3H), 0.86 (t, J = 7.3 Hz, 3H); 
13C NMR (151 MHz, CDCl3) δ 211.95, 169.06, 148.56, 147.77, 132.44, 127.79, 127.79, 123.71, 123.71, 
74.47, 56.87, 44.17, 32.90, 31.71, 29.26, 29.16, 29.05, 26.31, 22.58, 14.03; 
IR (neat) (cm-1) max: 3398, 2926, 2854, 1689, 1524, 1347, 1191, 856, 756, 536, 494; 
HRMS (m/z): calcd for C21H28 NO6 (M+HCOO)-, 390.1922, found 390.1922. 
 
Compound (+)-133w: The title compound was prepared from (R)-
125 (0.075 g, 0.38 mmol) octylmagnesium bromide (1.0 M 
solution in Et2O, 1.14 mL, 1.14 mmol) and isobutanal (0.046 g, 
0.058 mL, 0.63 mmol) according to the general procedure A. After 
purification on silica (hexanes/ EtOAc 7:1 to 3:1) title compound 
was obtained in 32% yield (0.033 g). 
Physical state: pale brown oil; 
TLC: Rf = 0.54 (hexanes/ EtOAc 5:1, UV-active, stains pale brown with vanillin); 
: 103.2 (c 0.65, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.70 (dd, J = 5.7, 2.4 Hz, 1H), 6.14 (dd, J = 5.7, 1.9 Hz, 1H), 3.80 (s, 1H), 
3.47 (ddd, J = 8.6, 3.2, 2.4 Hz, 1H), 2.70 – 2.61 (m, 1H), 2.13 (dd, J = 8.6, 2.4 Hz, 1H), 1.86 (dtd, J = 9.4, 
6.4, 2.9 Hz, 1H), 1.67 (s, 1H), 1.27 (s, 13H), 1.05 (d, J = 6.8 Hz, 3H), 0.96 (d, J = 6.7 Hz, 3H), 0.91 – 0.86 
(m, 3H); 
13C NMR (75 MHz, CDCl3) δ 213.72, 168.67, 132.95, 76.86, 53.21, 45.32, 33.37, 31.83, 31.44, 29.71, 
29.43, 29.20, 26.70, 22.64, 20.33, 15.58, 14.09; 
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IR (neat) (cm-1) max:3486, 2925, 2856, 1686, 1512, 1465, 1236, 1042, 792, 632, 536, 501; 
HRMS (m/z): calcd for C17H30 NaO2 (M+Na)+, 289.2138, found 289.2136. 
 
Compound (+)-133x: The title compound was prepared from (R)-125 
(0.075 g, 0.38 mmol) octylmagnesium bromide (1.0 M solution in Et2O, 
1.14 mL, 1.14 mmol) and 4-methoxy benzaldehyde (0.086 g, 0.076 mL, 
0.63 mmol) according to the general procedure A. After purification on 
silica (hexanes/ EtOAc 7:1 to 3:1) title compound was obtained in 36% 
yield (0.045 g). 
Physical state: pale brown oil; 
TLC: Rf = 0.25 (hexanes/ EtOAc 5:1, UV-active, stains deep brown with vanillin); 
: 114.2 (c 0.65, CHCl3); 
1H NMR (600 MHz, CDCl3) δ 7.65 (dd, J = 5.7, 2.5 Hz, 1H), 7.31 – 7.28 (m, 2H), 6.89 – 6.86 (m, 2H), 
6.15 (dd, J = 5.7, 1.9 Hz, 1H), 4.69 (s, 1H), 4.58 (d, J = 9.7 Hz, 1H), 3.80 (s, 3H), 2.49 – 2.45 (m, 1H), 
2.26 (dd, J = 9.7, 2.4 Hz, 1H), 1.26 (dd, J = 14.5, 7.2 Hz, 2H), 1.21 – 1.14 (m, 4H), 1.09 – 0.95 (m, 8H), 
0.87 (t, J = 7.3 Hz, 3H); 
13C NMR (151 MHz, CDCl3) δ 213.12, 169.24, 159.48, 133.69, 132.26, 128.04, 128.04, 113.75, 113.75, 
74.96, 57.43, 55.24, 44.59, 32.74, 31.77, 29.25, 29.17, 29.10, 26.23, 22.60, 14.06; 
IR (neat) (cm-1) max: 3463, 2926, 2854, 1686, 1613, 1513, 1464, 1303, 1246, 1173, 1036, 834, 632, 
539, 497; 
HRMS (m/z): calcd for C21H30 NaO3 (M+Na)+, 353.2087, found 353.209. 
 
 
 
 
 
 
 
 
 
 
 
 
D. Experimental Part 
   
94 
 
Table 11. Coupling constants 3JHa-Hb of (+)-133. 
 
 
Kobayashi et al.15 had established that for compound (+)-133 (anti-diols)  3JHa-Hb is in the range of 8.4 
to 9.7 Hz, while for the corresponding syn-diols 3JHa-Hb is around 3 Hz. 
 
All (-)-133 derivatives were synthesized from (S)-134 by using previous one pot conditions according 
to general procedure A.  
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Note: Characterization: Spectral data of (-)-133 a, b and c were matched with (+)-133 d, e and c.  
: (-)-133a = -232.0 (c 0.53, CHCl3), (-)-133b = -228.0 (c 0.15, CHCl3), (-)-133c = -202.0 (c 0.56, 
CHCl3). 
 
 
Note: Characterization: Spectral data of (-)-133 d, e, f and g were matched with (+)-133 f, g, h and i.  
: (-)-133d = -230.0 (c 0.14, CHCl3), (-)-133b = -222.0 (c 0.37, CHCl3), (-)-133c = -110.0 (c 0.71, 
CHCl3), (-)-133g = n.d. 
 
 
Note: Characterization: Spectral data of (-)-133 h, i and j were matched with (+)-133 k, l and m.  
: (-)-133h = -130.0 (c 0.14, CHCl3), (-)-133i = n.d, (-)-133j = -141.0 (c 0.14, CHCl3). 
 
 
Note: Characterization: Spectral data of (-)-133 k, l and m were matched with (+)-133 n, o and p.  
: (-)-133k = -127.0 (c 0.39, CHCl3), (-)-133l = -188.0 (c 0.48, CHCl3), (-)-133m = -129.0 (c 0.73, 
CHCl3). 
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Note Characterization: Spectral data of of (-)-133 n, o, p, q and r were matched with (+)-133 t, u, v, x 
and s.  
: (-)-133 n = -39.0 (c 0.19, CHCl3), (-)-133 o, p, q and r = n.d. 
 
4. Synthesis and characterization of natural products 
Compound 2: The title compound was prepared from (R)-125 (0.075 g, 
0.38 mmol) n-butyl magnesiumbromide (0.90 M solution in THF, 1.24 
mL, 1.14 mmol) and heptanal (0.068 g, 0.084 mL, 0.63 mmol) according 
to the general procedure A. After purification on silica (hexanes/EtOAc 10:1 to 5:1) 2 was obtained in 
38% yield (0.037 g). 
Physical state: pale yellow oil; 
TLC: Rf = 0.4 (hexanes/EtOAc 5:1, UV-active, stains pale brown with vanillin); 
:  48.6 (c 0.18, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.70 (dd, J = 5.7, 2.5 Hz, 1H), 6.14 (dd, J = 5.7, 1.9 Hz, 1H), 3.87 (s, 1H), 
3.68 (dd, J = 9.3, 4.8 Hz, 1H), 2.65 (ddd, J = 7.9, 5.6, 2.3 Hz, 1H), 2.04 – 2.00 (m, 1H), 1.67 – 1.62 (m, 
1H), 1.58 – 1.47 (m, 4H), 1.38 – 1.24 (m, 11H), 0.93 – 0.85 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ 213.20, 168.76, 132.86, 72.32, 55.94, 44.98, 35.59, 33.55, 31.85, 29.29, 
29.09, 25.37, 22.79, 22.64, 14.11, 13.96; 
IR (neat) (cm-1) v˜max: 3373, 2954, 2925, 2857, 1686, 1511, 1466, 1357, 1234, 1100, 1038, 827, 733, 
529, 489; 
HRMS (m/z): calcd for C16H28 NaO2 (M+Na)+ 275.1982, found 275.1982. 
 
Compound 3 [(–)-TEI-9826]: To a stirred solution of  CuCN  
(0.202 g, 2.25 mmol, 3.0 equiv) and anhydrous LiCl (0.190 g, 4.5 
mmol, 6.0 equiv) in anhydrous THF (10 mL) was added octyl 
magnesiumbromide (0.9 M in Et2O, 2.5 mL, 2.25 mmol, 3.0 
equiv) dropwise at –40 oC under stirring.  After the addition was completed, the reaction mixture was 
cooled to –78 oC. To this mixture was added a solution of (S)-134 (0.153 g, 0.75 mmol, 1.0 equiv) in 
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anhydrous THF (6 mL) at–78 oC. After 4 min of stirring at –78 oC, methyl-6-formylhexanoate (0.199 g, 
1.26 mmol, 1.68 equiv) was added. After the reaction was completed (ca. 5 min, monitored by TLC) 
the mixture was quenched by adding NH4Claq (5 mL) and allowed to warm to room temperature. The 
aqueous layer was removed with a pipette and the crude was dried under high vacuum. To a solution 
of the residue in DCM (10 mL) were added 4-(dimethylamino)-pyridine (0.486 g, 3.98 mmol) and 
methane sulfonylchloride (0.16 mL, 1.98 mmol) at ambient temperature. After stirring for 15 h, 
aqueous HCl solution was added. The layers were separated and the aqueous layer was extracted 
with EtOAc (3x 15 mL). The combined organic extracts were dried over Na2SO4, filtered and 
concentrated under reduced pressure. The residue was purified by column chromatography 
(hexanes/EtOAc 5:1)) to give (–)-TEI-9826 3 was obtained in 48% yield (0.12 g , 4 steps in one pot).  
Physical state: yellow oil; 
TLC: Rf = 0.36 (hexanes/EtOAc 5:1, UV-active, stains brown with vanillin); 
: –129.4 (c 0.43, CHCl3); lit.2 : –121 (c=0.58, CHCl3), lit.3 : 119 (c=1.10, CHCl3, ent-3); 
1H NMR (400 MHz, CDCl3) δ 7.55 – 7.49 (m, 1H), 6.51 (t, J = 7.7 Hz, 1H), 6.31 (dd, J = 6.0, 1.8 Hz, 1H), 
3.66 (s, 3H), 3.49 – 3.42 (m, 1H), 2.30 (t, J = 7.5 Hz, 2H), 2.28 – 2.15 (m, 2H), 1.81 (dd, J = 9.7, 4.0 Hz, 
1H), 1.65 (dd, J = 15.5, 7.6 Hz, 2H), 1.55 – 1.47 (m, 3H), 1.41 – 1.34 (m, 2H), 1.30 – 1.21 (m, 12H), 0.87 
(t, J = 6.9 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 197.2, 174.2, 162.2, 138.3, 135.4, 135.0, 51.7, 43.5, 34.1, 32.7, 32.0, 
30.0, 29.6, 29.4, 29.1, 29.1, 28.5, 26.1, 25.0, 22.8, 14.3; 
IR (neat) (cm-1) v˜max: 3373, 2954, 2925, 2857, 1686, 1511, 1466, 1357, 1234, 1100, 1038, 827, 733, 
529, 489; 
HRMS (m/z): calcd for C21H34 O3 (M)+ 334.2508, found 334.2504. 
 
Compound 141: To a stirred solution of  CuCN (0.33 g, 3.67 
mmol, 3.0 equiv) and anhydrous LiCl (0.310 g, 7.35 mmol, 6.0 
equiv) in anhydrous THF (13 mL) was added n-butyl 
magnesiumbromide (0.91 M in Et2O, 4.0 mL, 3.67 mmol, 3.0 equiv) dropwise at –40 oC under stirring. 
After the addition was completed, the reaction mixture was cooled to –78 oC. To this mixture was 
added a solution of (S)-134 (0.25 g, 1.225 mmol, 1.0 equiv) in anhydrous THF (2.5 mL) at–78 oC. After 
4 min of stirring at –78 oC, methyl-6-formylhexanoate (0.32 g, 2.06 mmol, 1.68 equiv) was added. 
After the reaction was completed (ca. 5 min, monitored by TLC) the mixture was quenched by adding 
NH4Claq (10 mL) and allowed to warm to room temperature. The aqueous layer was removed with a 
pipette and the crude was dried under high vacuum. To a solution of the residue in DCM (18 mL) 
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were added 4-(dimethylamino)-pyridine (0.79 g, 6.90 mmol) and methane sulfonylchloride (0.25 mL, 
3.45 mmol) at ambient temperature. After stirring for 15 h, aqueous HCl solution was added. The 
layers were separated and the aqueous layer was extracted with EtOAc (3x 20 mL). The combined 
organic extracts were dried over Na2SO4, filtered and concentrated under reduced pressure. The 
residue was purified by column chromatography (hexanes/EtOAc 5:1) to give 141 in 42% yield (0.145 
g, 4 steps in one pot).  
Physical state: yellow oil; 
TLC: Rf = 0.36 (hexanes/EtOAc 5:1, UV-active, stains brown with vanillin); 
: –121.0 (c 0.5, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.48 (ddd, J = 6.0, 2.6, 0.9 Hz, 1H), 6.46 (t, J = 7.7 Hz, 1H), 6.26 (dd, J = 
6.0, 1.9 Hz, 1H), 3.60 (s, 3H), 3.44 – 3.37 (m, 1H), 2.28 – 2.16 (m, 4H), 1.77 (ddd, J = 12.9, 5.8, 3.3 Hz, 
1H), 1.64 – 1.54 (m, 2H), 1.51 – 1.41 (m, 3H), 1.36 – 1.17 (m, 6H), 0.84 – 0.79 (m, 3H); 
13C NMR (75 MHz, CDCl3) δ 197.1, 174.1, 162.1, 138.1, 135.3, 134.8, 51.5, 43.3, 33.9, 32.1, 28.9, 28.9, 
28.3, 28.0, 24.7, 22.8, 13.95; 
IR (neat) (cm-1) v˜max: 3373, 2954, 2925, 2857, 1686, 1511, 1466, 1357, 1234, 1100, 1038, 827, 733, 
529, 489; 
HRMS (m/z): calcd for C17H26 O3 (M)+ 278.1882, found 278.1880. 
 
Compound 143: To a 25 mL 3-neck round bottom flask 
equipped with a stir bar and septum was added Cp2Zr(H)Cl 
(0.39 g, 1.5 mmol) followed by 4 mL of THF and 1-octyne (0.225 
mL, 1.5 mmol). Thw two-phase mixture shielded from light and allowed to stir for 30 min at room 
temperature. This mixture was the cooled to -78 oC, and at this temperature was added MeLi (1.6 M 
in Et2O, 0.94 mL, 1.5 mmol), dropwise over 1 min. At the same time, to another round bottom flask 
was added CuCN (0.0068g, 0.075 mmol), followed by 1 mL of THF. The mixture was cooled to -78 oC, 
and Me2Zn (2.0 M in heptanes, 0.39 mL, 0.75 mmol) was added dropwise, followed quickly by 
dropwise addition of MeLi (0.58 mL, 1.1 mmol). After 5 min this three phase slurry was placed in an 
ice-bath for 10 min. This solution was then cooled back to -78 oC and the solution containing methyl 
vinyl zirconocene, still at -78 oC was transferred to the flask, containing the zincate/catalytic cuprate 
mixture. After 5 min of stirring (S)-134 (0.153 g, 0.75 mmol, 1.0 equiv) in 1.0 mL THF was added 
during 5 min. After 5 min of additional stirring methyl-6-formylhexanoate (0.2 g, 1.26 mmol) was 
added. After 5 min stirring the mixture was quenched with aq. NH4Cl (5 mL). The layers were 
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separated and the aqueous layer was extracted with EtOAc (2X10 mL). The combined extracts were 
washed with brine (10 mL), dried, filtered and concentrated to give crude oil, which was directly 
subjected to the next step. 
To a solution of the residue in DCM (12 mL) were added 4-(dimethylamino)-pyridine (0.52 g, 4.29 
mmol) and methane sulfonylchloride (0.16 mL, 2.15 mmol) at ambient temperature. After stirring for 
15 h, aqueous HCl solution was added. The layers were separated and the aqueous layer was 
extracted with EtOAc (3x 20 mL). The combined organic extracts were dried over Na2SO4, filtered and 
concentrated under reduced pressure. The residue was purified by column chromatography 
(hexanes/EtOAc 5:1) to give 143 in 45% yield (0.113 g). 
Physical state: yellow oil; 
TLC: Rf = 0.63 (hexanes/EtOAc 3:1, UV-active, stains pale brown with vanillin); 
: –110.0 (c 0.5, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.34 (ddd, J = 5.8, 2.6, 0.7 Hz, 1H), 6.58 (t, J = 7.7 Hz, 1H), 6.30 (dd, J = 
5.9, 1.9 Hz, 1H), 5.63 (dd, J = 14.7, 7.3 Hz, 1H), 5.15 (ddt, J = 15.3, 8.5, 1.3 Hz, 1H), 3.96 (d, J = 8.5 Hz, 
1H), 3.65 (s, 3H), 2.24 (ddd, J = 14.8, 13.8, 7.4 Hz, 4H), 2.01 (dd, J = 12.2, 5.7 Hz, 2H), 1.60 (dd, J = 
15.1, 7.5 Hz, 2H), 1.49 – 1.40 (m, 2H), 1.36 – 1.23 (m, 10H), 0.87 (dd, J = 7.8, 4.7 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 196.8, 174.1, 161.1, 137.2, 136.9, 134.4, 133.8, 127.4, 51.6, 47.3, 33.9, 
32.4, 31.7, 29.3, 28.9, 28.8, 28.6, 28.2, 24.7, 22.6, 14.1; 
IR (neat) (cm-1) v˜max: 3373, 2954, 2925, 2857, 1686, 1511, 1357, 1110, 1038, 827, 733, 529; 
HRMS (m/z): calcd for C21H32 O3 (M)+ 332.2351, found 332.2350. 
 
Compound 146: To a stirred solution of  CuCN (0.503 g, 5.61 mmol, 3.0 
equiv) and anhydrous LiCl (0.472 g, 11.2 mmol, 6.0 equiv) in anhydrous THF 
(20 mL) was added iso propenyl magnesium bromide (0.83 M solution in 
THF, 5.61 mmol, 6.85 mL, 3.0 equiv) dropwise at –40 oC under stirring. After 
the addition was completed, the reaction mixture was cooled to –78 oC. To this mixture was added a 
solution of (R)-125 (0.37 g, 1.87 mmol, 1.0 equiv) in anhydrous THF (5 mL) at –78 oC. After 4 min of 
stirring at -78 oC, ±-148 (0.471 g, 0.374 mmol, 2.0 equiv) was added. After the reaction was 
completed (ca. 5 min) the mixture was quenched by adding NH4Claq (30 mL). Then the mixture was 
allowed to warm to room temperature. The layers were separated, and the aqueous layer was 
extracted with Et2O (2x15 mL). The combined organic extracts were dried over Na2SO4, filtered and 
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the solvent was removed under reduced pressure. After purification on silica (hexanes/EtOAc 7:1) 
146 was obtained in 68% yield (0.316 g). 
Physical state: brown color oil; 
TLC: Rf = 0.62 (hexanes/EtOAc 5:1, UV-active, stains dark brown with vanillin); 
: 100.7 (c 0.42, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.60 – 7.49 (dd, J=5.6, 2.6 Hz, 1H), 6.21 (dd, J = 5.6, 2.1 Hz, 1H), 5.81 (ddt, 
J = 17.1, 10.0, 7.1 Hz, 1H), 5.04 (ddd, J = 17.1, 3.5, 1.6 Hz, 1H), 4.99 – 4.90 (m, 3H), 4.00 (t, J = 1.4 Hz, 
1H), 3.93 – 3.83 (m, 1H), 3.24 (dd, J = 4.8, 2.4 Hz, 1H), 2.44 (dd, J = 9.2, 2.7 Hz, 1H), 2.25 – 2.14 (m, 
2H), 1.88 (dtd, J = 13.8, 6.9, 4.8 Hz, 1H), 1.66 (d, J = 0.8 Hz, 3H), 1.51 (t, J = 5.5 Hz, 1H), 0.93 (dt, J = 
13.2, 6.6 Hz, 6H); 
13C NMR (75 MHz, CDCl3) δ 213.58, 167.62, 142.98, 139.01, 133.37, 115.46, 114.51, 72.76, 53.58, 
51.39, 46.46, 30.96, 29.02, 20.87, 19.38, 18.97; 
IR (neat) (cm-1) v˜max: 3473, 2957, 2928, 1743, 1686, 1589, 1414, 1369, 1279, 1177, 1056, 901, 795, 
658, 624, 531, 496; 
HRMS (m/z): calcd for C16H24 NaO2 (M+Na)+ 271.1669, found 271.1669. 
 
Compound 157: A flask containing 146 (0.39 g, 1.57 mmol) was outfitted with a 
reflux condenser and evacuated and backfilled with dry nitrogen. 
Deoxygenated DCM (85 mL) was added, and the solution was heated to  
reflux (44 oC). A solution of Grubbs-II catalyst (0.09 g, 0.11 mmol) in 
deoxygenated DCM (5 mL) was added to the reaction mixture. The light brown reaction mixture was 
refluxed (44 oC) for 1.5 h and was then cooled to room temperature. The solvent was removed under 
reduced pressure. After purification on silica (hexanes/EtOAc 5:1 to 3:1) 157 was obtained in 94% 
yield (0.325 g). 
Physical state: pale brown color oil; 
TLC: Rf = 0.53 (hexanes/EtOAc 5:1, UV-active, stains dark brown with vanillin); 
: –25.6 (c 0.25, CHCl3); 
1H NMR (300 MHz, Acetone-d6): δ 8.03 – 7.90 (dd, J=5.7, 2.6 Hz, 1H), 6.12 (dd, J = 5.9, 2.8 Hz, 1H), 
5.57 – 5.49 (m, 1H), 4.23 – 4.15 (m, 1H), 3.60 (dd, J = 10.1, 8.8 Hz, 1H), 2.54 (dd, J = 9.7, 5.3 Hz, 1H), 
2.04 (dt, J = 8.7, 4.3 Hz, 1H), 1.96 (t, J = 4.1 Hz, 1H), 1.87 (dd, J = 2.3, 0.9 Hz, 3H), 1.81 – 1.62 (m, 2H), 
1.57 – 1.48 (m, 1H), 1.02 (d, J = 6.6 Hz, 3H), 0.93 (d, J = 5.8 Hz, 3H). 
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13C NMR (75 MHz, Acetone-d6) δ 212.17, 164.59, 136.88, 132.72, 127.66, 49.59, 49.54, 47.10, 29.56, 
27.87, 26.58, 22.16, 21.68, 21.42; 
IR (neat) (cm-1) v˜max: 3429, 2957, 2873, 1682, 1539, 1446, 1368, 1271, 1068, 976, 737, 632, 540, 
497; 
HRMS (m/z): calcd for C14H20 NaO2 (M+Na)+ 243.1463, found 243.1463 
 
Compound 145: The 157 (0.21 g, 0.95 mmol, 1.0 equiv) was dissolved in CHCl3 
(7.5 mL, filtered through basic alumina) along with diphenylsilane (0.29 ml, 
1.62 mmol, 1.7 equiv) and zinc chloride (0.067 g, 0.49 mmol, 0.52 equiv).  
Pd (PPh3)4 (0.015 g, 0.012 mmol, 0.013 equiv)6 was added and the mixture was 
stirred (inert atmosphere was not required) at room temperature for 20 min. The solvent was 
removed under reduced pressure and the crude was purified by column chromatography 
(hexanes/EtOAc 5:1) 145 was obtained in 80% yield (0.170 g). 
Physical state: white color solid; 
TLC: Rf = 0.56 (hexanes/EtOAc 5:1, stains brown with vanillin); 
: –63.5 (c 0.1, CHCl3); 
M.P.: 74 oC; 
1H NMR (300 MHz, CDCl3): δ 5.58 (dd, J = 8.8, 1.3 Hz, 1H), 4.13 – 4.01 (m, 1H), 3.33 (t, J = 1.4 Hz, 1H), 
2.57 (d, J = 11.6 Hz, 1H), 2.46 – 2.26 (m, 4H), 2.25 – 2.11 (m, 1H), 1.89 (dd, J = 17.4, 8.8 Hz, 1H), 1.71 
(d, J = 7.0 Hz, 3H), 1.66 (ddd, J = 11.3, 7.7, 2.4 Hz, 1H), 1.61 – 1.49 (m, 1H), 1.29 (td, J = 10.1, 4.3 Hz, 
1H), 1.00 (d, J = 6.6 Hz, 3H), 0.94 (d, J = 6.6 Hz, 3H); 
13C NMR (75 MHz, CDCl3): δ 223.93, 137.29, 127.81, 71.21, 59.00, 49.21, 42.26, 37.85, 28.58, 26.93, 
24.92, 21.98, 21.47, 20.99; 
IR (neat) (cm-1) v˜max: 3525, 2964, 2870, 1721, 1443, 1408, 1284, 1241, 1159, 1064, 1033, 975, 864, 
796, 636, 522; 
HRMS (m/z): calcd for C14H22 NaO2 (M+Na)+ 245.1512, found 245.1513. 
 
Compound 158: To a solution of 145 (0.044 g, 0.2 mmol) in anhydrous DMF 
(0.3 mL) was added imidazole (0.078 g, 1.15 mmol), DMAP (0.008 g, 0.06 
mmol) and triethyl chlorosilane (1.46 mL, 0.83 mmol). The clear reaction 
mixture was stirred at room temperature for 1 h, then directly subjected to column chromatography 
(hexanes/EtOAc 10:1) without further work-up to afford 158 in 88% yield (0.059 g). 
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Physical state: yellow color oil; 
TLC: Rf = 0.79 (hexanes/EtOAc 7:1, stains brown with vanillin staining); 
:  –48.7 (c 0.14, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 5.54 (dd, J = 8.1, 1.3 Hz, 1H), 4.20 (dt, J = 6.6, 2.0 Hz, 1H), 2.62 (d, J = 12.7 
Hz, 1H), 2.51 – 2.39 (m, 1H), 2.37 – 2.16 (m, 3H), 2.13 – 1.97 (m, 1H), 1.86 (dd, J = 17.8, 8.1 Hz, 1H), 
1.73 (d, J = 1.2 Hz, 3H), 1.61 – 1.50 (m, 2H), 1.25 (t, J = 7.4 Hz, 1H), 0.97 – 0.94 (m, 6H), 0.92 – 0.86 (m, 
9H), 0.74 – 0.59 (m, 6H); 
13C NMR (75 MHz, CDCl3) δ 219.56, 136.09, 127.75, 70.98, 62.55, 49.66, 43.01, 37.03, 28.71, 26.19, 
25.35, 22.21, 21.38, 21.25, 7.31, 5.66; 
IR (neat) (cm-1) v˜max: 2954, 2874, 1743, 1457, 1243, 1075, 999, 830, 738, 632, 534, 501; 
HRMS (m/z): calcd for C20H37O2Si (M+H)+ 337.2485, found 337.2488. 
 
Compound 144 [(–)-4,6-dihydroxy-1,5(H)-guai-9-ene]: CeCl3.7H2O 
(0.146 g, 0.39 mmol) was placed in 25 mL schlenck flask and, heated at 140 
oC in vacuo (0.01 mmHg) for 3.5 h, and then cooled. Dry THF (1.7 mL) was 
added while stirring under N2, and the solution was stirred for 2 h at room 
temperature under N2 atmosphere. The resulting suspension was cooled to –78 oC, and MeLi (1.6 M 
solution in Et2O, 0.24 mL, 0.17 mmol) was added. The resulting pale brown color mixture was stirred 
for 30 min, and then 158 (0.06 g, 0.18 mmol) in THF (1 mL) was added dropwise, and the mixture was 
stirred for a further 4 h at –78 oC. The reaction mixture was treated with a NH4Claq (15 mL), filtered 
through Celite and extracted with EtOAc (2x25 mL). The combined organic extracts were dried over 
Na2SO4 and evaporated under reduced pressure to give the crude product. Which was used for the 
next step without further purification. 
Ta a solution of above crude in dry THF (2 mL) was added TABF (1 M solution in THF, 0.17 mL) at 0 o C 
during 5 min. The reaction mixture was stirred at room temperature until the starting material 
disappeared (ca. 30 min).The solvent was removed under reduced pressure and the residue was 
purified on silica (hexanes/EtOAc 10:1 to 3:1) to give rise to 144 in 76% yield (0.032 g, over 2 steps). 
Physical state: pale yellow oil; 
TLC: Rf = 0.13 (hexanes/EtOAc 2:1, stains deep blue with vanillin); 
: –9.5 (c 0.44, CHCl3); lit.7 : 10.5 (c 0.60, CHCl3)] for natural (+)-4,6-dihydroxy-1,5(H)-
guai-9-ene; 
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1H NMR (600 MHz, CDCl3) δ 5.57 – 5.43 (m, 1H), 4.21 – 4.06 (m, 1H), 2.36 (d, J = 16.7 Hz, 2H), 2.34 – 
2.19 (m, 2H), 2.08 (dd, J = 12.0, 9.5 Hz, 1H), 1.89 – 1.68 (m, 5H), 1.66 (s, 3H), 1.64 – 1.54 (m, 1H), 1.31 
(s, 3H), 1.29 – 1.20 (m, 1H), 1.02 (d, J = 6.6 Hz, 3H), 0.98 – 0.93 (m, 3H); 
13C NMR (151 MHz, CDCl3) δ 139.22, 126.18, 81.12, 72.42, 57.46, 50.49, 42.32, 39.90, 28.45, 26.59, 
24.33, 24.17, 23.11, 21.41, 21.36; 
IR (neat) (cm-1) v˜max: 3420, 3310, 2957, 2936, 2868, 1475, 1447, 1387, 1366, 1300, 1150, 1126, 
1025, 963, 940, 885, 804, 690, 573, 543; 
HRMS (m/z): calcd for C15H26 NaO2 (M+Na)+ 261.1825, found 261.1825. 
 
 
(–)-Teuclatriol 72 and (–)-10-epi teuclatriol 159: 144 
(0.056 g, 0.24 mmol) and cobalt acetylacetonate 
(0.012 g, 0.047 mmol) were dissolved in THF (2 mL). 
Oxygen was bubbled through the solution for 1 h at 
room temperature, upon which PhSiH3 (0.15 mL, 
0.94 mmol)8 was added. The resulting reaction mixture was stirred at room temperature for 14 h in 
the presence of oxygen. The mixture was diluted with EtOAc, the solvent was evaporated and the 
crude was purified by column chromatography (hexanes/EtOAc 3:1to 1:1) to give rise to 72 in 52% 
yield (0.032 g) and 159 in 20% yield (0.012 g). 
(–)-Teuclatriol: 
Physical state: yellow color oil; 
TLC: Rf = 0.23 (hexanes/EtOAc 2:1, stains blue with vanillin); 
:  –16.8 (c 0.59, CHCl3), lit.9  :  16.9 (c 0.43, CHCl3) for natural (+)-teuclatriol ; 
1H NMR (600 MHz, CDCl3): δ 4.13 (dt, J = 13.4, 4.6 Hz, 1H), 1.98 – 1.93 (m, 1H), 1.86 (td, J = 10.5, 3.1 
Hz, 1H), 1.81 – 1.76 (m, 1H), 1.74 (d, J = 10.4 Hz, 1H), 1.69 (dd, J = 8.1, 6.0 Hz, 2H), 1.67 – 1.64 (m, 
1H), 1.59 – 1.56 (m, 1H), 1.55 – 1.51 (m, 1H), 1.39 (dd, J = 6.2, 3.4 Hz, 2H), 1.36 (dd, J = 6.5, 3.3 Hz, 
1H), 1.34 – 1.29 (m, 1H), 1.27 (d, J = 3.5 Hz, 3H), 1.25 (d, J = 4.2 Hz, 3H), 1.17 – 1.13 (m, 1H), 1.08 (dd, 
J = 8.3, 4.4 Hz, 1H), 1.02 (d, J = 6.6 Hz, 3H), 0.97 (d, J = 6.6 Hz, 3H); 
13C NMR (151 MHz, CDCl3): δ 81.11, 75.47, 71.40, 55.25, 52.03, 47.99, 45.48, 41.10, 29.56, 23.16, 
23.07, 22.14, 21.50, 21.14, 20.50; 
IR (neat) (cm-1): v˜max: 3420, 2960, 2934, 2872, 1508, 1463, 1376, 1218, 1145, 1106, 1036, 902, 852, 
789, 675, 635, 564, 471; 
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HRMS (m/z): calcd for C15H28 NaO3 (M+Na)+ 279.193, found 279.1931. 
 
(–)-10-epi teuclatriol: 
Physical state: pale yellow color oil; 
TLC: Rf = 0.15 (hexanes/EtOAc 2:1, stains deep blue with vanillin); 
: –17.2 (c 0.39, CHCl3), lit.9 : +17.8 (c 0.29, CHCl3) for natural (+)-10-epiteuclatriol; 
1H NMR (300 MHz, CDCl3): δ 4.10 (dt, J = 8.5, 4.4 Hz, 1H), 2.26 – 2.18 (m, 1H), 1.92 – 1.84 (m, 1H), 
1.80 – 1.72 (m, 2H), 1.72 – 1.67 (m, 2H), 1.67 – 1.60 (m, 2H), 1.58 (dd, J = 5.4, 2.5 Hz, 1H), 1.54 (dd, J = 
7.1, 2.0 Hz, 1H), 1.39 (ddd, J = 17.1, 10.4, 3.2 Hz, 2H), 1.29 (s, 3H), 1.25 (s, 1H), 1.21 (s, 1H), 1.17 (d, J = 
6.7 Hz, 3H), 1.14 (dd, J = 6.8, 2.6 Hz, 1H), 1.00 (t, J = 5.5 Hz, 3H), 0.96 (d, J = 6.6 Hz, 3H); 
13C NMR (75 MHz, CDCl3): δ 81.28, 73.19, 71.37, 54.02, 51.63, 46.87, 45.90, 40.93, 29.93, 29.81, 
23.67, 23.30, 21.37, 21.25, 19.97; 
IR (neat) (cm-1) v˜max: 3420, 2960, 2934, 2872, 1508, 1463, 1376, 1218, 1145, 1106, 1036, 902, 852, 
789, 675, 635, 564, 471; 
HRMS (m/z): calcd for C15H28 NaO3 (M+Na)+ 279.193, found 279.1931. 
 
Compound 160: Compound 145 (0.025 g, 0.112 mmol) and Co(acac)2 (0.006 
g, 0.022 mmol) were dissolved in THF (1.2 mL), and the solution was cooled to 
0 oC. Oxygen was bubbled through the solution for 2 h, and PhSiH3 (0.055 mL, 
0.448 mmol) was added afterwards. The reaction was stirred 18 h at room 
temperature in the presence of Oxygen balloon. Then the reaction was diluted with EtOAc and 
filtered through the silica gel. The solvent was removed and the crude was purified by column 
chromatography gave 160 in 62% yield (0.0165 g). 
Physical state: white solid; 
TLC: Rf = 0.21 (hexanes/EtOAc 1:1, stains deep brown with vanillin); 
M.P.: 96 oC; 
: n.d.; 
1H NMR (300 MHz, CDCl3): δ 3.99 (d, J = 3.4 Hz, 1H), 2.59 (t, J = 9.1 Hz, 1H), 2.52 – 2.22 (m, 2H), 2.19 – 
2.08 (m, 1H), 2.05 – 1.94 (m, 2H), 1.90 – 1.81 (m, 2H), 1.68 (dd, J = 15.7, 6.6 Hz, 2H), 1.53 – 1.28 (m, 
3H), 1.25 (s, 3H), 1.16 (dd, J = 14.8, 8.2 Hz, 1H), 0.96 (dd, J = 9.9, 6.6 Hz, 6H); 
13C NMR (75 MHz, CDCl3): δ 225.01, 71.6, 54.95, 51.07, 47.11, 46.63, 37.58, 29.66, 28.90, 23.84, 
21.82, 21.41, 21.11, 20.26; 
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IR (neat) (cm-1) v˜max: n.d; 
HRMS (m/z): calcd for C14H25 O3 (M+H)+ 241.173, found 241.1731 
 
 
Compound 161: To a suspension of Mg (0.0192 g, 0.8 mmol), TiCl4 (0.022 mL, 
0.2 mmol) in DCM (0.4 mL) at 0 oC was added over a 2 min of 160 (0.024 g, 0.1 
mmol) in mixture of DCM: THF (0.3 mL: 0.2 mL). After being stirred for 1.5 h at 
the same temperature, quenched with aq. K2CO3 (1 mL). The resulting mixture 
was extracted with EtOAc (5 mL) followed by washed with brine. The solution was dried, filtered and 
concentrated under reduced pressure. The crude was purified by column chromatography (hexanes: 
EtOAc- 5:1) gave 161 in 48% yield (0.012 g).  
Physical state: colorless oil; 
TLC: Rf = 0.39 (hexanes/EtOAc 7:1, stains deep blue with vanillin); 
: n.d.; 
1H NMR (300 MHz, CDCl3): δ 5.10 (s, 1H), 4.91 – 4.86 (m, 1H), 3.82 (dd, J = 7.8, 3.6 Hz, 1H), 2.67 (ddd, 
J = 10.1, 7.9, 2.2 Hz, 1H), 2.34 (dd, J = 15.3, 7.4 Hz, 1H), 2.28 – 2.16 (m, 1H), 1.89 – 1.82 (m, 2H), 1.78 
– 1.69 (m, 2H), 1.69 – 1.59 (m, 3H), 1.50 – 1.43 (m, 2H), 1.42 – 1.30 (m, 3H), 1.20 (s, 3H), 0.97 (dd, J = 
6.6, 3.0 Hz, 6H); 
13C NMR (75 MHz, CDCl3): δ 156.81, 105.39, 75.60, 72.19, 51.07, 50.4, 48.59, 46.58, 33.45, 29.99, 
29.91, 26.82, 21.39, 21.22, 20.4; 
IR (neat) (cm-1) v˜max: n.d.; 
HRMS (m/z): calcd for C15H27 O2 (M+H)+ 239.193, found 239.1931. 
 
Compound 165: To a suspension of CuI (4.53 g, 23.87 mmol, 1.623 equiv) in 
THF (140 mL) was added isopropenyl magnesiumbromide (0.6.M in THF, 39.8 
ml, 23.87 mmol, 1.623 equiv) dropwise at -78 oC. The solution was allowed to 
warm up to -45 oC upon which a solution of (S)-134 (3 g, 14.7 mmol, 1 equiv) in 
THF (36 mL) was added. After 10 min of stirring, the resulting solution was again cooled to -78 oC and 
HCHO (generated from 13.674 g, 441 mmol, 30 eq. of paraformaldehyde at 150oC) was passed 
through the above reaction mixture until disappearance of the starting material. Upon which the 
reaction was quenched with sat.NH4Cl solution. Aqueous layer was extracted with ether (4×150 mL). 
The combined organic phases were washed with brine (200 mL), dried (Na2SO4) and the solvent was 
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removed under reduced pressure. The crude was purified by flash chromatography on silica 
(hexanes/ EtOAc 5:1 to 2:1) to give compound 165 in 66% yield (1.48 g). 
Physical state: deep yellow oil; 
TLC: Rf = 0.23 (hexanes/ EtOAc 3:1, UV-active, stains dark green with vanillin); 
: 144.46 (c 1.00, CHCl3); 
1H NMR (300 MHz, CDCl3): δ 7.64 (dd, J = 5.7, 2.4 Hz, 1H), 6.23 (dd, J = 5.7, 2.1 Hz, 1H), 4.93 – 4.83 
(m, 1H), 4.81 (d, J = 0.5 Hz, 1H), 3.99 (dd, J = 10.7, 5.2 Hz, 1H), 3.83 – 3.65 (m, 1H), 3.38 (dd, J = 4.6, 
2.3 Hz, 1H), 2.48 (s, 1H), 2.34 (ddd, J = 6.4, 4.7, 3.0 Hz, 1H), 1.73 (dt, J = 20.4, 10.2 Hz, 3H); 
13C NMR (75 MHz, CDCl3): δ 211.27, 166.90, 144.04, 133.60, 112.84, 61.78, 52.82, 51.25, 20.46; 
IR (neat) (cm-1) max: 3418, 1691, 1511, 1057, 895; 
HRMS (m/z): calcd for C9H13O2 (M+H)+ 153.0910, found 153.0908. 
 
Compound 178: To a solution of 165 (2.28 g, 15.0 mmol) in CHCl3 (120 ml) was 
added Ph2SiH2 (4.8 ml, 25.5 mmol, 1.7 equiv), ZnCl2 (1.06 g, 7.8 mmol, 0.52 equiv) 
followed by Pd(PPh3)4 (225 mg, 0.2 mmol, 0.015 equiv).  The resulting deep green 
colored mixture was stirred at room temperature for 30 min. The solvent was 
removed under reduced pressure and the crude was purified by flash column chromatography 
(hexanes/ EtOAc 5:1), 178 was obtained in 75% yield (1.74 g). 
Physical state: deep brown oil; 
[D23= 72.72 (c 1.00, CHCl3); 
1H NMR (300 MHz, CDCl3) δ = 4.88 – 4.86 (m, 1H), 4.84 (d, J=0.6 Hz, 1H), 3.84 (dd, J=11.3, 4.2 Hz, 1H), 
3.65 (dd, J=11.3, 6.2 Hz, 1H), 2.66 (td, J=11.9, 5.8 Hz, 1H), 2.50 – 2.40 (m, 1H), 2.31 (dddd, J=11.9, 5.8, 
3.9, 1.3 Hz, 2H), 2.23 – 2.08 (m, 2H), 1.77 (s, 3H), 1.74 – 1.64 (m, 1H); 
13C NMR (75 MHz, CDCl3) δ = 221.01, 144.63, 111.83, 60.51, 54.07, 46.37, 38.04, 26.63, 19.37.  
 
Compound 179: CeCl3.7H2O (18.5 g, 49.8 mmol, 4.058 equiv) was 
placed in 500 mL three-necked flask and heated at 140o in vacuo 
(0.1 mmHg) for 3 h, and then cooled to room temperature. THF 
(75 mL) was added, and the suspension was stirred at room 
temperature for 2.5 h under N2 atmosphere. The resulting suspension was cooled to -78oC, and 
methyl lithium (1.6 M in Et2O, 30 ml, 49.2 mmol, 4.06 equiv) was added. The resulting pale brown 
colored mixture was stirred for 30 min, ketone 178 (1.88 g, 12.27 mmol, 1 equiv) in THF (45 mL) was 
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added dropwise, and the mixture stirred for a further 4 h at -78 oC. The reaction mixture was treated 
with a saturated solution of NH4Cl, filtered through Celite and extracted with EtOAc (4×150 mL). The 
combined organic layers were dried (Na2SO4) and concentrated under reduce pressure. The crude 
was purified by flash column chromatography (hexanes/ EtOAc 7:1 to 3:1) to give 179a-syn  diol (1.48 
g, 70%) 179b-anti diol (330 mg, 15%) as white solids. 
Syn diol: 179a 
1H NMR (300 MHz, CDCl3) δ = 4.76 (s, 1H), 4.74 – 4.71 (m, 1H), 3.88 (dd, J=11.3, 3.1 Hz, 1H), 3.73 – 
3.65 (m, 1H), 2.89 – 2.81 (m, 1H), 2.78 (d, J=4.8 Hz, 2H), 1.92 (dtd, J=12.6, 8.1, 6.1 Hz, 1H), 1.77 – 1.69 
(m, 2H), 1.68 (s, 3H), 1.56 (ddd, J=10.9, 4.8, 3.3 Hz, 1H), 1.52 – 1.43 (m, 1H), 1.38 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ = 146.93, 110.67, 81.58, 60.75, 52.44, 46.86, 41.52, 28.34, 27.94, 19.28. 
Data was in accordance with literature. 
Anti diol: 179b 
1H NMR (300 MHz, CDCl3) δ = 4.71 (s, 1H), 4.69 (dd, J=3.0, 1.6 Hz, 1H), 3.71 (dd, J=10.7, 4.7 Hz, 1H), 
3.67 – 3.57 (m, 1H), 2.40 (s, 2H), 2.24 – 2.06 (m, 2H), 1.87 – 1.73 (m, 2H), 1.72 (s, 3H), 1.70 – 1.55 (m, 
2H), 1.29 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ = 146.84, 110.74, 80.62, 63.13, 53.04, 47.50, 40.27, 26.94, 23.05, 18.75. 
Data was in accordance with literature. 
 
 Compound 164: To a solution of DMSO (3.06 g, 2.78 ml, 39 mmol, 5.27 equiv) in 
CH2Cl2 (16 mL) was added oxalyl chloride (1.66 ml, 20 mmol, 2.702 equiv) at -78o C. 
The resulting mixture was stirred at  this temperature for 30 min and solution of 
179a-syn diol (1.258 g, 7.4 mmol, 1 equiv) in CH2Cl2 (10 mL) was added over 30 min.  
The resulting mixture was stirred for 3 h, Et3N (11.8 mL, 84.32 mmol, 11.395 equiv) was added and 
the mixture was warmed to room temperature. The resulting mixture was diluted with cold water 
followed by extraction with DCM (4×50 mL). The combined organic layers were washed with brine 
(100mL) and dried. The solvent was removed under reduced pressure to give crude, which was 
purified by flash column chromatography (hexanes/ EtOAc 5:1) to give 164 in 52% yield (0.58 g). 
Physical state: deep pink color oil; 
Rf = 0.75 (hexanes/ EtOAc 3:1, stains deep blue with vanilin); 
[D23= 58.7 (c 1, CHCl3). (lit [α]D23= 56.1 c 1, CHCl3); 
 1H NMR (300 MHz, CDCl3) δ = 9.97 (s, 1H), 4.71 – 4.68 (m, 1H), 4.63 – 4.59 (m, 1H), 3.61 (d, J=9.3 Hz, 
1H), 2.62 (dt, J=17.9, 8.2 Hz, 1H), 2.52 – 2.38 (m, 1H), 2.18 (d,   J=1.2 Hz, 3H), 2.14 – 2.02 (m, 2H), 1.68 
(s, 3H). 
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13C NMR (75 MHz, CDCl3) δ = 188.00, 163.74, 146.8, 139.13, 109.73 50.74, 39.43, 28.55, 20.48, 14.56. 
Data was in accordance with literature. 
 
Compound 187: Under nitrogen atmosphere to a solution of 2-Isopropyl-1,3-
dithinae (0.5 g, 2.975 mmol, 0.649 equiv) in THF (8.5 mL) was added dropwise 
n-BuLi (1.44 M, 3.15 mL, 4.533 mmol, 0.990 equiv) at -25 oC. The resultant 
clear solution was stirred at the same temperature for 2 h. After cooling down 
to -78o C, aldehyde 164 (0.687 g, 4.58 mmol, 1 equiv) in THF (3 mL) was added dropwise. The 
reaction mixture was stirred for 1 h, then quenched with saturated solution of NH4Cl and warmed to 
ambient temperature. The layers were separated and aqueous layer was extracted with ether (3×50 
mL). The combined organic layers were washed with brine (50 mL), dried (Na2SO4), filtered and 
concentrated under vacuo. The crude was purified by flash column chromatography (hexanes/ EtOAc 
99.5:0.5 to 98:2) to give 187 in 70% yield (1.0 g). 
Physical state: colorless syrup; 
Rf = 0.64 (hexanes/ EtOAc 10:1, stains deep blue with vanilin); 
[D23= 62.5 (c 0.85, CHCl3); 
1H NMR (300 MHz, CDCl3) δ = 4.92 (d, J=7.4 Hz, 2H), 4.78 – 4.71 (m, 1H), 4.00 (d, J=8.7 Hz, 1H), 2.97 
(ddd, J=14.1, 9.0, 4.0 Hz, 1H), 2.89 – 2.81 (m, 2H), 2.79 – 2.71 (m, 2H), 2.50 – 2.30 (m, 2H), 2.20 (dd, 
J=16.3, 9.9 Hz, 1H), 2.12 – 2.02 (m, 1H), 1.93 (dd, J=12.0, 6.0 Hz, 2H), 1.80 – 1.74 (m, 6H), 1.63 – 1.57 
(m, 1H), 1.24 (d, J=6.9 Hz, 3H), 1.14 (d, J=6.8 Hz, 3H);  
13C NMR (75 MHz, CDCl3) δ = 152.42, 141.08, 134.28, 110.13, 74.66, 64.67, 53.74, 37.36, 35.16, 
29.41, 26.43, 26.43, 24.41, 20.16, 19.11, 18.51, 15.17; 
IR (neat) (cm-1) max: 3539, 2922, 1637, 1436, 1380, 1017, 894, 803;  
HRMS (ESI): calcd for C17H29OS2 (M+H)+ 313.1654, found 313.1653. 
 
Compound 163: The hydroxydithiane 187 (1.079 g, 3.46 mmol) was 
dissolved in acetonitrile (5 mL) and was added at once to a well stirred 
solution of NCS (1.40 g, 10.4 mmol, 3 equiv) and AgNO3 (2.05 g, 12.1 mmol, 
3.497 equiv) in 50 mL of 90% aq.MeCN at 0 oC, stirring was continued for 30 
min at the same temperature and then treated with sat.Na2S2O3 solution (25 mL). The reaction 
mixture was extracted with ether (2×100 mL), then combined organic layers were washed with 
aq.Na2CO3 (50 mL), water (50 mL) and brine (50 mL), dried, filtered and concentrated under vacuo. 
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The crude was purified by flash column chromatography on silica (hexanes/ EtOAc 98:2) to give 163 
in 75% yield (0.58 g). 
Physical state: pale red color oil; 
Rf = 0.36 (hexanes/ EtOAc 10:1, stains blue with vanilin); 
[]D23= 405.1 (c 0.52, CHCl3); 
1H NMR (300 MHz, CDCl3) δ = 5.06 (s, 1H), 4.67 (d, J=1.5 Hz, 1H), 4.61 (dd, J=2.1, 1.4, Hz 1H), 3.46 (s, 
1H), 3.08 (d, J=9.2 Hz, 1H), 2.74 – 2.62 (m, 1H), 2.48 (dtd, J=10.0, 7.6, 1.1 Hz, 1H), 2.33 – 2.21 (m, 1H), 
2.05 – 1.93 (m, 1H), 1.85 (d, J=1.2 Hz, 3H), 1.70 (ddd, J=8.3, 4.4, 2.1 Hz, 1H), 1.65 (s, 3H), 1.11 – 1.05 
(m, 6H); 
13C NMR (75 MHz, CDCl3) δ = 214.24, 149.62, 142.41, 132.19, 110.52, 72.94, 54.79, 37.90, 35.99, 
28.33, 19.59, 18.21, 17.80, 14.42; 
IR (neat) (cm-1) max: 3540, 2970, 2936, 1712, 1382, 1005, 884; 
HRMS (EI-MS): calcd for C14H23O2 (M+H)+ 223.1693, found 223.1693. 
 
Compound 188: Under nitrogen atmosphere to a solution of hydroxyketone 
163 (475 mg, 2.14 mmol, 1 equiv) in THF (38 mL) was added a solution of allyl 
magnesiumbromide (0.55 M in Et2O, 15.56 mL, 3.21 mmol, 1.5 equiv) at 0 oC, and 
was stirred at the same temperature for 1.5 h. The reaction mixture was 
quenched with saturated solution of NH4Cl. The layers were separated and the aqueous layer was 
extracted with ether (2×50 mL). The combined organic extracts were washed with brine (50 mL) and 
dried. The solvent was removed under reduce pressure. The crude was purified by flash column 
chromatography (hexanes/ EtOAc 10:1) to give 188 in 72% yield (0.41 g). 
Physical state: light red color oil; 
Rf= 0.41 (hexanes/ EtOAc 7:1, stains blue with vanilin); 
[]D23= 72.9 (c 0.48, CHCl3); 
1H NMR (300 MHz, CDCl3) δ = 6.03 (dqd, J=20.7, 10.4, 7.6 Hz, 1H), 5.17 – 5.00 (m,  2H), 4.83 (d, J=2.3 
Hz, 1H), 4.69 (dd, J=2.4, 1.3 Hz, 1H), 4.54 (d, J=5.8 Hz, 1H), 3.68 (d, J=9.0 Hz, 1H), 2.44 – 2.34 (m, 3H), 
2.26 – 2.11 (m, 2H), 2.06 – 1.94 (m, 1H), 1.80 – 1.72 (m, 6H), 1.62 – 1.53 (m, 1H), 1.29 – 1.24 (m, 1H), 
0.99 (d, J=6.9 Hz, 3H), 0.90 – 0.85 (m, 1H), 0.83 (dd, J=6.7, 3.4 HZ, 3H); 
 13C NMR (75 MHz, CDCl3) δ = 152.70, 140.10, 135.77, 134.55, 117.5, 109.62, 77.99, 73.55, 53.66, 
39.31, 37.31, 33.75, 29.19, 20.22, 17.48, 14.85; 
 IR (neat) (cm-1) max: 3547, 2939, 1638, 1439, 1371, 1059, 1371, 998, 893; 
HRMS (EI-MS): calcd for C17H29O2 (M+H)+ 265.2162, found 265.2164. 
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Compound 189: A flask containing diol 188 (400 mg, 1.515 mmol, 1 equiv) was 
outfitted with a reflux condenser and evacuated and backfilled with dry N2. 
DCM (100 mL) was added, and the solution was heated to reflux. A solution of 
Grubbs-II catalyst (66 mg, 0.0778 mmol, 0.117 equiv) in DCM (6.6 mL) was 
added to the reaction mixture, and the light brown color mixture was refluxed further for 3 h. The 
solvent was removed under reduced pressure and crude was purified by flash chromatography 
(hexanes/ EtOAc 5:1) to give 189 in 95% yield (0.34 g). 
Physical state: Pale brown color oil; 
Rf= 0.25 (hexanes/ EtOAc 5:1, stains deep blue with vanilin); 
[D23= 90.0 (c 1.07, CHCl3); 
1H NMR (300 MHz, Acetone) δ = 5.37 – 5.29 (m, 1H), 4.43 (s, 1H), 3.72 (d, J=4.2 Hz, 1H), 3.24 (t, J=9.1 
Hz, 1H), 2.33 (dd, J=5.1, 1.9 Hz, 1H), 2.28 (dt, J=3.7, 2.6 Hz, 1H), 2.18 – 2.09 (m, 1H), 2.06 (dd, J=4.5, 
2.3 Hz, 1H), 2.03 – 1.96 (m, 3H), 1.89 (dd, J=1.9, 1.0 Hz, 3H), 1.79 – 1.74 (m, 1H), 1.72 (d, J=1.0 Hz, 
3H), 1.06 (d, J=6.8 Hz, 3H), 0.91 – 0.86 (m, 3H); 
13C NMR (75 MHz, Acetone) δ = 141, 137.53, 134.16, 121, 81.75, 78.29, 53.40, 38.93, 35.98, 32.98, 
29.75, 23.81, 18.72, 18.64, 15.81; 
IR (neat)  (cm-1) max: 3472, 2961, 2914, 1741, 1445, 1373, 1072, 1013; 
HRMS (EI-MS): calcd for C15H25O2 (M+H)+ 237.1849, found 237.1843. 
 
Compound 192: Under nitrogen atmosphere to a solution of diol 189 (182 
mg, 0.771 mmol, 1 equiv) in DCM (38 mL) was added Hg (OAc)2 (302.5 mg, 
0.951 mmol, 1.233 equiv) at room temperature .The reaction mixture was 
stirred for 15 h. To this resultant mixture was added water and extracted with 
ether (4×50 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), 
dried (Na2SO4) and filtered. The solvent was removed under reduced pressure to give crude 162. This 
was used for the next step without further purification. 
To the above crude 162 in dry MeOH (23 mL), was added NaBH4 (500 mg, 5.11 mmol) at -78 oC. The 
resulting mixture was warmed to room temperature and stirred for 3 h. The reaction mixture was 
treated with water, extracted with EtOAc (2×100 mL). The combined organic layers were washed 
with brine (50 mL), water (50 mL), dried and filtered. The crude was concentrated under reduced 
pressure and purified by flash chromatography (hexanes/ EtOAc 3:1) to give 192 in 62% yield (0.11 g). 
Physical state: colorless oil; 
Rf = 0.6 (hexanes/ EtOAc 5:1, stains blue with vanilin); 
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[D23= 38.2 (c 0.25, CHCl3); 
 1H NMR (300 MHz, CDCl3) δ = 4.44 (s, 1H), 2.68 (t, J=7.5 Hz, 1H), 2.26 (dt, J=24.9, 11.3 Hz, 2H), 1.94 
(dd, J=13.1, 6.2 Hz, 1H), 1.89 (s, 3H), 1.85 – 1.74 (m, 2H), 1.73 – 1.59 (m, 2H), 1.51 (d, J=4.3 Hz, 1H), 
1.36 – 1.23 (m, 2H), 1.19 (d, J=4.7 Hz, 3H), 1.03 (t, J=6.9 Hz, 6H); 
13C NMR (75 MHz, CDCl3) δ = 133.49, 133.01, 86.66, 84.41, 73.89, 57.59, 39.05, 31.74, 31.68, 28.61, 
24.00, 23.97, 18.12, 17.26, 14.64;  
IR (neat) (cm-1) max = 3490, 2965, 2932, 2878, 1470, 1375, 1176, 1072, 1013, 901;  
HRMS (EI-MS): calcd for 237.1849 (M+H)+, found 237.1852. 
 
Compound 194: Under nitrogen atmosphere to a solution of alcohol 192 (185 
mg, 0.783 mmol, 1 equiv) in DCM (38 mL) was added Dess-Martin periodinane 
(370 mg, 0.870 mmol, 1.12 equiv) at 0o C. The resulting mixture was warmed to 
ambient temperature and stirred for 1 h, then treated with saturated Na2S2O3 
solution (20 mL), followed by addition of sat. NaHCO3 solution (20 mL) after 15 min. The resultant 
mixture was stirred for additional 15 min. The organic layer was separated and the aqueous layer 
was extracted with DCM (3×100 mL). The combined organic layers were washed with water (100 mL), 
brine (100 mL), dried over Na2SO4. The solvent was removed under reduced pressure, to give enone 
194, which was used for the next step without further purification (0.36 g, 98%). 
Rf= 0.87 (hexanes/ EtOAc 5:1, stains brown with vanilin); 
[]D23= -1.4 (c 0.47, CHCl3); 
1H NMR (300 MHz, CDCl3) δ = 3.22 (s, 1H), 2.59 – 2.42 (m, 1H), 2.35 – 2.23 (m, 1H), 2.16 (dt, J=13.7, 
6.9 Hz, 1H), 2.08 (dd, J=3.3, 2.3 Hz, 3H), 2.05 – 1.85 (m, 3H), 1.68 – 1.61 (m, 1H), 1.54 – 1.35 (m, 2H), 
1.33 (s, 3H), 1.03 (dd, J=6.9, 2.0 Hz, 6H); 
13C NMR (75 MHz, CDCl3) δ = 199.88, 154.45, 131.90, 91.07, 84.39, 57.90, 38.86, 33.27, 30.57, 30.04, 
25.98, 24.61, 18.41, 17.30, 15.96; 
IR (neat) (cm-1) max= 2965, 2877, 1689, 1625, 1375, 1268, 1077, 1004, 883; 
HRMS (EI-MS): calcd for C15H23O2 (M+H)+ 235.1693, found 235.1696. 
 
Orientalol-F 78: Under nitrogen atmosphere to a stirred solution of crude 194 
(81 mg, 0.346 mmol, 1 equiv) and CeCl3.7H2O (260 mg, 0.696 mmol, 2.011 
equiv) in MeOH (10 mL) was added NaBH4 (26.2 mg, 0.696 mmol, 2.011 equiv) 
at 0 oC. The mixture was stirred at room temperature for 20 h, then quenched 
by addition of water and extracted with EtOAc (2×50 mL). The combined organic layers were washed 
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with water (25 mL), brine (25 mL), dried, filtered and concentrated under reduce pressure. The crude 
was purified by flash chromatography (hexanes/ EtOAc 5:1) gave 78 (Orientalol-F) in 94% yield (0.076 
g). 
Physical state: pale yellow oil; 
Rf= 0.6 (hexanes/ EtOAc 5:1, stains blue with vanilin); 
[D23= 12.4 (c .67, DCM). (lit-[]D23= 12.2 (c 0.5, DCM);  
1H NMR (300 MHz, CDCl3) δ = 4.47 – 4.39 (m, 1H), 2.73 – 2.63 (m, 1H), 2.39 – 2.15 (m, 2H), 1.96 (dd, 
J=13.8, 6.9 Hz, 1H), 1.89 (dd, J=3.2, 2.3 Hz, 3H), 1.85 – 1.75 (m, 2H), 1.73 – 1.60 (m, 2H), 1.58 – 1.46 
(m, 1H), 1.28 (dddd, J=10.8, 9.7, 6.5, 2.5 Hz, 2H), 1.21 – 1.18 (m, 3H), 1.03 (t, J=6.9 Hz, 6H); 
13C NMR (75 MHz, CDCl3) δ = 133.49, 133.0, 86.65, 84.41, 73.89, 57.59, 39.05, 31.73, 31.68, 28.60, 
24.03, 23.97, 18.11, 17.26, 14.64; 
IR (neat) (cm-1) max= 3490, 2965, 2931, 2878, 1469, 1375, 1177, 1072, 1013, 901; 
HRMS (EI-MS): calcd for C15H25O2 (M+H)+ 237.1849, found 237.1852. Data was in accordance with 
literature. 
 
Compound 197: Under nitrogen atmosphere m-CPBA (70%, 252 mg, 1.02 
mmol, 1.2 equiv) was added to a stirred solution of 78 (200 mg, 0.85 mmol, 1 
equiv) in DCM (4 mL) at 0o C. The resultant mixture was stirred for 2 h at the 
same temperature, then quenched with saturated Na2CO3 solution (3 mL), and 
diluted with water (10 mL).The aqueous layer was extracted twice with DCM (2×15 mL). The 
combined organic extracts were washed with water (10 mL), brine (10 mL) dried and filtered. The 
solvent was removed under reduced pressure to give 197 as a white crystalline compound. This was 
used for the recrystallyzation from n-heptane without further purification.  
Rf= 0.50 (hexanes/ EtOAc 3:1, stains deep blue with vanilin). 
[]D23= 0.64 (c .36, CHCl3); 
M.P = 68 oC; 
1H NMR (300 MHz, CDCl3) δ = 4.34 (s, 1H), 2.16 (d, J=9.4 Hz, 1H), 2.04 – 1.75 (m, 6H), 1.75 – 1.68 (m, 
1H), 1.67 (s, 3H), 1.65 – 1.40 (m, 3H), 1.26 (s, 3H), 1.03 (dd, J=8.9, 6.9 Hz, 6H); 
13C NMR (75 MHz, CDCl3) δ = 86.67, 83.97, 73.55, 72.11, 71.76, 52.07, 34.58, 33.22, 31.99, 28.85, 
24.54, 21.5, 17.81, 17.53, 16.72; 
IR (neat) (cm-1) max= 3406, 2970, 2895, 1474, 1375, 1085, 1005, 888, 722; 
HRMS (EI-MS): calcd for C15H25O3 (M+H)+ 253.1798, found 253.1797. 
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Under N2 atmosphere allyl magnesiumbromide (0.55 M in Et2O, 15.56 mL, 3.21 mmol, 1.5 equiv) was 
added to a solution of 163 (475 mg, 2.14 mmol, 1 equiv) in THF (38 mL) at 0 oC and stirring was 
continued for 1.5 h at the same temperature. The solvent was removed under reduced pressure, 
then dry DCM (100 mL) was added to this residue followed by addition Grubbs-II catalyst (66 mg, 
0.0778 mmol, 0.117 equiv) in CH2Cl2 (6.6 mL) at room temperature. The resultant brown colored 
solution was refluxed for 3 h, to this solution was added Hg (OAc)2 (520 mg, 1.622 mmol, 2.1 equiv) 
at ambient temperature. The resultant mixture was stirred for 15 h at the same temperature, and 
then quenched by addition of brine (75 mL). The aqueous layer was removed with pipette, and the 
resultant organic phase was concentrated in vacuo. To this residue in dry MeOH (50 mL) was added 
NaBH4 (1 g, 10.2 mmol) at -78 oC. The reaction mixture was stirred at room temperature for 3 h, then 
the reaction was quenched with water, and extracted with EtOAc (4 X 50 mL). The combined organic 
layers were washed with brine (50 mL), water (50 mL) dried, filtered and concentrated in vacuo. The 
crude was purified by flash chromatography on silica (hexanes/ EtOAc 3:1) to give 192 (0.23 g, 45%) 
as colorless oil. 
 
Oxygen was bubbled through the solution of NaBH4 (210 mg, 5.55 mmol) in dry DMF (20 mL) for 45 
min at room temperature, at which point suspension of residue (the crude obtained after 
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oxymercuration step from the above procedure) in dry DMF (20 mL) was introduced dropwise with 
syringe pump with continuous oxygen bubbling during 1 h. Upon, completion of the addition the 
resulting mixture was stirred with continuous oxygen bubbling at the same temperature for 30 min, 
and the reaction mixture was filtered through Celite pad, and washed celite pad with EtOAc, 
combined organic phases were washed with water, dried, filtered and concentrated in vacuo. The 
crude was purified by flash chromatography (hexanes/ EtOAc 3:1 to 1:1) to give 193 (0.22 g, 40%) as 
white color powder. 
Rf= 0.25 (hexanes/ EtOAc 5:1, stains deep blue with vanilin). 
[]D23= 11.8 (c .49, CH2Cl2); 
1H NMR (300 MHz, CDCl3) δ 4.39 (s, 1H), 3.93 (t, J = 6.7 Hz, 1H), 2.78 – 2.64 (m, 1H), 2.43 – 2.19 (m, 
3H), 2.01 – 1.93 (m, 1H), 1.86 (d, J = 6.6 Hz, 3H), 1.64 – 1.49 (m, 3H), 1.37 (d, J = 8.7 Hz, 1H), 1.33 – 
1.25 (m, 1H), 1.19 (s, 3H), 1.06 (dd, J = 6.9, 3.4 Hz, 6H). 
13C NMR (75 MHz, CDCl3) δ 133.7, 132.2, 86.8, 85.6, 73.5, 73.4, 56.1, 40.5, 38.9, 30.9, 23.6, 18.8, 17.8, 
17.2, 14.6; 
IR (neat) (cm-1) max= 3490, 3398, 2965, 2931, 2878, 1469, 1375, 1181, 1031, 901; 
HRMS (EI-MS): calcd for C15H24O3 (M+H)+ 252.1726, found 253.173. 
                 
 
Under nitrogen atmosphere to a solution of diol 193 (252 mg, 1 mmol, 1 equiv) in DCM (20 mL) was 
added Dess-Martin periodinane (1.272 g, 3 mmol, 3 equiv) at 0o C. The resulting mixture was stirred 
for 4 h at the room temperature, then quenched with saturated Na2S2O3 solution (40 mL) followed by 
addition of sat.NaHCO3 solution (40 mL) after 15 min. The resulting mixture was stirred for additional 
15 min. The organic layer was separated and the aqueous layer was extracted with DCM (3×100 mL). 
The combined organic layers were washed with water (100 mL), brine (100 mL), and dried over 
Na2SO4. Solvent was removed in vacuo, to give di ketone 195, which was unstable at room 
temperature. 
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To a solution of the above crude di ketone 195 in dry MeOH (15 mL) was added NaBH4 (38 mg, 1 
mmol, 1 equiv) at 0 oC. After 30 min of stirring at the same temperature, the reaction mixture was 
quenched with saturated aq. NH4Cl and extracted twice with EtOAc (20 mL). The combined organic 
phases were washed with brine and dried over Na2SO4. The residue was concentrated in vacuo and 
the crude was purified by flash chromatography (hexanes/ EtOAc 3:1 to 1:1) to give 196 as a white 
color powder in 72% yield (0.18 g). 
Rf= 0.25 (hexanes/ EtOAc 5:1, stains deep blue with vanilin). 
[]D23= 2.8 (c .49, CH2Cl2); 
1H NMR (300 MHz, CDCl3) δ (300 MHz, CDCl3) δ 4.55 (s, 1H), 3.95 (dd, J = 10.7, 6.2 Hz, 1H), 2.83 (s, 
1H), 2.39 (dd, J = 10.3, 6.7 Hz, 2H), 2.29 – 2.21 (m, 1H), 2.16 – 2.08 (m, 1H), 2.07 – 1.99 (m, 1H), 1.91 
(d, J = 5.1 Hz, 3H), 1.89 – 1.76 (m, 2H), 1.66 (dd, J = 13.5, 6.2 Hz, 2H), 1.26 (s, 3H), 1.00 (dd, J = 7.7, 7.1 
Hz, 6H). 
13C NMR (75 MHz, CDCl3) δ 133.5, 133.4, 84.8, 81.9, 81.3, 74.1, 57.5, 39.3, 39.0, 31.1, 22.8, 21.6, 17.2, 
16.8, 14.6; 
IR (neat) (cm-1) max= 3490, 3398, 2965, 2931, 2878, 1469, 1375, 1181, 1031, 901; 
HRMS (EI-MS): calcd for C15H24O3 (M+H)+ 252.1726, found 253.173. 
 
Compound 199: According to general procedure A: To a stirred solution of  
CuCN (3.12 g, 34.85 mmol, 3.0 equiv) and anhydrous LiCl (2.97 g, 69.69 mmol, 
6.0 equiv) in THF (120 mL) was added iso propenylmagnesium bromide (1.18 
M solution in THF, 34.85 mmol, 30 mL, 3.0 equiv) dropwise at –40 oC. The 
reaction mixture was cooled to –78 oC upon which a solution of (R)-125 (2.3 g, 11.61 mmol, 1.0 equiv) 
in THF (15 mL) was added. After 4 min of stirring, 198 (1.96 g, 19.52 mmol, 1.68 equiv) was added. 
After the starting material had disappeared, aq. NH4Cl (100 mL) was added and the reaction mixture 
was extracted with Et2O (2x150 mL). The combined organic extracts were dried over Na2SO4, filtered 
and the solvent was removed under reduced pressure. After purification on silica (hexanes/EtOAc 
5:1) 199 was obtained in 81% yield (1.95 g). 
Rf= 0.33 (hexanes/ EtOAc 5:1, UV-active, stains bluish-green with vanilin). 
1H NMR (300 MHz, CDCl3) δ 7.51 (dd, J = 5.7, 2.5 Hz, 1H), 6.16 (dd, J = 5.7, 2.0 Hz, 1H), 5.21 – 5.15 (m, 
1H), 4.82 – 4.80 (m, 1H), 4.68 (s, 1H), 4.42 (t, J = 8.9 Hz, 1H), 3.69 (s, 1H), 3.14 (dd, J = 4.5, 2.2 Hz, 1H), 
2.26 (dd, J = 8.6, 2.5 Hz, 1H), 1.67 (dd, J = 6.4, 1.3 Hz, 6H), 1.62 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 212.4, 167.6, 143.8, 136.7, 133.2, 125.1, 113.4, 69.2, 55.4, 52.0, 25.7, 
20.2, 18.5; 
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HRMS (EI-MS): calcd for C13H18O2Na (M+Na)+ 229.1307, found 229.1310. 
 
Compound 200: To a solution of unsaturated compound 199 (0.15 g, 
0.728 mmol) in CHCl3 (6 mL) was added Ph2SiH2 (0.23 ml, 1.24 mmol, 1.7 
equiv), ZnCl2 (0.051 g, 0.38 mmol, 0.52 equiv) and Pd (PPh3)4 (0.011 g, 0.011 
mmol, 0.015 equiv). The mixture was stirred at room temperature for 3 h. The 
solvent was removed under reduced pressure, the crude was purified by flash column 
chromatography (hexanes/ EtOAc 5:1) to give 200 as pale brown oil in 28% yield (0.043 g). 
To a solution of unsaturated compound 199 (0.029 g, 0.14 mmol) in THF (0.5 mL) was added 
Bu3SnH (0.08 ml, 0.28 mmol, 2.0 equiv), ZnCl2 (0.042 g, 0.308 mmol, 2.2 equiv) and Pd (PPh3)4 (0.005 
g, 0.0042 mmol, 0.03 equiv). The mixture was stirred at room temperature for 3 h. The solvent was 
removed under reduced pressure, the crude was purified by flash column chromatography on silica 
(hexanes/ EtOAc 5:1) to give 200 as pale brown oil in 30% yield (0.045 g). 
To a suspension of LiAlH4 (0.332 g, 8.73 mmol) in THF (38 mL) at -78 oC was added CuI (1.66 g, 8.73 
mmol) dissolved in THF: DMPU (4:1, 38 mL). The resulting mixture was stirred for 1 h at the sma 
temperature, and then added 199 (1.8 g, 8.73 mmol) in THF (4 mL). After stirring 2 h at -78 oC, the 
mixture was quenched with aq. NH4Cl (50 mL) followed by ether (100 mL). The aqueous layer was 
extracted twice with Et2O. The combined organic extracts were washed with brine, dried, filtered and 
concentrated under reduced pressure gave crude. The crude was purified by flash chromatography 
(hexanes/ EtOAc 3:1) gave 200 in 82% yield (1.5 g). 
Rf= 0.25 (hexanes/ EtOAc 5:1, stains brown with vanilin). 
1H NMR (300 MHz, CDCl3) δ 5.36 – 5.28 (m, 1H), 4.82 – 4.77 (m, 2H), 4.47 (ddd, J = 9.0, 6.0, 2.8 Hz, 
1H), 3.12 (d, J = 3.3 Hz, 1H), 2.69 (td, J = 11.1, 6.6 Hz, 1H), 2.46 – 2.36 (m, 1H), 2.33 – 2.18 (m, 2H), 
2.10 – 2.03 (m, 1H), 1.73 (s, 3H), 1.72 – 1.70 (m, 1H), 1.66 (dd, J = 9.7, 1.3 Hz, 6H); 
 
13C NMR (75 MHz, CDCl3) δ 221.2, 145.5, 135.9, 124.9, 111.6, 68.4, 57.2, 47.3, 38.4, 26.9, 25.7, 19.1, 
18.2; 
HRMS (EI-MS): calcd for C13H20O2Na (M+Na)+ 231.1466, found 231.1467. 
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Compound 202: Under the nitrogen atmosphere to a solution of 199 (0.064 g, 
0.31 mmol) in DCM (3 mL) at 0 oC was added m-CPBA (0.152 g, 2.0 equiv) at 
once. The reaction mixture was allowed to stir for 20 min at the same 
temperature. The solvent was removed under reduced pressure and the 
crude was purified by flash column chromatography (hexanes/ EtOAc 2:1) gave 202 in 88% yield 
(0.061 g).  
Rf= 0.28 (hexanes/ EtOAc 3:1, UV-active, stains deep pink with vanilin). 
1H NMR (300 MHz, CDCl3) δ 7.61 (dd, J = 5.7, 2.5 Hz, 1H), 6.24 (dd, J = 5.7, 2.1 Hz, 1H), 4.90 (p, J = 1.4 
Hz, 1H), 4.83 (d, J = 0.6 Hz, 1H), 3.78 (dd, J = 7.7, 4.9 Hz, 1H), 3.56 (dd, J = 4.7, 2.2 Hz, 1H), 3.16 (d, J = 
7.7 Hz, 1H), 2.43 (dd, J = 4.9, 2.9 Hz, 1H), 1.75 – 1.72 (m, 3H), 1.33 (d, J = 3.3 Hz, 6H); 
13C NMR (75 MHz, CDCl3) δ 209.2, 166.7, 143.9, 134.0, 113.3, 70.1, 64.8, 60.5, 53.8, 51.7, 24.8, 20.2, 
19.3; 
HRMS (EI-MS): calcd for C13H19O3 (M+H)+ 223.126, found 223.1261. 
 
Compound 203: To a solution of unsaturated compound 202 (0.07 g, 
0.315 mmol) in CHCl3 (3 mL) was added Ph2SiH2 (0.099 ml, 0.535 mmol, 1.7 
equiv), ZnCl2 (0.022 g, 0.38 mmol, 0.16 equiv) and Pd (PPh3)4 (0.005 g, 0.004 
mmol, 0.015 equiv), and the mixture was stirred at the room temperature for 
30 min. The solvent was removed under reduced pressure, the crude was purified by flash column 
chromatography (hexanes/ EtOAc 5:1) to give 203 as pale brown oil in 28% yield (0.02 g). 
Rf= 0.31 (hexanes/ EtOAc 7:1, stains blue with vanilin). 
1H NMR (300 MHz, CDCl3) δ 4.96 – 4.88 (m, 2H), 4.26 – 4.16 (m, 2H), 3.74 (d, J = 4.6 Hz, 1H), 3.53 (d, J 
= 3.7 Hz, 1H), 3.02 – 2.87 (m, 1H), 2.52 – 2.42 (m, 1H), 2.33 – 2.28 (m, 1H), 2.28 – 2.16 (m, 2H), 1.79 
(s, 3H), 1.64 (s, 3H), 1.54 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 223.4, 144.5, 112.6, 78.1, 72.3, 66.9, 57.4, 47.4, 39.0, 30.5, 27.0, 26.5, 
19.2; 
HRMS (EI-MS): calcd for C13H21O3 (M+H)+ 225.141, found 225.140. 
 
Compound 205: CeCl3.7H2O (1.63 g, 4.36 mmol, 
4.05 equiv) was place in a 25 mL three-necked flask 
and heated at 140o in vacuo (0.1 mmHg) for 3 h, 
and then cooled to room temperature. THF (10 mL) 
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was added and stirring was continued for 2.5 h at room temperature. The resulting suspension was 
cooled to -78oC, and methyl lithium (1.49 M in Et2O, 3.0 ml, 4.315 mmol, 4.01 equiv) was added. The 
resulting pale brown colored mixture was stirred for 1 h, ketone 200 (0.224 g, 1.07 mmol, 1.0 equiv) 
in THF (5 mL) was added, and the reaction mixture was stirred for further 4 h at the same 
temperature. The reaction mixture was quenched with aq.NH4Cl solution, filtered through Celite and 
extracted with EtOAc (4×15 mL). The combined organic layers were dried (Na2SO4). The solvent was 
removed under reduce pressure, the products were separated by flash column chromatography 
(hexanes/ EtOAc 7:1 to 3:1) to give 205-syn  diol (0.074 g, 30%) 205-anti diol  (0.11 g, 46%) as 
colorless oils. 
205-syn  diol: 
Rf= 0.72 for syn and 0.6 for anti (hexanes/ EtOAc 5:1, stains pale blue with vanilin); 
1H NMR (300 MHz, CDCl3) δ 5.36 – 5.26 (m, 1H), 4.68 (s, 2H), 4.52 (dd, J = 9.2, 6.6 Hz, 1H), 2.58 (dd, J 
= 17.1, 8.9 Hz, 1H), 1.90 – 1.81 (m, 1H), 1.78 – 1.72 (m, 2H), 1.68 (s, 3H), 1.66 (s, 6H), 1.57 – 1.44 (m, 
2H), 1.42 (s, 3H), 1.39 – 1.24 (m, 2H); 
13C NMR (75 MHz, CDCl3) δ 147.4, 134.3, 127.2, 110.4, 81.3, 70.3, 56.0, 49.7, 42.3, 31.0, 29.4, 25.7, 
19.5, 18.2; 
HRMS (EI-MS): calcd for C14H25O2 (M+H)+ 225.1776, found 225.177. 
205-anti diol:   
Rf=  (hexanes: ethyl acetate=5:1). 
1H NMR (300 MHz, CDCl3) δ 5.11 – 5.00 (m, 1H), 4.58 – 4.49 (m, 2H), 4.40 (t, J = 9.6 Hz, 1H), 3.36 (s, 
1H), 2.26 – 2.14 (m, 1H), 1.96 (dd, J = 28.5, 18.0 Hz, 2H), 1.86 – 1.76 (m, 2H), 1.75 – 1.70 (m, 1H), 1.67 
– 1.64 (m, 6H), 1.61 (d, J = 1.2 Hz, 3H), 1.51 – 1.43 (m, 1H), 1.36 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 147.8, 135.1, 126.9, 109.9, 80.8, 71.1, 55.9, 47.1, 40.0, 27.9, 55.6, 23.0, 
18.6, 18.4; 
HRMS (EI-MS): calcd for C14H25O2 (M+H)+ 225.1776, found 225.177. 
 
Compound 206: Under nitrogen to a solution of 205 syn-diol (0.052 g, 0.233 
mmol) in DCM (3 mL) was added m-CPBA (0.084 g, 1.1 equiv) at once at 0 oC. 
The reaction mixture was allowed to stir for 20 min at the same 
temperature. The solvent was removed under reduced pressure and the 
crude was purified by flash column chromatography (hexanes/ EtOAc 2:1) gave 206 in 85% yield 
(0.046 g).  
Rf= 0.35 (hexanes/ EtOAc 2:1, stains deep blue with vanilin); 
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1H NMR (300 MHz, CDCl3) δ 4.74 – 4.65 (m, 2H), 3.56 – 3.46 (m, 1H), 2.70 (d, J = 8.7 Hz, 1H), 2.32 – 
2.23 (m, 1H), 2.22 – 2.15 (m, 1H), 1.91 – 1.79 (m, 2H), 1.75 (s, 3H), 1.73 – 1.65 (m, 1H), 1.61 – 1.38 
(m, 2H), 1.31 (d, J = 6.5 Hz, 6H), 1.26 (d, J = 7.2 Hz, 1H), 1.22 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 146.8, 110.7, 80.8, 72.5, 67.4, 62.2, 52.7, 46.3, 39.4, 28.5, 24.5, 23.0, 19.7, 
19.3; 
HRMS (EI-MS): calcd for C14H25O3 (M+H)+ 241.1725, found 241.1728. 
                               
                         
                          
To a solution of i-Pr2NH (2.8 mL, 20 mmol) in THF (30 mL) was added n-BuLi (1.45 M in hexanes, 13.8 
mL, 20 mmol) at 0 oC and the resulting solution was stirred for 30 min at the same temperature, then 
cooled to -78 oC. Ketone 211 (2.14 mL, 20 mmol) was added dropwise and the resulting mixture was 
stirred for 45 min at -78 oC, and was then added TMSCl (3.0 mL, 24 mmol) followed by quenched with 
aq. NH4Cl. The reaction was warmed to room temperature. The aqueous layer was extracted with 
Et2O. The combined organic extracts were washed with brine, dried, filtered and concentrated under 
reduced pressure gave crude 212 which we can use directly for the next step.  
To the above crude 212 solution in DCM (125 mL) was added m-CPBA (5.94 g) at 0 oC. The reaction 
mixture was allowed to warm room temperature during 30 min, and was quenched with water. The 
aqueous layer was extracted with DCM. The combined organic extracts were washed with brine, 
dried, filtered and concentrated under reduced pressure gave crude 213.  
To the above crude 213 (0.83 g, 4.74 mmol) in Et2O(30 mL) was added allyl magnesium bromide (0.74 
M in Et2O, 19 mL, 14.22 mmol) at 0 oC. The reaction was stirred at the same temperature for 30 min 
and was allowed to warm to room temperature for 30 min. The reaction was quenched with aq. 
NH4Cl and extracted twice with Et2O. The combined organics were washed with brine; dried, filtered 
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and removed solvent under reduced pressure gave crude. This crude was purified by flash column 
(hexanes/ EtOAc 7:1) gave diol 214 in 70% yield (0.72 g). 
Rf=  0.64 (hexanes/ EtOAc 10:1, stains blue with vanilin). 
1H NMR (300 MHz, CDCl3) δ 5.92 – 5.70 (m, 1H), 5.07 – 5.03 (m, 1H), 5.00 (ddd, J = 5.3, 2.3, 1.3 Hz, 
1H), 3.48 – 3.35 (m, 2H), 2.18 (dddd, J = 13.4, 9.0, 7.0, 3.7 Hz, 3H), 1.80 (dq, J = 13.5, 6.8 Hz, 1H), 0.87 
(d, J = 7.0 Hz, 6H), 0.11 – 0.04 (m, 9H); 
13C NMR (75 MHz, CDCl3) δ 145.8, 118.0, 75.6, 65.9, 39.2, 33.5, 17.7, 17.4, 3X0.00(TMS); 
HRMS (EI-MS): calcd for C11H25O2 Si(M+H)+ 217.155, found 217.157. 
To the above diol 214 (0.084 g, 0.392 mmol) in DCM (1.2 mL) was added DMSO (0.29 mL, 4.11 mmol) 
followed by the addition of iPr2NEt (0.35 mL, 2.03 mmol) after 15 min at 0 oC. To this solution was 
added Py.SO3 complex (0.193 g, 1.21 mmol). The reaction mixture was stirred at the same 
temperature for an hour, and was quenched with aq. NaHCO3 followed by extraction with DCM. The 
combined organics were washed with brine, dried, filtered and concentrated under reduced 
pressure. The resulting crude was purified by flash column (hexanes/ EtOAc 7:1) gave aldehyde 210 
in 80% yield (0.045g). 
Rf= 0.65 (hexanes/ EtOAc 5:1, stains pale brown with vanilin). 
1H NMR (300 MHz, CDCl3) δ 9.53 (s, 1H), 5.78 – 5.57 (m, 1H), 5.16 – 5.12 (m, 1H), 5.09 (d, J = 1.1 Hz, 
1H), 3.15 (s, 1H), 2.51 (dt, J = 1.9, 1.1 Hz, 1H), 2.49 (dd, J = 2.6, 1.2 Hz, 1H), 2.01 (dd, J = 13.7, 6.8 Hz, 
1H), 1.01 (d, J = 6.8 Hz, 3H), 0.89 – 0.86 (m, 3H); 
13C NMR (75 MHz, CDCl3) δ 205.2, 131.8, 119.4, 81.8, 38.8, 32.7, 17.0, 16.0; 
HRMS (EI-MS): calcd for C15H24O3 (M+H)+, found. 
Compound 215: According to general procedure A: To a stirred solution of  
CuCN (0.051mmol, 0.561 mmol, 3.0 equiv) and anhydrous LiCl (0.048 g, 1.122 
mmol, 6.0 equiv) in THF (2 mL) was added isopropenylmagnesium bromide 
(0.92 M solution in THF, 0.561 mmol, 0.61 mL, 3.0 equiv) dropwise at –40 oC. 
The reaction mixture was cooled to –78 oC upon which a solution of (R)-125 (0.038 g, 0.187 mmol, 1.0 
equiv) in THF (0.5 mL) was added. After 4 min of stirring at -78 oC, 210 (0.053 g, 0.37 mmol, 2.0 equiv) 
was added. After the reaction was completed (ca. 5 min), the mixture was quenched with NH4Claq 
(100 mL) and the aqueous layer was extracted with Et2O (2x5 mL). The combined organic extracts 
were washed with brine, dried, filtered and the solvent was removed under reduced pressure. After 
purification on silica (hexanes/EtOAc 7:1-5:1) 215 was obtained in 12% yield (0.006 g). 
Rf= 0.25 (hexanes/ EtOAc 5:1, UV-active, stains blue with vanilin); 
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1H NMR (300 MHz, CDCl3) δ 7.68 (dd, J = 5.7, 2.2 Hz, 1H), 6.21 (dd, J = 5.7, 2.1 Hz, 1H), 6.09 – 5.94 (m, 
1H), 5.15 – 5.01 (m, 2H), 4.95 (dd, J = 3.8, 2.3 Hz, 2H), 4.51 (s, 1H), 3.89 (d, J = 7.6 Hz, 1H), 3.81 (q, J = 
2.5 Hz, 1H), 2.84 (d, J = 8.7 Hz, 1H), 2.63 (dd, J = 3.1, 1.7 Hz, 1H), 2.38 (dd, J = 14.5, 7.0 Hz, 2H), 1.95 
(dd, J = 13.7, 6.9 Hz, 1H), 1.71 (s, 3H), 1.13 (d, J = 6.8 Hz, 3H), 0.83 (d, J = 7.0 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 212.1, 169.0, 142.9, 135.6, 134.0, 116.7, 114.8, 72.9, 54.1, 53.1, 37.6, 
36.1, 23.9, 19.5, 17.5, 14.6;  
HRMS (EI-MS): calcd for C16H24O3 (M+H)+ 264.1726, found 265.173. 
 
Compound 222: According to general procedure A: To a stirred solution of  
CuCN (0.215 g, 2.4 mmol, 3.0 equiv) and dried LiCl (0.202 g,  4.8 mmol, 6.0 
equiv) in THF (8 mL) was added isopropenylmagnesium bromide (0.92 M 
solution in THF, 2.4 mmol, 2.6 mL, 3.0 equiv) dropwise at –40 oC. The 
reaction mixture was cooled to –78 oC upon which a solution of (R)-125 
(0.16 g, 0.8 mmol, 1.0 equiv) in THF (2 mL) was added. After 4 min successive stirring at -78 oC, 
aldehyde 221 (0.21 g, 1.34 mmol, 1.68 equiv) was added. After the reaction was completed (ca. 10 
min), the mixture was quenched with aq.NH4Cl (10 mL), and the reaction mixture was extracted with 
Et2O (2x25 mL). The combined organic extracts were washed with brine (25 mL), dried over Na2SO4, 
filtered and concentrated under vacuo. The crude was purified by flash chromatography on silica 
(hexanes/ EtOAc 5:1 to 2:1) obtained enone 222 in 66 % yield (0.145 g). 
Physical state: deep yellow oil; 
TLC: Rf = 0.3 (hexanes/ EtOAc 2:1, UV-active, stains pale green with vanillin); 
:  n.d. 
1H NMR (300 MHz, CDCl3) δ 7.49 (dd, J = 5.7, 2.4 Hz, 1H), 6.22 (dd, J = 5.6, 2.2 Hz, 1H), 5.85 – 5.69 (m, 
1H), 5.15 (s, 1H), 5.12 – 5.08 (m, 1H), 4.96 – 4.92 (m, 1H), 4.90 (s, 1H), 4.68 – 4.58 (m, 2H), 3.77 – 3.72 
(m, 1H), 3.16 (dd, J = 5.3, 2.6 Hz, 1H), 2.81 (dd, J = 16.9, 9.2 Hz, 1H), 2.49 – 2.33 (m, 3H), 2.19 (dd, J = 
16.9, 9.1 Hz, 1H), 2.10 – 2.05 (m, 1H), 1.59 (s, 3H);  
13C NMR (75 MHz, CDCl3) δ 212.31, 176.04, 167.66, 142.14, 133.32, 132.41, 119.15, 115.30, 79.76, 
69.52, 52.65, 51.35, 43.95, 38.32, 28.29, 18.47; 
IR (neat) (cm-1) max: 3485, 2919, 1773, 1686, 1440, 1229, 967, 905, 535, 494; 
HRMS (m/z): calcd for C16H21O4 (M+H)+ 277.1361, found 277.1362. 
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Compound 223: A flask containing enone 222 (0.146 g, 0.53 mmol) was 
outfitted with reflux condenser and evacuated and backfilled with N2 3 
times. Deoxygenated DCM (25 mL) was added, and the solution was heated 
to reflux (40 oC). A solution of Grubbs-II catalyst (0.045 g) in deoxygenated 
DCM (2.5 mL) was added to the reaction mixture. The light brown reaction mixture was refluxed for 
48 h and was then cooled to room temperature. The solvent was removed under reduced pressure. 
After purification on silica (hexanes/ EtOAc 5:1 to 2:1) 223 was obtained in 45 % yield (0.059 g). 
Physical state: pale yellow oil; 
TLC: Rf = 0.5 (hexanes/ EtOAc 1:1, UV-active, stains deep brown with vanillin); 
:  n.d.; 
1H NMR (300 MHz, CDCl3) δ 7.66 (dd, J = 5.7, 2.2 Hz, 1H), 6.27 (dd, J = 5.7, 2.3 Hz, 1H), 5.33 (d, J = 6.6 
Hz, 1H), 4.86 – 4.76 (m, 2H), 3.73 (t, J = 9.9 Hz, 1H), 3.46 (d, J = 1.6 Hz, 1H), 2.97 (ddt, J = 18.0, 5.4, 2.6 
Hz, 1H), 2.85 – 2.67 (m, 2H), 2.60 – 2.49 (m, 1H), 2.37 – 2.24 (m, 1H), 2.11 (dd, J = 10.2, 4.3 Hz, 1H), 
1.64 – 1.60 (m, 3H); 
13C NMR (75 MHz, CDCl3) δ 211.16, 175.54, 165.95, 134.44, 133.88, 121.54, 80.22, 74.27, 56.26, 
46.24, 44.75, 35.81, 33.77, 20.79; 
IR (neat) (cm-1) max: 2923, 1780, 1690, 1578, 1414, 1261, 1227, 1045, 985, 898, 539, 497; 
HRMS (m/z): calcd for C14H17O4 (M+H)+ 249.105, found 249.1044. 
 
Compound 220: To a solution of the aldehyde 221 (0.057 g, 0.37 mmol, 1 
equiv) in dry MeOH (0.075 M) was added Grubbs-II catalyst (10 mol %) at 
room temperature. The suspension was then heated at 60o C. After 10 
minutes, the catalyst completely dissolved and the resulting deep brown color solution was stirred at 
same temperature for further 15 h. After reaction was completed the solvent was removed under 
vacuo. The residue was purified by flash chromatography (hexanes/ EtOAc 5:1 to 2:1) the isomerized 
aldehyde 220 was obtained in 85 % yield (E/Z- 5:1, 0.049 g). 
Physical state: deep brown oil; 
TLC: Rf = 0.13 (hexanes/ EtOAc 2:1, stains deep green with vanillin); 
: 147.36 (c 0.11, CHCl3); 
1H NMR (300 MHz, CDCl3) δ; 1H NMR (300 MHz, CDCl3) δ 9.75 – 9.71 (m, 1H), 5.96 – 5.78 (m, 1H), 5.63 
– 5.45 (m, 1H), 3.30 – 3.14 (m, 1H), 2.93 – 2.83 (m, 1H), 2.79 – 2.70 (m, 1H), 2.53 (dt, J = 14.4, 6.6 Hz, 
1H), 1.79 – 1.72 (m, 3H); 
13C NMR (75 MHz, CDCl3) δ 197.15, 173.99, 132.27, 127.11, 79.32, 53.13, 28.84, 17.72; 
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IR (neat) (cm-1) max: 3080, 2980, 2841, 1774, 1727, 1419, 1359, 1193, 921; 
HRMS (m/z): calcd for C8H11O3 (M+H)+ 155.0703, found 155.0702. 
 
Compound 218: According to general procedure A: To a stirred solution of  
CuCN (0.215 g, 2.4 mmol, 3.0 equiv) and dried LiCl (0.202 g,  4.8 mmol, 6.0 
equiv) in THF (8 mL) was added isopropenylmagnesium bromide (0.92 M 
solution in THF, 2.4 mmol, 2.6 mL, 3.0 equiv) dropwise at –40 oC. The 
reaction mixture was cooled to –78 oC upon which a solution of (R)-125 
(0.16 g, 0.8 mmol, 1.0 equiv) in THF (2 mL) was added. After 4 min successive stirring at -78 oC, 
aldehyde 220 (0.21 g, 1.34 mmol, 1.68 equiv) was added. After the reaction was completed (ca. 10 
min), the mixture was quenched by adding aq.NH4Cl (10 mL), and the reaction mixture was extracted 
with Et2O (2x25 mL). The combined organic extracts were washed with brine (25 mL), dried over 
Na2SO4, filtered and concentrated under vacuo. The crude was purified by flash chromatography on 
silica (hexanes/ EtOAc 5:1 to 2:1) obtained enone 218 in 66 % yield (0.145 g). 
Physical state: deep yellow oil; 
TLC: Rf = 0.3 (hexanes/ EtOAc 2:1, UV-active, stains pale green with vanillin); 
:  11.1 (c 0.11, CHCl3); 
1H NMR (300 MHz, CDCl3) δ; 1H NMR (300 MHz, CDCl3) δ 7.54 (dd, J = 5.6, 2.4 Hz, 1H), 6.28 – 6.23 (m, 
1H), 5.95 – 5.77 (m, 1H), 5.49 – 5.37 (m, 1H), 5.00 – 4.96 (m, 2H), 4.91 (dd, J = 15.8, 7.4 Hz, 1H), 4.70 
(d, J = 6.2 Hz, 1H), 3.75 (d, J = 5.4 Hz, 1H), 3.29 – 3.20 (m, 1H), 2.90 – 2.80 (m, 1H), 2.37 – 2.22 (m, 
2H), 2.13 (dt, J = 10.2, 3.4 Hz, 1H), 1.75 – 1.71 (m, 3H), 1.64 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 212.44, 175.95, 167.79, 142.16, 133.23, 132.92, 127.72, 115.32, 81.86, 
68.21, 52.48, 51.51, 46.56, 28.42, 18.45, 17.86; 
IR (neat) (cm-1) max: 3485, 2919, 1773, 1686, 1440, 1229, 1188, 967, 905, 728, 535, 494; 
HRMS (m/z): calcd for C16H21O4 (M+H)+ 277.1361, found 277.1362. 
 
Compound 217: A flask containing enone 218 (0.145 g, 0.53 mmol) was 
outfitted with reflux condenser and evacuated and backfilled with N2 3 
times. Deoxygenated DCM (25 mL) was added, and the solution was heated 
to reflux (40 oC). A solution of Grubbs-II catalyst (0.045 g) in deoxygenated 
DCM (2.5 mL) was added to the reaction mixture.The light brown reaction mixture was refluxed for 
15 h and was then cooled to room temperature. The solvent was removed under reduced pressure. 
After purification on silica (hexanes/ EtOAc 5:1 to 2:1) 217 was obtained in 84 % yield (0.104 g). 
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Physical state: deep brown oil; 
TLC: Rf = 0.5 (hexanes/ EtOAc 1:1, UV-active, stains deep brown with vanillin); 
:  17.4 (c 0.18, CHCl3); 
1H NMR (300 MHz, CDCl3) δ; 1H NMR (300 MHz, CDCl3) δ 7.80 (dd, J = 5.9, 2.0 Hz, 1H), 6.30 (dd, J = 
5.9, 2.6 Hz, 1H), 5.86 – 5.82 (m, 1H), 4.91 – 4.83 (m, 2H), 3.50 (d, J = 2.6 Hz, 1H), 2.95 – 2.87 (m, 1H), 
2.49 – 2.44 (m, 1H), 2.24 (ddd, J = 10.1, 6.1, 2.5 Hz, 1H), 2.13 – 2.08 (m, 1H), 1.99 (td, J = 4.1, 2.2 Hz, 
1H), 1.87 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 209.77, 175.32, 162.15, 136.67, 134.12, 126.58, 78.63, 74.63, 55.04, 
48.87, 45.41, 34.24, 19.97; 
IR (neat) (cm-1) max: 2923, 1780, 1690, 1578, 1414, 1261, 1227, 1045, 985, 898, 734, 631, 539, 497; 
HRMS (m/z): calcd for C13H15O4 (M+H)+ 235.0969, found 235.0965. 
 
Compound 226: To a suspension of LiAlH4 (0.0038 g, 0.1 mmol) in THF (0.45 
mL) at -78 oC was added CuI (0.019 g, 0.1 mmol) dissolved in THF: DMPU 
(4:1, 0.45 mL). The resulting mixture was stirred for 1 h at the same 
temperature, and then was added 217 (0.024 g, 0.1 mmol) in THF (0.1 mL). 
After stirring 2 h at -78 oC, the mixture was quenched with aq. NH4Cl (5 mL) followed by ether (10 
mL). The aqueous layer was extracted twice with Et2O. The combined organic extracts were washed 
with brine, dried, filtered and concentrated under reduced pressure gave crude. The crude was 
purified by flash chromatography (hexanes/ EtOAc 3:1) gave 226 in 76% yield (0.018 g). 
Physical state: pale yellow oil; 
TLC: Rf = 0.48 (hexanes/ EtOAc 1:1, stains deep brown with vanillin); 
:  n.d.; 
1H NMR (300 MHz, CDCl3) δ 5.77 (s, 1H), 5.14 (d, J = 10.4 Hz, 1H), 4.03 (dd, J = 9.1, 5.0 Hz, 1H), 3.54 (s, 
1H), 3.11 – 2.99 (m, 1H), 2.67 – 2.56 (m, 2H), 2.43 (ddd, J = 22.7, 12.0, 5.8 Hz, 3H), 2.26 – 2.16 (m, 
2H), 1.83 (d, J = 1.4 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 221.0, 175.8, 139.1, 126.6, 76.0, 65.7, 59.1, 46.6, 42.2, 37.2, 29.6, 26.8, 
22.0; 
IR (neat) (cm-1) max: 2923, 1780, 1690, 1578, 1414, 1261, 1227, 1045, 985; 
HRMS (m/z): calcd for C13H17O4 (M+H)+ 237.105, found 237.1049. 
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E. Appendix 
1. NMR Spectra: 
 
(R)-125, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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(S)-134, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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(+)-133a, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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(+)-133a, HSQC, CDCl3, 600 MHz 
147a 
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(+)-133b, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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(+)-133c, CDCl3, 600 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 151 MHz 
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(+)-133c, HSQC, CDCl3, 600 MHz 
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(+)-133d, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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(+)-133e, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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(+)-133f, d6-Acetone, 300 MHz 
 
 
 
 
 
 
 
 
 
D6-Acetone, 75 MHz 
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(+)-133g, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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(+)-133h, d6-Acetone, 300 MHz 
 
 
 
 
 
 
 
 
D6-Acetone, 75 MHz 
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(+)-133i, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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(+)-133j, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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(+)-133k, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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(+)-133l, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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(+)-133m, d6-Acetone, 300 MHz 
 
 
 
 
 
 
 
 
 
D6-Acetone, 75 MHz 
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(+)-133n, CDCl3, 600 MHz 
 
 
 
 
 
 
 
 
CDCl3, 151 MHz 
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(+)-133o, CDCl3, 600 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 151 MHz 
 
 
 
 
 
 
 
 
E. Appendix 
   
144 
 
 
 
 
(+)-133o, HSQC, CDCl3, 600 MHz 
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(+)-133p, CDCl3, 600 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 151 MHz 
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(+)-133p, HSQC, CDCl3, 600 MHz 
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(+)-133q, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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(+)-133r, CDCl3, 600 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 151 MHz 
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(+)-133r, HSQC, CDCl3, 600 MHz 
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(+)-133s, CDCl3, 600 MHz 
 
 
 
 
 
 
 
 
 
 
CDCl3, 151 MHz 
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(+)-133s, HSQC, CDCl3, 600 MHz 
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(+)-133t, CDCl3, 600 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 151 MHz 
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(+)-133t, HSQC, CDCl3, 600 MHz 
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(+)-133u, CDCl3, 600 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 151 MHz 
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(+)-133u, HSQC, CDCl3, 600 MHz 
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(+)-133v, CDCl3, 600 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 151 MHz 
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(+)-133v, HSQC, CDCl3, 600 MHz 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E. Appendix 
   
158 
 
 
 
(+)-133w, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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(+)-133x, CDCl3, 600 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 151 MHz 
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(+)-133x, HSQC, CDCl3, 600 MHz 
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2, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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3, CDCl3, 400 MHz 
 
 
 
 
 
 
 
 
 
 
CDCl3, 100 MHz 
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141, CDCl3, 300 MHz 
 
 
CDCl3, 75 MHz 
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143, CDCl3, 300 MHz 
 
 
 
 
CDCl3, 75 MHz 
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146, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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157, d6-Acetone, 300 MHz 
 
 
 
 
 
 
 
 
D6-Acetone, 75 MHz 
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145, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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HSQC, CDCl3, 600 MHz 
 
 
 
 
 
 
 
 
HMBC, CDCl3, 600 MHz 
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COSY, CDCl3, 600 MHz 
 
 
 
 
 
 
 
 
 
Noesy, CDCl3, 600 MHz 
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158, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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144, CDCl3, 600 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 151 MHz 
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HSQC, CDCl3, 600 MHz 
 
 
 
 
 
 
 
HMBC, CDCl3, 600 MHz 
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COSY, CDCl3, 600 MHz 
 
 
 
 
 
 
 
Noesy, CDCl3, 600 MHz 
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72, CDCl3, 600 MHz 
 
 
 
 
 
 
 
 
CDCl3, 151 MHz 
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159, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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160, CDCl3, 300 MHz 
 
CDCl3, 75 MHz 
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161, CDCl3, 300 MHz 
 
 
CDCl3, 75 MHz 
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165, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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178, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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179a-syn, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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179b-anti, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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164, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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187, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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163, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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188, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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189, d6-Acetone, 300 MHz 
 
 
d6-Acetone, 75 MHz 
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192, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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194, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
 
 
 
 
 
 
 
 
 
E. Appendix 
   
189 
 
 
 
 
78 (+)-Orientalol-F, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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197, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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193, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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196, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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199, CDCl3, 300 MHz 
 
 
CDCl3, 75 MHz 
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200, CDCl3, 300 MHz 
 
 
 
CDCl3, 75 MHz 
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202, CDCl3, 300 MHz 
 
 
CDCl3, 75 MHz 
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203, CDCl3, 300 MHz 
 
 
CDCl3, 75 MHz 
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205-syn, CDCl3, 300 MHz 
 
 
CDCl3, 75 MHz 
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205-anti, CDCl3, 300 MHz 
 
 
CDCl3, 75 MHz 
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206, CDCl3, 300 MHz 
 
 
CDCl3, 75 MHz 
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214a, CDCl3, 300 MHz 
 
 
 
CDCl3, 75 MHz 
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214b, CDCl3, 300 MHz 
 
 
 
CDCl3, 75 MHz 
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210, CDCl3, 300 MHz 
 
CDCl3, 75 MHz 
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215, CDCl3, 300 MHz 
 
 
CDCl3, 75 MHz 
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222, CDCl3, 300 MHz 
 
CDCl3, 75 MHz 
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223, CDCl3, 300 MHz 
 
 
 
CDCl3, 75 MHz 
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220, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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218, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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217, CDCl3, 300 MHz 
 
 
 
 
 
 
 
 
CDCl3, 75 MHz 
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226, CDCl3, 300 MHz 
 
CDCl3, 75 MHz 
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2. HPLC data: 
 
                             HPLC condition: (CHIRALCEL OJ-H, Hept: iPrOH-99:1, 1.0 mL/min, 215 nm)   
                                  Racemic   
 
 
 
 
           Table 6, entry-1          
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Table 6, entry-2          
 
 
 
 
 
           Table 6, entry-3         
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 Table 6, entry-4          
 
 
 
 
 
            Table 6, entry-5 
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 Table 6, entry-6 
 
 
 
 
           Table 6, entry-7 
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 50 g scale 
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                      HPLC condition:  (Daicel CHIRALCEL OD-H, Hex: iPrOH-9:1, 0.5 mL/min, 220 nm)   
                            Racemic    
 
Peak  RetTime Type   Width     Area     Height    Area   
  #     [min]        [min]   [mAU*s]    [mAU]       % 
----|-------|----|-------|----------|----------|--------| 
  1   28.529  BV    0.6120 5.69962e4  1445.68945  49.8721 
  2   30.858  VB    0.6769 5.72885e4  1308.09363  50.1279 
 
Totals :                  1.14285e5  2753.78308 
 
Table 6, entry-1          
min10 20 30 40 50
mAU
0
100
200
300
400
500
600
700
800
 DAD1 A, Sig=220,10 Ref=off (NANAJI\L2239_0000002.D)
 28
.50
1
 30
.77
5
 
Peak  RetTime Type Width     Area     Height      Area 
  #      [min]      [min]    [mAU*s]    [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
1     28.501  BB   0.5658  381.90018  10.36617    1.0384 
2     30.775  BB   0.6580  3.63969e4  856.15778  98.9616 
Totals : 3.67788e4 866.52394 
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Table 6, entry-2 
 
min10 20 30 40 50
mAU
0
100
200
300
400
500
600
700
800
 DAD1 A, Sig=220,10 Ref=off (NANAJI\L2239_0000003.D)
 28
.67
8
 30
.89
4
 
Peak RetTime Type  Width     Area      Height    Area 
 #     [min]       [min]    [mAU*s]     [mAU]      % 
----|-------|----|-------|----------|----------|--------| 
1     28.678  BB   0.5527  412.48117   11.38510   1.0947 
2     30.894  BB   0.6656  3.72674e4  866.83331  98.9053 
Totals : 3.76799e4 878.21841 
 
Table 6, entry-3 
min10 20 30 40 50
mAU
0
100
200
300
400
500
600
700
 DAD1 A, Sig=220,10 Ref=off (NANAJI\L2239_0000004.D)
 28
.96
9
 31
.14
3
 
Peak  RetTime Type  Width    Area       Height     Area 
 #    [min]         [min]    [mAU*s]     [mAU]      % 
----|-------|----|-------|----------|----------|--------| 
 1    28.969  BB   0.5692   493.40097  13.22828   1.4578 
 2    31.143  BB   0.6704   3.33532e4  768.38739 98.5422 
Totals : 3.38467e4 781.61567 
 
 
E. Appendix 
   
217 
 
Table 6, entry-4 
min10 20 30 40 50
mAU
0
100
200
300
400
 DAD1 A, Sig=220,10 Ref=off (NANAJI\L2239_0000005.D)
 29
.11
2
 31
.29
8
 
Peak  RetTime Type Width     Area      Height     Area 
 #     [min]       [min]    [mAU*s]    [mAU]       % 
----|-------|----|-------|----------|----------|--------| 
 1    29.112  BB   0.5748  442.20560  11.70512    2.0492 
 2    31.298  BB   0.6663  2.11368e4  490.88638  97.9508 
Totals : 2.15790e4 502.59151 
 
Table 6, entry-5 
 
Peak RetTime Type  Width     Area      Height     Area   
#     [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1  28.607   BB    0.5767 4304.28711  115.53338   4.1854 
  2  30.727   BB    0.7513 9.85356e4  2062.82935  95.8146 
 
Totals :                  1.02840e5  2178.3627 
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Table 6, entry-6 
min10 20 30 40 50
mAU
0
100
200
300
400
500
600
700
 DAD1 A, Sig=220,10 Ref=off (NANAJI\L2239_0000007.D)
 29
.17
8
 31
.33
3
 
Peak  RetTime Type  Width     Area      Height     Area 
 #     [min]        [min]    [mAU*s]     [mAU]      % 
----|-------|----|-------|----------|----------|--------| 
 1    29.178  BV   0.5912  1018.88660  26.70000   2.9599 
 2    31.333  VB   0.6731  3.34046e4  765.46082  97.0401 
 
Totals : 3.44234e4 792.16082 
 
 
Table 6, entry-7 
min10 20 30 40 50
mAU
0
50
100
150
200
250
300
 DAD1 A, Sig=220,10 Ref=off (NANAJI\L2239_0000008.D)
 29
.18
3
 31
.40
0
 
 Peak RetTime Type Width    Area     Height      Area 
 #    [min]        [min]   [mAU*s]     [mAU]       % 
----|-------|----|-------|----------|----------|--------| 
 1    29.183  BB   0.5944  732.45392  19.05536    5.0130 
 2    31.400  BB   0.6611  1.38787e4  323.13040  94.9870 
Totals : 1.46111e4 342.18576 
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50 g scale 
 
 
 
Peak RetTime Type  Width     Area      Height     Area   
#     [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1  28.607   BB    0.5767 4304.28711  115.53338   4.1854 
  2  30.727   BB    0.7513 9.85356e4  2062.82935  95.8146 
 
Totals :                  1.02840e5  2178.3627 
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Racemic (Daicel CHIRALCEL OD-H, Hex: iPrOH-9:1, 0.5 mL/min, 220 nm)   
 
Peak RetTime Type   Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1  16.032   BV   0.3624  1.16628e4  499.58316  49.8767 
  2  16.944   VB   0.3867  1.17205e4  467.19119  50.1233 
 
Totals :                  2.33833e4   966.77435 
           Pure 
 
Peak RetTime  Type  Width     Area      Height     Area   
 #    [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1   16.925  BB   0.3939  2.43745e4  954.45892  100.0000 
 
Totals :                  2.43745e4   954.45892 
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Racemic (Daicel CHIRALCEL OD-H, Hex: iPrOH-9:1, 0.5 mL/min, 220 nm)   
 
Peak RetTime Type  Width     Area      Height     Area   
 #   [min]        [min]    [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1  16.874  VB    0.4014 1.04194e4   400.64154  50.1847 
  2  20.673  BB    0.5337 1.03428e4   297.44733  49.8153 
 
Totals:                  2.07622e4   698.08887 
 
                               Pure 
 
 Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1  20.458   BB   0.5635  2.32976e4  624.16785  100.0000 
  
Totals :                  2.32976e4   624.16785 
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Racemic (Daicel CHIRALCEL OD-H, Hex: iPrOH-9:1, 0.5 mL/min, 220 nm)   
 
Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1  13.871  BB    0.3389 9760.70703  443.21783  49.3695 
  2  16.354  VB    0.4246 9771.88867  353.38275  49.4261 
  3  18.653  BB    0.5165  238.11638    6.22131   1.2044 
 
Totals :                  1.97707e4   802.82189 
                                   Pure 
 
Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1  16.267   BB    0.4414 2.15171e4  744.00293  100.0000 
Totals :                  2.15171e4   744.00293 
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                                  Racemic  (Daicel CHIRALCEL OD-H, Hex: iPrOH-9:1, 0.5 mL/min, 220 nm)   
 
Peak RetTime  Type  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1  37.001   BB   1.0551  1.91694e4   279.18158  50.2680 
  2  45.566   BB   1.3402  1.89650e4   211.48711  49.7320 
 
Totals :                  3.81344e4   490.66869 
                                   Pure 
 
Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
 1   45.562   BB   1.3518  1.93902e4   216.71927 100.0000 
 
Totals :                  1.93902e4   216.71927 
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              Racemic (Daicel CHIRALCEL OD-H, Hex: iPrOH-9:1, 0.5 mL/min, 220 nm)   
         
 
 
Peak RetTime Type Width    Area       Height     Area 
 #    [min]        [min]   [mAU*s]      [mAU]      % 
----|-------|----|-------|----------|----------|--------| 
1    11.513  BB    0.2258  1.05228e4  714.52783  50.0456 
2    12.798  BB    0.2576  1.05037e4  626.44678  49.9544 
Totals : 2.10265e4 1340.97461 
 
                        Pure 
 
 
 
Peak RetTime Type  Width      Area     Height     Area 
#     [min]         [min]   [mAU*s]    [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
1     11.485  VB   0.2296  2.09386e4 1406.85852 100.0000 
Totals : 2.09386e4 1406.85852 
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                               Racemic (Daicel CHIRALCEL OD-H, Hex: iPrOH-9:1, 0.5 mL/min, 220 nm)   
 
 
 
 
Peak RetTime  Type  Width     Area      Height     Area 
#      [min]        [min]   [mAU*s]     [mAU]       % 
----|-------|----|-------|----------|----------|--------| 
 1    12.427  BB   0.2390  9467.62305 603.64832  50.3922 
 2    15.479  BB   0.3344  9320.26563 430.74310  49.6078 
Totals : 1.87879e4 1034.39142 
               Pure 
 
 
 
Peak  RetTime Type Width     Area     Height     Area 
#      [min]       [min]    [mAU*s]    [mAU]       % 
----|-------|----|-------|----------|----------|--------| 
1      12.381 BB   0.2450   2.11340e4 1318.22864 100.0000 
Totals : 2.11340e4 1318.22864 
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Racemic (Daicel CHIRALCEL OD-H, Hex: iPrOH-9:1, 0.5 mL/min, 220 nm)   
 
 
Peak RetTime Type Width    Area      Height     Area 
  #    [min]        [min]    [mAU*s]   [mAU]       % 
----|-------|----|-------|----------|----------|--------| 
  1    8.835  BV   0.1681  7372.73145 671.32239  49.8038 
  2    10.580 BB   0.2238  7430.82373 510.52188  50.1962 
Totals : 1.48036e4 1181.84427 
                          
                                  Pure 
 
Peak RetTime  Type  Width     Area     Height    Area 
#      [min]       [min]    [mAU*s]     [mAU]      % 
----|-------|----|-------|----------|----------|--------| 
 1     8.796  VV   0.1709  1.61348e4  1460.01709 100.0000 
Totals: 1.61348e4 1460.01709 
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                               Racemic (Phenomenex Lux Cellulose-2, n-Hep: iPrOH-1:1, 0.5    mL/min, 
254 nm) 
 
                  Pure 
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                                         Racemic (Chiralpak AS-H, n-Hep: iPrOH-7:3, 0.5 mL/min, 215 nm) 
 
 
# Name Time [Min] Quantity [% Area] Height 
[mAU] Area [mAU.Min] Area % [%]  
1 UNKNOWN 37,85 49,81 554,4 706,0 49,812
  
2 UNKNOWN 53,44 50,19 443,5 711,3 50,188
 Total 100,00 997,8 1417,3 100,000 
                                          Pure 
 
# Name Time [Min] Quantity [% Area] Height     
[mAU]   Area [mAU.Min] Area % [%]  
1 UNKNOWN 37,78 1,54 10,0 10,7 1,541
  
2 UNKNOWN 52,50 98,46 441,9 684,0 98,459
  
Total 100,00 451,9 694,7 100,000  
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Racemic (Daicel CHIRALCEL OD-H, Hex: iPrOH-9:1, 0.5 mL/min, 220 nm)   
 
Peak RetTimeType  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1  10.281   VV   0.1967  9210.60352  712.91986  50.6279 
  2  11.759   VB   0.2505  8982.14063  544.43036  49.3721 
 
Totals :                  1.81927e4  1257.35022 
               Pure      
 
 
  Peak RetTimeType  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1  10.291  VB    0.2013 1.74345e4  1326.84680  97.5320 
  2  11.878  VB    0.2892  441.18079   22.45942   2.4680 
Totals :                  1.78757e4  1349.30622 
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Racemic (Daicel CHIRALCEL OD-H, Hex: iPrOH-9:1, 0.5 mL/min, 220 nm)   
 
 Peak RetTime Type  Width     Area      Height     Area   
   #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1   8.748   BB   0.1746  6796.20410  597.86981  49.7955 
  2   10.204  BV   0.2187  6852.02930  479.49533  50.2045 
 
Totals :                  1.36482e4  1077.36514 
                           Pure 
 
Peak RetTime  Type  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1   8.765   VB   0.1764  1.44741e4  1256.32727  99.4524 
  2  10.070   BV   0.2340   79.69231    5.16510   0.5476 
 
Totals :                  1.45538e4  1261.4923 
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Racemic (Phenomenex Lux Cellulose-2, n-Hep: iPrOH-7:3, 0.5    
mL/min, 215 nm) 
 
# Name Time [Min] Quantity [% Area] Height       
[mAU] Area [mAU.Min] Area % [%]  
1 UNKNOWN 28,67 49,16 1144,9 1582,4 49,165
  
2 UNKNOWN 36,90 50,84 898,0 1636,1 50,835
  
        
Total 100,00 2042,9 3218,5 100,000 
                 Pure                      
 
# Name Time [Min] Quantity [% Area] Height 
[mAU] Area [mAU.Min] Area % [%]  
1 UNKNOWN 27,51 100,00 1400,6 2075,5 100,000
 Total 100,00 1400,6 2075,5 100,000 
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Racemic (Daicel CHIRALCEL OD-H, Hex: iPrOH-9:1, 0.5 mL/min, 220 nm)   
 
 Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1   8.795  VB    0.1794  7092.45117  611.27081  49.7676 
  2  10.302  VV    0.2306  7158.68506  478.45273  50.2324 
 
Totals :                  1.42511e4  1089.72354 
                Pure 
 
 Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
 1   8.788    BB    0.1799 1.28671e4  1104.21106 100.0000 
 
Totals :                  1.28671e4  1104.21106 
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Racemic (Daicel CHIRALCEL OD-H, Hex: iPrOH-9:1, 0.5 mL/min, 220 nm)   
 
 Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1  15.888  BB    0.3596 1.21483e4   521.80676  49.9664 
  2  18.730  BB    0.4566 1.21646e4   411.81943  50.0336 
 
Totals :                  2.43129e4   933.62619 
                                   Pure 
 
 Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1  15.873  BB    0.3658  1.94189e4   821.36072 100.0000 
 
Totals :                  1.94189e4   821.36072 
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                                       Racemic (Daicel CHIRALCEL OD-H, Hex: iPrOH-9:1, 0.5 mL/min, 220 nm)   
 
 Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1  14.009  BB    0.3094 1.15398e4   571.83917  50.1461 
  2  15.938  BB    0.3829 1.14726e4   463.29245  49.8539 
 
Totals :                  2.30124e4  1035.13162 
                                                      Pure 
 
 Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1  14.011   BB   0.3103 1.09369e4  539.99188  100.0000 
 
Totals :                  1.09369e4   539.99188 
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                                     Racemic (Daicel CHIRALCEL OD-H, Hex: iPrOH-9:1, 0.5 mL/min, 220 nm)        
 
 Peak RetTime Type  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1   7.901   VV    0.1567 4571.86377  449.38071  49.4026 
  2   8.922   VV    0.1924 4682.43164  373.02985  50.5974 
 
Totals :                  9254.29541  822.41055 
                     Pure         
 
 Peak RetTimeType  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1   7.896   VB   0.1584  8418.02637 815.66779 100.0000 
 
Totals :                  8418.02637  815.6677 
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Racemic  (Daicel CHIRALCEL OD-H, Hex: iPrOH-9:1, 0.5 mL/min, 220 nm)     
 
Peak RetTime  Type  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1  13.188   BV   0.261   8066.14697 476.19882  49.8447 
  2  14.235   VB   0.2916  8116.41406 431.12695  50.1553 
 
Totals :                  1.61826e4   907.32578 
                                  Pure 
 
Peak RetTime  Type  Width     Area      Height     Area   
  #   [min]         [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
 1    13.014  BB   0.2496  1.18239e4  727.64905 100.0000 
 
Totals :                  1.18239e4   727.64905 
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(-)-133a 
 
 
Peak RetTime  Type  Width     Area      Height     Area   
  #   [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1  37.001   BB   1.0551  1.91694e4   279.18158  50.2680 
  2  45.566   BB   1.3402  1.89650e4   211.48711  49.7320 
 
Totals :                  3.81344e4   490.66869 
 
 
 
 
 
 
 
 
 
Peak RetTime Type   Width     Area     Height     Area    
 #     [min]        [min]   [mAU*s]    [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
 1    36.665  BB   1.0582  3.77625e4   547.85675  96.3837  
 2    45.942  BB   1.0578  1416.82507   17.25836   3.6163 
 
Totals :                  3.91793e4   565.11511 
 
min20 25 30 35 40 45 50 55
mAU
0
100
200
300
400
500
 DAD1 A, Sig=220,10 Ref=off (NANAJI\L2242_000004.D)
 36
.66
5
 45
.94
2
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(-)-133c 
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(-)-133d 
 
 
 
Peak RetTime Type Width    Area       Height     Area 
 #    [min]        [min]   [mAU*s]      [mAU]      % 
----|-------|----|-------|----------|----------|--------| 
1    11.513   BB    0.2258  1.05228e4  714.52783  50.0456 
2    12.798   BB    0.2576  1.05037e4  626.44678  49.9544 
Totals : 2.10265e4 1340.97461 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peak RetTime Type  Width     Area      Height     Area   
 #    [min]        [min]   [mAU*s]     [mAU]        % 
----|-------|----|-------|----------|----------|--------| 
  1   11.464  BB   0.2259  322.78360   21.65867   2.9755 
  2   12.688  BB   0.2521  1.05252e4   639.23163  97.0245 
 
Totals :                  1.08480e4   660.89030 
 
min8 10 12 14 16 18 20
mAU
0
100
200
300
400
500
600
 DAD1 A, Sig=220,10 Ref=off (NANAJI\L2242_000002.D)
 11
.46
4
 12
.68
8
E. Appendix 
   
241 
 
 (-)-133g 
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(-)-133h 
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(-)-133j 
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(-)-133k 
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(-)-133l 
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(-)-133n 
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(-)-133r 
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3. X-Ray structure of epoxy-Orientalol-F 197: 
 
 
 
 
Table 1. Crystal data and structure refinement for 197.  
Identification code  l274  
Empirical formula  C15H24O3 
Formula weight  252.34  
Temperature/K  123.01(10)  
Crystal system  orthorhombic  
Space group  P212121 
a/Å  6.08287(12)  
b/Å  9.5429(2)  
c/Å  24.1276(6)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3 1400.56(5)  
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Z  4  
ρcalcg/cm3 1.197  
μ/mm-1 0.650  
F(000)  552.0  
Crystal size/mm3 0.1731 × 0.1344 × 0.1244  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  7.32 to 147.52  
Index ranges  -7 ≤ h ≤ 6, -11 ≤ k ≤ 7, -29 ≤ l ≤ 26  
Reflections collected  6079  
Independent reflections  2648 [Rint = 0.0205, Rsigma = 0.0214]  
Data/restraints/parameters  2648/0/166  
Goodness-of-fit on F2 1.079  
Final R indexes [I>=2σ (I)]  R1 = 0.0374, wR2 = 0.1038  
Final R indexes [all data]  R1 = 0.0399, wR2 = 0.1061  
Largest diff. peak/hole / e Å-3 0.39/-0.23  
Flack parameter 0.0(2) 
 
 
  
Table 2. Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement Parameters 
(Å2×103) for l274. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
O1 -278.0(19) 4268.7(12) 807.3(5) 29.3(3) 
O2 2033.9(19) 3132.9(12) 2133.9(5) 30.4(3) 
O3 259.0(18) 5948.4(12) 2393.8(5) 28.6(3) 
C1 1217(3) 3494.9(17) 1154.6(7) 28.0(4) 
C2 3507(3) 4114.7(19) 1022.5(7) 33.0(5) 
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C3 2985(3) 5545.8(19) 756.5(7) 33.6(5) 
C4 474(3) 5697.3(18) 821.1(7) 29.4(4) 
C5 -212(3) 6302.8(16) 1385.1(7) 28.0(4) 
C6 771(2) 5410.1(16) 1842.7(6) 24.3(4) 
C7 629(3) 3841.8(16) 1761.8(6) 24.4(4) 
C8 927(3) 1922.0(19) 1030.4(8) 37.1(5) 
C9 -1454(3) 1454.4(19) 1107.8(9) 43.4(6) 
C10 1689(5) 1511(3) 458(1) 60.1(8) 
C11 -615(3) 6464(2) 343.1(8) 41.2(5) 
C12 570(4) 7811.2(18) 1520.0(8) 38.9(5) 
C13 2556(3) 7680.8(19) 1907.6(8) 39.0(5) 
C14 2441(3) 6220.6(17) 2150.5(7) 30.0(4) 
C15 4359(3) 5689(2) 2473.9(8) 37.9(5) 
 
Table 3. Anisotropic Displacement Parameters (Å2×103) for l274. The Anisotropic displacement factor 
exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
O1 25.5(5) 29.8(6) 32.5(6) 2.1(4) -2.3(4) 1.6(5) 
O2 25.4(6) 25.6(5) 40.2(6) 10.0(5) -5.9(5) 0.2(5) 
O3 23.4(5) 28.0(6) 34.4(6) -3.4(4) 4.5(4) -3.1(5) 
C1 23.1(7) 27.6(8) 33.2(8) 0.5(6) -2.1(6) 4.2(6) 
C2 23.1(7) 37.2(9) 38.6(8) -2.6(7) 4.3(6) 5.0(7) 
C3 25.5(8) 39.1(9) 36.1(8) 3.6(7) 5.4(6) -1.4(7) 
C4 23.9(7) 29.9(8) 34.4(8) 6.9(6) 1.4(6) 0.0(7) 
C5 23.0(7) 22.9(7) 38.0(8) 7.3(6) 3.0(6) 3.9(6) 
C6 19.8(7) 23.6(7) 29.5(7) 1.1(6) 2.5(6) 1.3(6) 
C7 19.6(7) 21.2(7) 32.4(7) 3.4(6) -1.3(6) 1.9(6) 
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C8 35.6(9) 29.5(8) 46.2(10) -8.0(7) -6.0(8) 8.3(7) 
C9 43.1(10) 25.2(8) 61.9(12) -6.6(8) -2.9(9) -2.8(8) 
C10 65.4(14) 54.6(13) 60.4(13) -24.0(11) 12.3(12) -2.5(12) 
C11 38.1(9) 44.3(10) 41.3(9) 16.1(8) -4.5(8) -2.4(9) 
C12 45.5(10) 23.1(8) 48.1(10) 5.4(7) 8.5(9) 1.3(8) 
C13 39.8(9) 27.7(8) 49.6(10) -1.9(7) 8.8(8) -9.1(8) 
C14 24.7(7) 27.2(8) 38.1(8) -1.5(6) 5.7(7) -4.4(6) 
C15 23.5(8) 43.7(10) 46.4(10) -2.3(8) -3.0(7) -5.8(7) 
 
Table 4. Bond Lengths for l274. 
Atom Atom Length/Å 
 
Atom Atom Length/Å 
O1 C1 1.440(2) 
 
C4 C11 1.518(3) 
O1 C4 1.438(2) 
 
C5 C6 1.517(2) 
O2 C7 1.412(2) 
 
C5 C12 1.551(2) 
O3 C6 1.4591(19) 
 
C6 C7 1.512(2) 
O3 C14 1.474(2) 
 
C6 C14 1.477(2) 
C1 C2 1.547(3) 
 
C8 C9 1.527(3) 
C1 C7 1.544(2) 
 
C8 C10 1.509(3) 
C1 C8 1.541(2) 
 
C12 C13 1.533(3) 
C2 C3 1.542(3) 
 
C13 C14 1.513(2) 
C3 C4 1.542(3) 
 
C14 C15 1.492(3) 
C4 C5 1.536(2) 
    
 
Table 5 Bond Angles for l274. 
Atom Atom Atom Angle/˚ 
 
Atom Atom Atom Angle/˚ 
C1 O1 C4 105.76(12) 
 
O3 C6 C7 117.00(12) 
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C6 O3 C14 60.46(9) 
 
O3 C6 C14 60.28(10) 
O1 C1 C2 104.64(13) 
 
C5 C6 C7 116.06(12) 
O1 C1 C7 107.21(13) 
 
C5 C6 C14 110.05(13) 
O1 C1 C8 108.30(14) 
 
C7 C6 C14 128.51(13) 
C2 C1 C7 108.80(14) 
 
O2 C7 C1 111.12(13) 
C2 C1 C8 115.83(15) 
 
O2 C7 C6 110.95(12) 
C7 C1 C8 111.53(14) 
 
C1 C7 C6 108.76(12) 
C1 C2 C3 103.83(14) 
 
C1 C8 C9 111.69(15) 
C2 C3 C4 104.18(14) 
 
C1 C8 C10 113.34(17) 
O1 C4 C3 102.93(13) 
 
C9 C8 C10 109.11(18) 
O1 C4 C5 106.90(13) 
 
C5 C12 C13 107.13(15) 
O1 C4 C11 107.49(14) 
 
C12 C13 C14 105.94(15) 
C3 C4 C5 113.19(14) 
 
O3 C14 C6 59.26(10) 
C3 C4 C11 113.62(14) 
 
O3 C14 C13 110.98(14) 
C5 C4 C11 111.91(14) 
 
O3 C14 C15 115.83(14) 
C4 C5 C6 109.05(13) 
 
C6 C14 C13 108.62(14) 
C4 C5 C12 116.86(15) 
 
C6 C14 C15 128.50(15) 
C6 C5 C12 104.33(14) 
 
C13 C14 C15 118.64(15) 
O3 C6 C5 112.42(12) 
     
 
Table 6. Hydrogen Bonds for l274. 
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
C2 H2A O2 0.9900 2.5700 2.979(2) 105.00 
O2 H2O O31 0.76(3) 1.99(3) 2.7549(16) 177(3) 
C15 H15C O22 0.9800 2.3900 3.339(2) 164.00 
1-X,-1/2+Y,1/2-Z; 21-X,1/2+Y,1/2-Z 
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Table 7. Torsion Angles for l274. 
A B C D Angle/˚ 
 
A B C D Angle/˚ 
O1 C1 C2 C3 19.31(16) 
 
C5 C6 C7 O2 165.72(13) 
O1 C1 C7 O2 -179.50(12) 
 
C5 C6 C7 C1 43.20(18) 
O1 C1 C7 C6 -57.09(17) 
 
C5 C6 C14 O3 105.01(13) 
O1 C1 C8 C9 -55.95(19) 
 
C5 C6 C14 C13 1.17(18) 
O1 C1 C8 C10 67.8(2) 
 
C5 C6 C14 C15 -154.93(17) 
O1 C4 C5 C6 57.59(17) 
 
C5 C12 C13 C14 -19.1(2) 
O1 C4 C5 C12 175.52(15) 
 
C6 O3 C14 C13 99.77(15) 
O3 C6 C7 O2 -57.76(17) 
 
C6 O3 C14 C15 -121.12(16) 
O3 C6 C7 C1 179.72(12) 
 
C6 C5 C12 C13 19.46(19) 
O3 C6 C14 C13 -103.84(15) 
 
C7 C1 C2 C3 -95.01(15) 
O3 C6 C14 C15 100.06(19) 
 
C7 C1 C8 C9 61.8(2) 
C1 O1 C4 C3 43.94(15) 
 
C7 C1 C8 C10 -174.49(18) 
C1 O1 C4 C5 -75.54(16) 
 
C7 C6 C14 O3 -102.35(17) 
C1 O1 C4 C11 164.16(14) 
 
C7 C6 C14 C13 153.81(15) 
C1 C2 C3 C4 6.38(17) 
 
C7 C6 C14 C15 -2.3(3) 
C2 C1 C7 O2 -66.87(17) 
 
C8 C1 C2 C3 138.45(15) 
C2 C1 C7 C6 55.55(17) 
 
C8 C1 C7 O2 62.10(18) 
C2 C1 C8 C9 -173.07(15) 
 
C8 C1 C7 C6 -175.48(14) 
C2 C1 C8 C10 -49.3(2) 
 
C11 C4 C5 C6 175.02(14) 
C2 C3 C4 O1 -29.91(16) 
 
C11 C4 C5 C12 -67.1(2) 
C2 C3 C4 C5 85.10(16) 
 
C12 C5 C6 O3 52.35(17) 
C2 C3 C4 C11 -145.81(15) 
 
C12 C5 C6 C7 -169.19(14) 
C3 C4 C5 C6 -55.03(18) 
 
C12 C5 C6 C14 -12.79(18) 
C3 C4 C5 C12 62.9(2) 
 
C12 C13 C14 O3 -52.17(18) 
C4 O1 C1 C2 -40.05(16) 
 
C12 C13 C14 C6 11.18(19) 
C4 O1 C1 C7 75.39(15) 
 
C12 C13 C14 C15 170.00(16) 
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C4 O1 C1 C8 -164.15(13) 
 
C14 O3 C6 C5 -101.05(14) 
C4 C5 C6 O3 177.91(12) 
 
C14 O3 C6 C7 120.91(15) 
C4 C5 C6 C7 -43.63(18) 
 
C14 C6 C7 O2 14.5(2) 
C4 C5 C6 C14 112.77(15) 
 
C14 C6 C7 C1 -108.07(18) 
C4 C5 C12 C13 -101.01(18) 
      
 
Table 8. Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters (Å2×103) for 
l274. 
Atom x y z U(eq) 
H2A 4387 4232 1365 40 
H2B 4323 3506 762 40 
H2O 1430(40) 2530(30) 2275(9) 37 
H3A 3413 5557 361 40 
H3B 3764 6311 952 40 
H5 -1851 6268 1415 34 
H7 -917 3537 1834 29 
H8 1843 1392 1303 44 
H9A -2403 1976 853 52 
H9B -1913 1638 1490 52 
H9C -1574 449 1030 52 
H10A 3245 1754 415 72 
H10B 818 2014 180 72 
H10C 1499 499 408 72 
H11A -342 5953 -3 49 
H11B -4 7411 314 49 
H11C -2202 6521 409 49 
H12A 991 8307 1176 47 
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H12B -622 8345 1703 47 
H13A 3942 7810 1699 47 
H13B 2484 8395 2205 47 
H15A 5329 5151 2229 45 
H15B 3836 5084 2775 45 
H15C 5172 6482 2630 45 
Experimental 
Single crystals of C15H24O3 [l274] were []. A suitable crystal was selected and [] on a SuperNova, Single 
source at offset), Atlas diffractometer. The crystal was kept at 123.01(10) K during data collection. 
Using Olex2 [1], the structure was solved with the [2] structure solution program using and refined 
with the [3] refinement package using minimisation. 
1. Dolomanov, O.V., Bourhis, L.J., Gildea, R.J, Howard, J.A.K. & Puschmann, H. (2009), J. Appl. 
Cryst. 42, 339-341. 
2.  
3.  
Crystal structure determination of [l274] 
Crystal Data for C15H24O3 (M =252.34 g/mol): orthorhombic, space group P212121 (no. 19), a = 
6.08287(12) Å, b = 9.5429(2) Å, c = 24.1276(6) Å, V = 1400.56(5) Å3, Z = 4, T = 123.01(10) K, μ(CuKα) = 
0.650 mm-1, Dcalc = 1.197 g/cm3, 6079 reflections measured (7.32° ≤ 2Θ ≤ 147.52°), 2648 unique (Rint 
= 0.0205, Rsigma = 0.0214) which were used in all calculations. The final R1 was 0.0374 (I>2σ(I)) and 
wR2 was 0.1061 (all data). 
Refinement model description 
Number of restraints - 0, number of constraints - ?. 
Details: 
1. Others 
 Fixed Uiso: H2A(0.04) H2B(0.04) H2O(0.037) H3A(0.04) H3B(0.04) H5(0.034) 
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 H7(0.029) H8(0.044) H9A(0.052) H9B(0.052) H9C(0.052) H10A(0.072) H10B(0.072) 
 H10C(0.072) H11A(0.049) H11B(0.049) H11C(0.049) H12A(0.047) H12B(0.047) 
 H13A(0.047) H13B(0.047) H15A(0.045) H15B(0.045) H15C(0.045) 
 Fixed X: H2A(0.4387) H2B(0.4323) H3A(0.3413) H3B(0.3764) H5(-0.1851) H7(- 
 0.0917) H8(0.1843) H9A(-0.2403) H9B(-0.1913) H9C(-0.1574) H10A(0.3245) 
 H10B(0.0818) H10C(0.1499) H11A(-0.0342) H11B(-0.0004) H11C(-0.2202) 
 H12A(0.0991) H12B(-0.0622) H13A(0.3942) H13B(0.2484) H15A(0.5329) H15B(0.3836) 
 H15C(0.5172) 
 Fixed Y: H2A(0.4232) H2B(0.3506) H3A(0.5557) H3B(0.6311) H5(0.6268) 
 H7(0.3537) H8(0.1392) H9A(0.1976) H9B(0.1638) H9C(0.0449) H10A(0.1754) 
 H10B(0.2014) H10C(0.0499) H11A(0.5953) H11B(0.7411) H11C(0.6521) H12A(0.8307) 
 H12B(0.8345) H13A(0.781) H13B(0.8395) H15A(0.5151) H15B(0.5084) H15C(0.6482) 
 Fixed Z: H2A(0.1365) H2B(0.0762) H3A(0.0361) H3B(0.0952) H5(0.1415) 
 H7(0.1834) H8(0.1303) H9A(0.0853) H9B(0.149) H9C(0.103) H10A(0.0415) 
 H10B(0.018) H10C(0.0408) H11A(-0.0003) H11B(0.0314) H11C(0.0409) H12A(0.1176) 
 H12B(0.1703) H13A(0.1699) H13B(0.2205) H15A(0.2229) H15B(0.2775) H15C(0.263) 
This report has been created with Olex2, compiled on 2014.06.27 svn.r2953 for OlexSys. Please let us 
know if there are any errors or if you would like to have additional features. 
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